

Why Researchers Choose  
PLOS ONE

Scope

Criteria for Publication

Peer Review at PLOS ONE

Ready to Submit?

Journal Timings

Publication Fees

Open Access

Journal and Article Metrics

Indexing and Archiving

PLOS

Contact

## Journal Information

*PLOS ONE* is an inclusive journal community working together to advance science for the benefit of society, now and in the future. Founded with the aim of accelerating the pace of scientific advancement and demonstrating its value, we believe all rigorous science deserves to be published and should be discoverable, widely disseminated and freely accessible to all.

## Why Researchers Choose PLOS ONE

### Inclusive publication criteria and scope

*PLOS ONE* accepts research in over two hundred subject areas across science, engineering, medicine, and the related social sciences and humanities. We evaluate research on the basis of scientific validity, strong methodology, and high ethical standards—not perceived significance. Multidisciplinary and interdisciplinary research, replication studies, negative and null results are all in scope. We also publish Registered Reports and Protocols.

**“I published with *PLOS ONE* because I love the idea that acceptance is based on quality of the work, not whether it’s trendy or important in the eyes of a few editors.”**

- Alison Turnbull, Outcomes After Critical Illness and Surgery (OACIS) Group, Johns Hopkins University, Baltimore, Maryland, United States of America



### Fair and robust review

*PLOS ONE* staff and our expert board of Academic Editors work together to ensure that the peer review process is fair, fast and thorough and that the work we publish meets high ethical and methodological standards in line with our editorial policies. We offer our reviewers the opportunity to sign their reviews and authors the choice to publish their Peer Review History supporting transparency, accountability and credit.



**“Everything was very fast from the time I sent the article to the time I got the first review and later on with the two rebuttal letters, plus modifications I sent. The reviewers were quite rigorous and that substantially improved our manuscript and we are definitely grateful for that.”**

- José Ribamar Ferreira-Júnior, Escola de Artes, Ciências e Humanidades, Universidade de São Paulo, São Paulo, Brazil

### Reach

Research published in *PLOS ONE* is immediately available to the widest possible audience. To help authors broaden their reach both in and outside of their discipline, our dedicated media team works with an extensive network of journalists to highlight noteworthy research. *PLOS ONE* articles received more than 100,000 mentions in media outlets around the world in 2022.

### Multi-disciplinary assessment

With more than 20,000 new authors joining the *PLOS ONE* community every year in over 200 research areas, *PLOS ONE* facilitates connections within and between disciplines

### Openness

The *PLOS ONE* community paved the way with open access. Now we’re doing the same with open science.

*PLOS* applies the Creative Commons Attribution (CC BY) license to works we publish. Under this license authors retain the copyright to their work and grant permission for anyone, anywhere in the world to read, share, and reuse these articles, as long as the author and original source are properly cited.

Throughout the peer review and publication process, *PLOS ONE* encourages transparency and practices that increase the visibility, trust, and reuse of research. We offer enhanced author attribution and identification through the CRediT authorship taxonomy and ORCID iD, publicly posted protocols and data sets, facilitated preprint posting, and optional [Published Peer Review History](#).

**“I see the Open Access movement as a means by which scientific inquiry and discovery can truly serve the community at large, rather than being locked behind paywalls and accessible only to academic insiders. By promoting free and open exchange of information, research findings can be more easily applied to solve pressing real-world problems.”**

- Serge Wiltshire, Food Systems, University of Vermont, Burlington, Vermont, United States of America



### Meaningful metrics

*PLOS* promotes the use of individualized article-level metrics to track the impact and reach of your unique work with precision. Every article we publish provides viewership, downloads, media mentions, social sharing, and citations through Altmetric.

# Scope

## Types of articles

*PLOS ONE* welcomes original research submissions from the natural sciences, medical research, engineering, as well as the related social sciences and humanities, including:

- › **Primary research** that contributes to the base of scientific knowledge, including interdisciplinary, replication studies, and negative or null results.
- › **Systematic reviews** whose methods ensure the comprehensive and unbiased sampling of existing literature.
- › **Submissions describing methods, software, databases, or other tools** that meet the [journal's criteria](#) for utility, validation and availability.
- › **Qualitative research** that adheres to appropriate study design and reporting guidelines.
- › **Protocols**, including Lab Protocols that describe verified methodologies and Study Protocols that describe detailed plans for research projects.

**i** Participate in a Call for Papers to be published as part of a highly visible PLOS Collection. [View our Calls for Papers](#) and [learn more about publishing in a Collection](#).

**i** [Read more about the article types we publish.](#)

## Criteria for Publication

1. [The study presents the results of original research.](#)
2. [Results reported have not been published elsewhere.](#)
3. [Experiments, statistics, and other analyses are performed to a high technical standard and are described in sufficient detail.](#)
4. [Conclusions are presented in an appropriate fashion and are supported by the data.](#)
5. [The article is presented in an intelligible fashion and is written in standard English.](#)
6. [The research meets all applicable standards for the ethics of experimentation and research integrity.](#)
7. [The article adheres to appropriate reporting guidelines and community standards for data availability.](#)

## Peer Review at PLOS ONE

*PLOS ONE* is a fully peer reviewed journal with a rigorous multi-stage editorial screening and assessment process.

First, we undertake an initial in-house quality check to identify potential issues such as competing interest, compliance with ethical standards for studies involving human and animal subjects, financial disclosures, data availability, and other scientific and policy requirements. Submissions may be returned to authors for changes or clarifications at this stage.

After passing quality control, each manuscript is placed with a member of the Editorial Board who conducts peer review and makes the decision to accept, invite revision, or reject the submitted manuscript. [Read the detailed Editorial and Peer Review Process overview.](#)

## Ready to Submit?

[Submission Guidelines](#)

[Submission System](#)

## Journal Timings

In line with our founding mission, we do all we can to ensure a fast and thorough review process based on expertise from the research community. We know that prompt editorial assessment and publication are important to scientific advancement, and we're always working to improve. Journal timings vary by subject area and manuscript, we transparently display our timings below as a guide but please be advised this may not reflect our most up-to-date improvements.

Further journal and article metrics are available [here](#).

|   | Jan - Jun 20 | Jul - Dec 20 | Jan - Jun 21 | Jul - Dec 21 | Jan - Jun 22 | Jul - Dec 22 | Jan - Jun 23 |
|---|--------------|--------------|--------------|--------------|--------------|--------------|--------------|
| Time to First Editorial Decision (Rejection or Peer Review) | 12           | 16           | 12           | 15           | 17           | 22           | 17           |
| Time to First Decision                                      | 44           | 47           | 48           | 53           | 62           | 56           | 45           |

|  | Jan - Jun 20 | Jul - Dec 20 | Jan - Jun 21 | Jul - Dec 21 | Jan - Jun 22 | Jul - Dec 22 | Jan - Jun 23 |
|--|--------------|--------------|--------------|--------------|--------------|--------------|--------------|
| Time to Final Decision (Rejection or Acceptance) | 83           | 84           | 90           | 105          | 118          | 117          | 87           |
| Time to Acceptance                               | 144          | 149          | 157          | 170          | 196          | 200          | 188          |
| Time to Publication                              | 169          | 162          | 170          | 177          | 205          | 215          | 204          |
| Time from Acceptance to Publication              | 13           | 11           | 10           | 9            | 10           | 10           | 10           |
| Desk Rejections without peer review (%)          | 23.0%        | 22.8%        | 21.50%       | 21.40%       | 22.90%       | 22.08%       | 30.82%       |
| Acceptance Rate*                                 | 48.2%        | 49.0%        | 49.9%        | 47.9%        | 41.36%       | 37.26%       | 30.74%       |

All times are in days and are median numbers

\*Acceptance rates are calculated from submission cohorts and are therefore only available with delay

## Publication Fees

PLOS employs several business models to support equitable Open Access. A full list of our publication fees, funding initiatives and fee assistance information is available [here](#).

## Open Access

PLOS applies the Creative Commons Attribution (CC BY) license to works we publish. Under this license authors agree to make articles legally available for reuse, without permission or fees, for virtually any purpose. Anyone may copy, distribute, or reuse these articles, as long as the author and original source are properly cited. [Learn more](#).

## Journal and Article Metrics

All of our journals have a range of metrics available, including Article-Level Metrics (ALMs), SJR, CiteScore, and h-index. We do not consider Impact Factor to be a reliable or useful metric to assess the performance of individual articles but will provide the metric to individuals when specifically requested. Metrics for all of our journals, including publication timings and acceptance rates are available [here](#).

## Indexing and Archiving

All PLOS journals are widely indexed by major services such as Crossref, Dimensions, DOAJ, Google Scholar, PubMed, PubMed Central, Scopus, and Web of Science.

*PLOS ONE* is also indexed by the following services to ensure research content is accessible and discoverable as widely as possible: AGRICOLA, Biological Abstracts, BIOSYS Previews, CABI CAB Abstracts, CABI Global Health, CAPES, CAS, CNKI, EconBiz, Embase, Food Science and Technology Abstracts, Journal Guide, MEDLINE, Psychinfo, RePEc, and Zoological Record.

➤ [See publishing details for all PLOS journal titles](#), including ISSN and indexing and archiving information.

## PLOS

PLOS is a non-profit organization on a mission to drive open science forward with measurable, meaningful change in research publishing, policy, and practice. We believe in a better future where science is open to all, for all.

## Contact

[Visit the Contact page](#) for details about whom to contact with different queries.

Senior Editorial Leadership

Behavioral and Social  
Sciences, Neuroscience,  
Mental Health

Life Sciences

Medicine

Physical Sciences and  
Engineering

Public Health and  
Epidemiology


Staff Editors

## Senior Editorial Leadership



**Emily Chenette**

*Editor-in-Chief*


 [orcid.org/0000-0003-0393-395X](https://orcid.org/0000-0003-0393-395X)

Emily studied biochemistry at Columbia University as an undergraduate, and went on to earn her PhD in genetics and molecular biology from the University of North Carolina at Chapel Hill. She then completed postdoctoral research at Duke University, where she analysed gene expression signatures in lung cancer. Emily has always loved scientific writing and policy and left the bench to pursue an editorial career in 2007. Before joining *PLOS One* in 2018, she held editorial positions at *Nature Cell Biology* and *The FEBS Journal*. She is excited to support *PLOS One's* commitment to community and open science.



**George Vousden**

*Deputy Editor-in-Chief*

 [orcid.org/0000-0002-9644-599X](https://orcid.org/0000-0002-9644-599X)


George joined *PLOS One* in 2017 following his PhD and subsequent post-doctoral research at the University of Cambridge. He has a background in psychology and neuroscience, specialising in the use of rodents to better understand human disease. George helps to oversee the *PLOS One* editorial team, working alongside other teams at PLOS to ensure the journal publishes high-quality, rigorously reviewed, and robust research. He led the development of PLOS' policy on Inclusivity in Global Research.

## Behavioral and Social Sciences, Neuroscience, Mental Health



**Laura Kelly**

*Division Editor*

 [orcid.org/0009-0006-2944-8943](https://orcid.org/0009-0006-2944-8943)

Laura joined PLOS in 2019, after completing her PhD at the University of Exeter focusing on endonucleolytic cleavage in RNA metabolism and transcriptional termination. She has a background in molecular biology and translational neuroscience. Laura first worked in the Editorial Board Services team at PLOS, leading recruitment of our Editorial Board Members, and in 2024 joined the *PLOS One* Editorial team



**Vanessa Carels**

*Senior Editor*


 [orcid.org/0000-0001-6643-6112](https://orcid.org/0000-0001-6643-6112)

Vanessa earned an undergraduate degree in Neuroscience from the University of Minnesota. They spent some time studying what happens in bird brains when they learn to sing, then left the Midwest to pursue a PhD in Neuroscience from the University of California, Berkeley. Their research focused on the encoding of complex sounds in auditory cortex and the ways that modulating attention can change the sensory code. They worked as a freelance science writer and editor as a graduate student, and came to PLOS in 2017 excited to contribute to open scientific communication.



**Avanti Dey**

Senior Editor


 [orcid.org/0000-0002-1307-6771](https://orcid.org/0000-0002-1307-6771)

Avanti received her undergraduate degree in Psychology from Queen's University in Canada before heading to the U.S. to obtain a PhD in Psychological and Brain Sciences in 2016 from Washington University in St Louis. Her graduate research examined the interaction between cognitive abilities during speech perception in aging, with a focus on executive function and language. She went on to complete a year of postdoctoral training in behavioural economics and decision-making at Columbia University, before returning to the field of cognitive aging to examine issues of age-related neural compensation at the Center for Vital Longevity at University of Texas at Dallas as a postdoctoral research scientist. Avanti has also worked as an Associate Editor with The POSTDOCKET, the official newsletter of the National Postdoctoral Association, and joined *PLOS One* in 2020.



**Annesha Sil**

Senior Editor


 [orcid.org/0000-0003-4270-2310](https://orcid.org/0000-0003-4270-2310)

Annesha received her undergraduate degree in Biotechnology from VIT University, Vellore, India. Following this, she completed a Masters in Neuroscience in 2013 from King's College London and a PhD in Neuroscience (cum laude) in 2017 from the University of Cagliari, Italy in the field of addiction neuroscience using both clinical and animal-based approaches. She then went on to pursue her postdoctoral fellowship at the University of Aberdeen in international projects aimed at enhancing reproducibility in neuroscience and dementia research as well as investigating dementia risk factors such as sex, diet, and pollution. Her passion for open science, reproducibility and previous editorial experience during the course of her research career led her to join *PLOS One* in 2024.



**Jenna Scaramanga**

Associate Editor

 [orcid.org/0000-0001-5219-6672](https://orcid.org/0000-0001-5219-6672)


Jenna completed her PhD in education at UCL in 2017, looking at the experiences of students who attended private evangelical schools in England. She has a background in music and has worked in music education, as well as publishing her research as an independent scholar. She joined *PLOS One* in 2025 and is committed to supporting clear and open science communication.

## Life Sciences



**Patrick Goymer**

Division Editor


 [orcid.org/0000-0002-2789-9373](https://orcid.org/0000-0002-2789-9373)

Patrick received his undergraduate degree in Natural Sciences from the University of Cambridge, specializing in genetics. He then completed a DPhil at the University of Oxford on experimental microbial evolution, and conducted postdoctoral research on *Drosophila* ageing and response to environmental temperature. He started his editorial career in 2005 at *Nature Reviews Genetics* and *Nature Reviews Cancer*, before moving to *Nature* in 2008 to handle research manuscripts in ecology and evolution, and then becoming the launch chief editor of *Nature Ecology & Evolution* in 2016. He joined the *PLOS One* team in 2024.



**Miquel Vall-Ilosera Camps**

*Senior Editor*


 [orcid.org/0000-0003-2644-2643](https://orcid.org/0000-0003-2644-2643)

Miquel received his BSc in Biology from the University of Barcelona. In 2012 he completed a PhD in Ecology at the Autonomous University of Barcelona. His topic of research was the ecology of avian invasions, particularly what makes a species a successful invader and how this knowledge can be used to prevent the impacts of the invaders. He then moved to the University of Adelaide for a postdoctoral position examining the pet trade as a pathway of introduction of invasive bird species. In 2017 he became an Assistant Professor at Shinshu University researching international exotic bird trade. Miquel has a wide range of interests in life sciences including biodiversity conservation, global change ecology, natural history, evolutionary biology, and paleontology. He joined *PLOS One* in June 2018.



**Jianhong Zhou**

*Senior Editor*


 [orcid.org/0000-0002-9590-7339](https://orcid.org/0000-0002-9590-7339)

Following her undergraduate studies in Pharmaceutical Administration, Jianhong obtained a Masters in Bioinformatics from China Pharmaceutical University and a PhD in Systems Biology at Soochow University spending two years in Indiana University for her PhD training. Her doctoral research initially focused on protein structure/function predictions, and later changed into protein disorder/function predictions. She then worked as a postdoc at iHuman institute in ShanghaiTech University investigating the functions of intrinsically disordered regions in signaling and regulatory proteins. She joined *PLOS One* in July 2019.




**Sarah Jose**

*Associate Editor*


 [orcid.org/0000-0003-2737-6473](https://orcid.org/0000-0003-2737-6473)

After receiving her BSc in Biology from Cardiff University, Sarah moved to the University of Bristol for a Ph.D. in Plant Biology, which she completed in 2016. Her research focused on the genetic links between the formation of stomata (breathing pores) and the waxy surfaces of leaves. During her postgraduate studies, Sarah became involved in science communication, and subsequently worked as a freelance science writer and copyeditor across a diverse range of life sciences topics. She joined the *PLOS One* team in November 2024.



**Xin Sun**

*Associate Editor*

 [orcid.org/0000-0002-7993-1419](https://orcid.org/0000-0002-7993-1419)


Xin studied for her BSc in Zoology at Sun Yat-Sen University, Guangzhou and her MPhil at the Hong Kong University of Science and Technology. She went on to earn her PhD in molecular genetics at the University of Toronto, focusing on chromatin remodeling factors in embryonic heart development. She then investigated the roles of extracellular matrix in heart regeneration and fibrosis after myocardial infarction during postdoctoral research at the University of Oxford. She joined *PLOS One* in October 2025, where she is excited to further contribute to open science communication.

## Medicine



**James Mockridge**

Division Editor


 <https://orcid.org/0000-0002-8244-4486>

James studied Biology as an undergraduate at the University of Bath and received his PhD from the University of Cambridge for a project investigating the signaling mechanisms of growth hormone. After completing postdoctoral research in the Department of Cardiology at King's College London, he moved from the bench into scientific publishing and worked at Portland Press and then at Springer Nature as an Editor in the *BMC Series* handling a portfolio of medical journals. Before joining *PLOS One* in July 2021, James was the Managing Editor of the *British Journal of Cancer*.



**Johanna Pruller**

Senior Editor


 [orcid.org/0000-0002-1946-9920](https://orcid.org/0000-0002-1946-9920)

Johanna studied Biomedical Engineering (BSc) and Tissue Engineering and Regenerative Medicine (MSc) at the University of Applied Sciences Technikum in Vienna, Austria, followed by a Wellcome Trust funded PHD at King's College London in Stem Cells and Regenerative Medicine, where she developed a gene therapy for the rare childhood cancer rhabdomyosarcoma. She then stayed at King's for a post-doc and fellowship investigating neuromuscular diseases. During this time, Johanna got interested in the publishing world, and this led to her joining *PLOS One* in August 2023.



**Jennifer Tucker**

Associate Editor


 [orcid.org/0000-0001-6981-8984](https://orcid.org/0000-0001-6981-8984)

Jenny obtained her PhD in Medical Studies, with a focus potential novel interventions in two toxicological models of Parkinson's disease through the University of Plymouth, with a large portion of her research undertaken at Florida International University. Following her PhD, Jenny worked at the University of Bath investigating imprinted genes and lncRNAs in breast and colon cancer. She joins the *PLOS One* team in August 2023 with over two years' experience in scientific publishing at *Frontiers*.



**Alejandro Torrado Pacheco**

Associate Editor


 [orcid.org/0000-0003-4879-5343](https://orcid.org/0000-0003-4879-5343)

Alejandro studied Physics at Imperial College London before developing an interest in neuroscience and obtaining a PhD from Brandeis University focused on mechanisms of brain plasticity and their modulation by sleep. He then worked as a Postdoctoral Fellow at Oregon Health & Science University where he investigated the behavioral and cognitive effects of the serotonergic psychedelic psilocybin. His interest in open science and publishing led him to join the *PLOS One* team in 2025.



**Jen Edwards**

Associate Editor

 [orcid.org/0000-0003-4152-6140](https://orcid.org/0000-0003-4152-6140)


Jen did an undergraduate degree in Artificial Intelligence and Computer Science at the University of Sheffield, before switching fields and earning a doctorate in Biosciences at the same institution. Subsequently she worked in the Institute of Medical and Biological Engineering at the University of Leeds as a postdoctoral researcher and then a University Academic Fellow. Her research explored the use of biological scaffolds derived from human and animal ligaments to repair the knee and ankle. Throughout her career, she led a variety of public engagement activities and acted as a reviewer for a range of journals. This passion for communicating science broadly and for the benefit of all led her to PLOS, joining the *PLOS One* team in 2025.

## Physical Sciences and Engineering



**Carla Pegoraro**

*Division Editor*


 [orcid.org/0000-0002-9157-1049](https://orcid.org/0000-0002-9157-1049)

Carla grew up in Pisa, where she obtained BEng and MEng degrees in Biomedical Engineering working on molecularly imprinted membranes for the recognition of specific biomolecules. She then earned a doctorate from the University of Sheffield, UK, with a project focused on transdermal needle free drug delivery under the supervision of professors Sheila MacNeil and Giuseppe Battaglia. During her PhD and research fellowship working on polymersome vaccine delivery, she became intrigued by the other side of scientific research: communication and publishing. This led her to the Royal Society of Chemistry in Cambridge, UK. There she worked for 4 years as a Publishing Editor on a variety of journals covering all aspects of chemistry. She was also strongly involved in cover commissioning and writing for *Chemistry World*. She joined *PLOS One* in November 2016.



**Joanna Tindall**

*Associate Editor*


 [orcid.org/0000-0002-7093-6694](https://orcid.org/0000-0002-7093-6694)

Joanna received her BSc(Hons) in Physical Geography and MSc in Quaternary Science from Royal Holloway, University of London (RHUL) where she developed a particular interest in palaeoclimatology and human-environment interactions. Her PhD focused on lacustrine oxygen isotope records as tracers of past climate change in NW Europe across the Holocene based at UCL and RHUL. This led to a postdoctoral research position at the University of Nottingham that integrated palaeolimnology and palaeoecology with the ancient Maya archaeology record in Belize. She has a keen interest in science communication and has been involved in a variety of projects encouraging the public to engage with geography and natural history more broadly. She joined the *PLOS One* team in 2024.



**Daniel Parkes**

*Associate Editor*


 [orcid.org/0009-0009-0887-7193](https://orcid.org/0009-0009-0887-7193)

Dan received his BSc (Hons) in Physical Geography and MSc in Quaternary Science from Royal Holloway, University of London (RHUL) where he became interested in palaeoclimatology and palaeoceanography. His PhD at RHUL and UCL focused on investigating abrupt climate change events as a response of North Atlantic ocean circulation to Greenland Ice sheet melt in the geological past, and what that may tell us about climate change in the future. Recently, he has been working on a number of outreach initiatives to encourage under-represented groups into the Environmental Sciences in addition to researching the Indian Ocean in the geological past. He joined the *PLOS One* team in 2024.



**Jason Morgan**

*Associate Editor*


 [orcid.org/0000-0003-2785-8165](https://orcid.org/0000-0003-2785-8165)

Jason received an undergraduate masters degree in physics from the University of Warwick (2007) and a PhD from the University of Leeds (2011) for research into magnetic ordering in nanostructured thin films. He continued this work as a Postdoctoral Fellow before taking on a postdoctoral position at the University of Cambridge studying the control of domain walls in magnetic nanowire devices. He has subsequently held various roles in research publishing and funding, including as an Associate/Senior Editor for condensed matter physics with Nature Communications, a Digital Economy Portfolio Manager with the EPSRC, a freelance consultant for journal submissions and funding proposals, and a Journal Launch Specialist with Frontiers. More recently, he revisited the lab as a Process Engineer for the Institute for Compound Semiconductors (Cardiff University). Jason joined *PLOS One* in 2025.



**Brian Weaver**

*Associate Editor*

 [orcid.org/0000-0002-9717-1070](https://orcid.org/0000-0002-9717-1070)


Brian completed his PhD in Physics at the University of Southern California in 2025, where he studied the formation and transport properties of bacterial outer membrane vesicles. As an undergraduate, he studied Astronomy and Astrophysics at Pennsylvania State University, with a focus on the orbital dynamics of exoplanet systems. He was drawn to PLOS by an interest in open science communication and publishing. He joined *PLOS One* in November 2025.

## Public Health and Epidemiology



**Marianne Clemence**

*Division Editor*


 [orcid.org/0000-0001-6301-5064](https://orcid.org/0000-0001-6301-5064)

Marianne studied Biological Sciences at the University of Oxford and subsequently completed a doctoral training programme in Infection, Immunology and Translational Medicine. After her DPhil, Marianne spent some time as a medical writer, supporting the development of publications in rare genetic disorders. She developed a particular interest in open science practices in the publication of clinical research, which led her to join *PLOS One* in August 2020. During this time she has been involved in several projects relating to our policies and guidelines including human ethics, systematic reviews and Study Protocols.



**Steve Zimmerman**

*Senior Editor*


 [orcid.org/0000-0003-2990-0013](https://orcid.org/0000-0003-2990-0013)

Steve received an undergraduate degree in Communication Studies from Nottingham Trent University and a master's degree in Intelligent Systems from the University of Nottingham. He stayed at Nottingham to pursue a PhD in Psychology, using cognitive modelling to examine language development. After graduating, Steve took a lecturing position at the University of Derby and then moved to the US to become an Assistant Professor at Illinois State University. His research focused on the development of scientific reasoning. He then worked as a freelance copyeditor before joining *PLOS One* in 2022.



**Emma Campbell**


*Associate Editor*

 [orcid.org/0000-0001-9564-9408](https://orcid.org/0000-0001-9564-9408)

Emma received an integrated MBIol undergraduate degree in Pharmacology from the University of Leeds. Following this, she continued her studies at the University of Leeds and completed a PhD in bioengineering supported by Defence Science and Technology Laboratories. Her doctoral research focused on the development of protein switch biosensors with rapid diagnostic and disease monitoring capabilities. During this time Emma developed an interest in scientific publishing, and after completing a short post-doctoral research project continuing her work on diagnostic biosensors, she joined *PLOS One* in February 2024.

**Katrien Janin**

*Associate Editor*


 [orcid.org/0000-0002-0463-2940](https://orcid.org/0000-0002-0463-2940)

Katrien earned an undergraduate and master's degree in Biological Archaeology from the University of Leicester. She was part of multiple research and fieldwork projects before pursuing a PhD in Evolutionary Biology at the University of Cambridge. She is particularly interested in the evolutionary changes in the morphological patterns of fossil and extant mammals, and investigated what the role of integration and modularity can tell us about the evolvability of species. Katrien started her editorial career at *PLOS One* in February 2022.



**Katherine Kokkinias**

*Associate Editor*


 [orcid.org/0000-0002-1422-6372](https://orcid.org/0000-0002-1422-6372)

Katherine received a bachelor's degree with honors in research in Biology and minor in Global Health from the University of Wisconsin-Madison. This was followed by a fellowship working at the Center for Disease Control Public Health Associate program. After this, Katherine received her PhD in Microbiology, Immunology, and Pathology from Colorado State University. Her research focused on *Salmonella* infection and the gut microbiome. She also studied science communication about microbes and microbiomes. She has joined *PLOS One* in April 2025.



**Ilse Bloom**

*Associate Editor*

 [orcid.org/0000-0002-4893-1790](https://orcid.org/0000-0002-4893-1790)

Ilse completed a BSc in Dietetics and Nutrition at the University of Lisbon and then went on to obtain an MSc in Public Health Nutrition from the University of Southampton. Following this, she continued her studies at the University of Southampton and completed a PhD with a focus on improving the diets of community-living older people. Her subsequent post-doctoral research focused on assessing the feasibility of an intervention for promoting diet, physical activity and health in older people, and on investigating methods of early nutritional screening in older adults, to prevent the development of malnutrition. She joined *PLOS One* in November 2025.

## Editorial Board

The *PLOS ONE* Editorial Board is powered by thousands of academic experts from all over the world. Our board comprises working scientists who are established principal investigators/group leaders with extensive publication records.

Academic Editors oversee the peer review process for the journal, including evaluating submissions, selecting reviewers and assessing their comments, and making editorial decisions. Together with fellow Editorial Board Members and internal staff, Academic Editors uphold journal policies and ethics standards and work to promote the *PLOS ONE* mission to provide free public access to scientific research.

Editorial board members affiliated with the Centers for Disease Control and Prevention, the World Health Organization or any other government agency are serving in a personal capacity. The views expressed are their own and do not necessarily represent the views of the Centers for Disease Control and Prevention or the United States Government.

## Interested in serving on the Editorial Board?

PLOS welcomes volunteers to the Editorial Board who support our mission, values, and commitment to providing a high-quality experience for our authors. [Explore the Academic Editor role](#) and [apply online](#).

## Academic Editors

To find a member, browse the list, or search by name, country/region, Section or [Classification](#).

The list of Editorial Board members syncs daily with Editorial Manager. If you are a Board member and would like to update any of the information below or do not see your information listed, please contact [edboardsupport@plos.org](mailto:edboardsupport@plos.org).

Q Search

Displaying 1-50 of 8874 Editors.

< 1 2 3 4 5 ... 178

### Natraj N. A.

[orcid.org/0000-0002-8726-5284](https://orcid.org/0000-0002-8726-5284)

Symbiosis International (Deemed University)

India

**Sections:** Computer and information sciences - Cryptography and computer security, Engineering and technology - Communication technologies, Engineering and technology - Systems science and computational engineering

**Classifications:** Natural language processing, Optical computing, Mathematical computing, Medicine and health sciences, Network bandwidth, Internet, Control sequences, Computer applications, Cloud computing, Science and technology workforce, Fuzzy logic, Target detection, Science policy, Electronics engineering, Technology regulation, Encryption, Databases, Broadband, Health information technology, Information storage and retrieval, Technology development, Computerized simulations, Telecommunications, Internet of Things, Computer security, Computing systems, Computer architecture, Quantum computing, Information technology, Microprocessors, Multiplexing, Computer hardware, Engineering and technology, Cryptography, Computer inferencing, Electronics, Prototypes, Web-based applications, Computing methods, Computer and information sciences, Machine learning, Artificial neural networks, Computer engineering, Expert systems, Carrier frequencies, Computer vision, Computer networks, Health care, Artificial intelligence

### Ahmad Khalid Aalemi

[orcid.org/0000-0003-0111-634X](https://orcid.org/0000-0003-0111-634X)

The University of Manchester Faculty of Biology Medicine and Health

United Kingdom of Great Britain and Northern Ireland

**Sections:** Dermatology

**Classifications:** Oral health, Warts, Blisters, Dermatology, Skin neoplasms, Oral diseases, Oral medicine, Pigmentary disorders, Dentistry, Medicine and health sciences

### Katriina Aalto-Setälä

University of Tampere

Finland

**Sections:** Developmental biology - Cell differentiation; Cell fate determination; Stem cells; Embryology; Fertilization

**Classifications:** Model organisms, Personalized medicine, Cardiology, Genetics of disease, Molecular genetics, Genetic testing, Animal models, Cardiovascular anatomy, Clinical genetics, Arrhythmia, Genetics, Stem cells, Induced pluripotent stem cells, Human genetics, Medicine and health sciences, Mouse models, Embryonic stem cells, Biology and life sciences, Genetic association studies, Cellular types, Developmental biology, Electrophysiology, Cell differentiation

### Nik Hisamuddin Nik Ab. Rahman

Universiti Sains Malaysia

Malaysia

**Sections:** Health care - Health services research, Public health and epidemiology - Health policies, systems and management, Toxicology

**Classifications:** Medicine and health sciences, Critical care and emergency medicine

### Andrew Max Abaasa

[orcid.org/0000-0002-6770-5588](https://orcid.org/0000-0002-6770-5588)

London School of Hygiene & Tropical Medicine Faculty of Epidemiology and Population Health

Uganda

**Sections:** Infectious diseases - Epidemiology and prevention, Public health and epidemiology - Biostatistics and methods

**Classifications:** Research and analysis methods, Epidemiology, Research design, Clinical trials, Health care, Medicine and health sciences

**Nidaa Ababneh**

[orcid.org/0000-0002-2155-3013](https://orcid.org/0000-0002-2155-3013)

University of Jordan

Jordan

**Sections:** Genetics - Mutation; Genetics of disease; Heredity, Neuroscience - Neurodegenerative diseases and dementia, Stem cells and regenerative medicine

**Classifications:** Neurology, Medicine and health sciences

**Yacine Abadou**

[orcid.org/0000-0002-0248-0728](https://orcid.org/0000-0002-0248-0728)

Universite Ziane Achour de Djelfa

Algeria

**Sections:** Engineering and technology - Materials and manufacturing engineering, Engineering and technology - Systems science and computational engineering, Materials science - Structural materials

**Classifications:** Structural engineering, Physical sciences, Built structures, Engineering and technology, Materials design, Materials science, Civil engineering

**Amanuel Abajobir**

[orcid.org/0000-0002-6878-0627](https://orcid.org/0000-0002-6878-0627)

African Population and Health Research Center

Ethiopia

**Sections:** Health care - Health services research, Public health and epidemiology - Health policies, systems and management, Women's and maternal health

**Classifications:** Scientific publishing, Research design, Medicine and health sciences, Women's health, Research and analysis methods

**Yared Reta Abayneh**

[orcid.org/0000-0002-8509-2287](https://orcid.org/0000-0002-8509-2287)

Hawassa University College of Medicine and Health Sciences

Ethiopia

**Sections:** Mental health and psychiatry - General

**Classifications:** Mental health and psychiatry, Medicine and health sciences

**Gianmarco Abbadessa**

[orcid.org/0000-0001-8912-3055](https://orcid.org/0000-0001-8912-3055)

Universita degli Studi della Campania Luigi Vanvitelli

Italy

**Sections:** Digital health, Neuroscience - Cellular and molecular, Neuroscience - Neurobiology of disease; Neuropathology

**Classifications:** Telemedicine, Medical services, Clinical immunology, Neuroimmunology, Immunology, Demyelinating disorders, Medicine and health sciences, Multiple sclerosis, Neurology, Autoimmune diseases, Health care

**Cristiana Abbafati**

[orcid.org/0000-0003-2811-6251](https://orcid.org/0000-0003-2811-6251)

Sapienza University of Rome

Italy

**Sections:** Economics - Health economics, Health care - General, Public health and epidemiology - Health policies, systems and management

**Classifications:** Morbidity, Health care, Public and occupational health, Social sciences, Health care policy, Health care facilities, Health care providers, Economics, Health economics, Health statistics, Hospitals, Socioeconomic aspects of health, Quality of life, Medicine and health sciences, Community based intervention, Health services research, Outpatient clinics, Health services administration and management, Health care utilization, Health care quality

**Sohail Abbas**

[orcid.org/0000-0003-1194-064X](https://orcid.org/0000-0003-1194-064X)

Henan University, Kaifeng

China

**Sections:** Agriculture - Plants, Earth sciences - Physical geography, Ecology - Ecosystems

**Classifications:** Monsoons, Watersheds, Drought, Social sciences, Ecology and environmental sciences, Physical geography, Natural disasters, Atmospheric science, Climatology, Climate change, Sociology, Meteorology, Geography, Climate modeling, Environmental geography, Hydrology, Earth systems, Ecology, Earth sciences, El Niño Southern Oscillation, Atmosphere, Education

**Alhamzah F. Abbas**

[orcid.org/0000-0002-7508-9340](https://orcid.org/0000-0002-7508-9340)

Universiti Teknologi Malaysia

Malaysia

**Sections:** Economics - General, Management science

**Classifications:** Medicine and health sciences, Quality of life, Health care quality, Health care, Quality of care

**Mazhar Abbas**

Universiti Utara Malaysia

Malaysia

**Sections:** Management science

**Classifications:** Research design, Economics, Social sciences, Research and analysis methods

**Asad Abbas**

[orcid.org/0000-0003-1395-4009](https://orcid.org/0000-0003-1395-4009)

Tecnologico de Monterrey

Mexico

**Sections:** Education research, Management science

**Classifications:** Political science, Sociology, Public administration, Social sciences, Education

### Faisal Abbas

MY University Islamad

Pakistan

**Sections:** Biotechnology - General, Immunology - General, Immunology - Immunity

**Classifications:** Ecology and environmental sciences, Economics, Social sciences, Environmental economics

### Muhammad Sibte-Abbas

[id orcid.org/0000-0002-0786-6742](https://orcid.org/0000-0002-0786-6742)

Muhammad Nawaz Shareef University of Agriculture

Pakistan

**Sections:** Agriculture - General, Food science and technology, Nutrition

**Classifications:** Sensory perception, Nutrition, Oils, Food, Peanut, Plant science, Protein extraction, Emulsions, Protein isolation, Agriculture, Wheat, Garlic, Biology and sciences, Flour, Fats, Absorption

### Faisal Abbas

[id orcid.org/0000-0002-9312-5659](https://orcid.org/0000-0002-9312-5659)

National University of Sciences and Technology

Pakistan

**Sections:** Economics - Health economics, Public health and epidemiology - Global health, Public health and epidemiology - Health policies, systems and management

**Classifications:** Development economics, Economic development, Human capital, Nutrition, Macroeconomics, Health economics, Agricultural economics, Welfare economics, Economics, Social sciences, Economic crises, Economic analysis, Experimental economics, Economic models

### Sameen Abbas

[id orcid.org/0000-0002-7260-3973](https://orcid.org/0000-0002-7260-3973)

Quaid-i-Azam University

Pakistan

**Sections:** Gastroenterology and hepatology, Public health and epidemiology - Health behavior, health promotion and society, Research assessment

**Classifications:** Gastrointestinal motility disorders, Gastroenterology and hepatology, Medicine and health sciences, Global health, Health promotion, Public and occupational health

### Mahdi Abbasi

[id orcid.org/0000-0002-5373-5778](https://orcid.org/0000-0002-5373-5778)

Bu Ali Sina University

Iran, Islamic Republic of

**Sections:** Computer and information sciences - Artificial intelligence, machine learning and data science, Computer and information sciences - Computer Hardware, Computer and information sciences - General

**Classifications:** Random number generators, Network theory, Digital imaging, Internet, Microprocessors, Network control, Computer vision, Machine learning, Feedforward neural networks, Computer and information sciences, Signaling networks, Digital computing, Artificial intelligence, Real time computing, Genetic programming, Neural networks, Internet of Things, Network analysis, Computing systems, Recurrent neural networks, Computing methods, Computer hardware, Artificial neural networks, Expert systems, Computers, Computer networks, Computer architecture, Computer applications

### Roohollah Abbasi Shureshjani

[id orcid.org/0000-0002-4141-933X](https://orcid.org/0000-0002-4141-933X)

Hazrat E Masoumeh Univ

Iran, Islamic Republic of

**Sections:** Economics - General, Management science, Mathematics - Multidisciplinary

**Classifications:** Optimization, Computer and information sciences, Decision analysis, Physical sciences, Applied mathematics, Linear programming, Data management, Mathematical and statistical techniques, Research and analysis methods, Fuzzy logic, Mathematical functions, Mathematics, Computing methods, Decision theory

### A. M. Abd El-Aty

[id orcid.org/0000-0001-6596-7907](https://orcid.org/0000-0001-6596-7907)

Cairo University

Egypt

**Sections:** Food science and technology, Pharmacology, Veterinary science

**Classifications:** Supercritical fluid extraction, Water analysis, Liquid chromatography, Drugs, Drug-food interactions, Liquid chromatography-tandem mass spectrometry, Analytical chemistry, Phytopharmacology, Pharmacologic analysis, Pharmacokinetic analysis, Pharmacology, Chromatographic techniques, Physical sciences, Research analysis methods, Extraction techniques, Liquid-liquid extraction, Phytochemistry, Phytochemicals, Pharmacogenetics, Medicine and health sciences, Pharmacokinetics, Pharmacodynamics, Chemistry, Solid-phase extraction, Antimicrobials, Environmental chemistry, Chemical analysis, Drug interactions

### Diaa Abd El-Moneim

[id orcid.org/0000-0003-3285-0563](https://orcid.org/0000-0003-3285-0563)

Arish university, Faculty of agricultural and environmental sciences

Egypt

**Sections:** Agriculture - Plants, Genetics - Gene expression; Epigenetics; Alternative splicing; RNA splicing; Molecular genetics, Genetics - Population genetics; Evolutionary genetics

**Classifications:** Biology and life sciences, Genetics, Agriculture, Plant science, Molecular biology

**Mahfouz Mohamed Mostafa Abd-Elgawad**

[orcid.org/0000-0002-4731-5988](https://orcid.org/0000-0002-4731-5988)

National Research Centre

Egypt

**Sections:** Agriculture - Plants, Pathology

**Classifications:** Integrated control, Pest control, Pesticides, Agriculture, Biology and life sciences

**Yasmina Abd-Elhakim**

[orcid.org/0000-0002-3646-6385](https://orcid.org/0000-0002-3646-6385)

Zagazig University

Egypt

**Sections:** Pharmacology, Pollution research and control, Toxicology

**Classifications:** Toxicology, Immunology, Aquatic environments, Medicine and health sciences, Pharmacology, Chromatographic techniques, Pharmaceutics, Veterinary science, Research and analysis methods, Animal studies, Ecology and environmental sciences, Agriculture, Biology and life sciences

**Mohamed Ezzat Abd El-Hack**

[orcid.org/0000-0002-2831-8534](https://orcid.org/0000-0002-2831-8534)

Zagazig University Faculty of Agriculture

Egypt

**Sections:** Nutrition, Veterinary science

**Classifications:** Zoology, Agriculture, Nutrition, Biology and life sciences

**Hassan Abdalla**

[orcid.org/0000-0001-7955-955X](https://orcid.org/0000-0001-7955-955X)

University of Udine

Italy

**Sections:** Engineering and technology - Systems science and computational engineering, Materials science - Structural materials

**Classifications:** Research and analysis methods, Mechanical properties, Material properties, Composite materials, Materials science, Materials, Simulation and modeling, Physical sciences, Elasticity, Stiffness, Mathematical modeling

**Mena Abdalla**

King's College Hospital NHS Foundation Trust

United Kingdom of Great Britain and Northern Ireland

**Sections:** Health care - Health services research, Obstetrics and gynecology, Women's and maternal health

**Classifications:** Maternal health, Women's health, Maternal mortality, Contraception, Management of high-risk pregnancies, Female subfertility, Stillbirths, Pregnancy complications, Chorioamnionitis, Gynecologic infections, Pregnancy, Menstrual abnormalities, Birth, Hypertensive disorders in pregnancy, Termination of pregnancy, Obstetrics and gynecology, Antenatal care, Gynecologic diseases, Gynecologic cancers, Assisted reproductive technology, Medicine and health sciences

**Mervat A. Abdel-Latif**

[orcid.org/0000-0002-7996-0121](https://orcid.org/0000-0002-7996-0121)

Damanhour University Faculty of Veterinary Medicine

Egypt

**Sections:** Agriculture - Animals, Nutrition

**Classifications:** Metabolism, Micronutrient deficiencies, Nutrition, Amino acid metabolism, Vitamin D deficiency, Biology and life sciences, Nutritional diseases, Agriculture, Biochemistry, Iron deficiency, Nutritional deficiencies, Animal production, Animal management, Antioxidants, Nutrients, Animal performance, Carbohydrate metabolism

**Muhammad Abdel-Gawad**

[orcid.org/0000-0002-0204-4715](https://orcid.org/0000-0002-0204-4715)

Al-Azhar University

Egypt

**Sections:** Gastroenterology and hepatology, Infectious diseases - Hepatitis

**Classifications:** Gastrointestinal cancers, Megacolon, Cirrhosis, Gastroesophageal reflux disease, Acute liver failure, Fatty liver, Pancreatitis, Primary biliary cirrhosis, Gastroenterology and hepatology, Liver function tests, Nonalcoholic steatohepatitis, Ascites, Biliary disorders, Cholelithiasis, Liver fibrosis, Chronic liver disease, Autoimmune hepatitis, Barrett's esophagus, Portal hypertension, Peptic ulcer disease, Hepatomegaly, Primary sclerosing cholangitis, Splenomegaly, Hepatocellular carcinoma, Crohn's disease, Medicine and health sciences, Colitis, Celiac disease, Gastrointestinal infections, Liver diseases, Enteropathies, Liver disease and pregnancy, Wilson's disease, Infectious hepatitis, Alcoholic liver disease, Inflammatory bowel disease, Diarrhea, Dysentery, Cholecystitis and biliary colic, Hemochromatosis, Hepatosplenomegaly, Zollinger-Ellison syndrome, Constipation

**Ahmed E. Abdel Moneim**

[orcid.org/0000-0002-2654-2591](https://orcid.org/0000-0002-2654-2591)

Capital University

Egypt

**Sections:** Molecular biology, Neuroscience - General, Toxicology

**Classifications:** Toxicology, Histology, Biology and life sciences, Biochemistry, Neuroscience, Immunology

**Shady H.E. Abdel Aleem**

[orcid.org/0000-0003-2546-6352](https://orcid.org/0000-0003-2546-6352)

Institute of Aviation Engineering and Technology

Egypt

**Sections:** Engineering and technology - General, Engineering and technology - Systems science and computational engineering, Science education

**Classifications:** Energy and power, Power engineering, Electrical faults, Electrical circuits, Engineering and technology, Electrical engineering

**Muhammad Tarek Abdel Ghafar**

[orcid.org/0000-0002-0621-4291](https://orcid.org/0000-0002-0621-4291)

Tanta University Faculty of Medicine

Egypt

**Sections:** Cancer - Biomarkers, molecular diagnostics and screening, Cancer - Immunotherapy and tumor immunology, Genetics - Gene expression; Epigenetics; Alternative splicing; RNA splicing; Molecular genetics

**Classifications:** Genetic causes of cancer, Hematology, Endocrinology, Epidemiology, Clinical genetics, Diagnostic medicine, Oncology, Immunology, Cancer risk factors, Biomarker epidemiology, Cancer epidemiology, Medicine and health sciences, Autoimmunity, Molecular epidemiology, Genetic epidemiology, Pathology and laboratory medicine, Clinical medicine, Genetics of the immune system, Clinical immunology

**Ahmed S. Abdel-Moneim**

[orcid.org/0000-0002-3148-6782](https://orcid.org/0000-0002-3148-6782)

Sultan Qaboos University

Oman

**Sections:** Infectious diseases - Viral diseases, Microbiology - Virology, Virology

**Classifications:** Viral genetics, Viral diseases, Zoonoses, Infectious diseases, Influenza, Pulmonology, Orthomyxoviruses, Viral evolution, Influenza viruses, Virology, Medicine and health sciences, Medical microbiology, Viral pathogens, Pathology and laboratory medicine, Biology and life sciences, Respiratory infections, Microbial pathogens, S. Viral disease diagnosis, Microbiology, Coronaviruses, Emerging viral diseases, SARS coronavirus, Pathogens, Avian influenza

**Abdelaziz Abdelaal**

[orcid.org/0000-0003-3787-5970](https://orcid.org/0000-0003-3787-5970)

Harvard Medical School

Egypt

**Sections:** Ear, nose and throat (ENT), Ophthalmology, Public health and epidemiology - Biostatistics and methods

**Classifications:** Scientific publishing, Hematology, Research assessment, Research design, Cardiology, Anesthesiology, Complementary and alternative medicine, Health care, Ophthalmology, Critical care and emergency medicine, Pediatrics, Research and analysis methods, Epidemiology, Neurology, Cardiovascular medicine, Imaging techniques, Mental health and psychiatry, Urology, Medicine and health sciences, Endocrinology, Pain management, Otorhinolaryngology, Infectious diseases, Vascular medicine, Pathology and laboratory medicine, Nephrology, Clinical medicine

**Tarek Samy Abdelaziz**

[orcid.org/0000-0002-1238-1045](https://orcid.org/0000-0002-1238-1045)

Cairo University Kasralainy Faculty of Medicine

Egypt

**Sections:** Nephrology, Research assessment

**Classifications:** Nephrology, Medicine and health sciences

**Hala Abdelmoneim Abdallah Abdelgaffar**

[orcid.org/0000-0002-5746-6624](https://orcid.org/0000-0002-5746-6624)

KIMEP University

Kazakhstan

**Sections:** Management science

**Classifications:** Qualitative studies, Sustainability science, Education, Careers, Universities, Egypt, Refugees, Sexual harassment, Employment

**Amr Mohamed Abdelghany**

[orcid.org/0000-0001-8953-0056](https://orcid.org/0000-0001-8953-0056)

National Research Centre (NRC)

Egypt

**Sections:** Biophysics, Materials science - General, Physics and astronomy - Applied physics

**Classifications:** Materials characterization, Biophysics, Computational techniques, States of matter, Materials physics, Physical sciences, Physics, Research and analysis methods, Materials science, Chemical characterization, Spectrum analysis techniques

**Islam Abdeljawad**

[orcid.org/0000-0003-2625-698X](https://orcid.org/0000-0003-2625-698X)

An-Najah National University

Palestine, State of

**Sections:** Economics - Econometrics, Economics - Financial, Economics - General

**Classifications:** Social sciences, Capital markets, Financial markets, Insurance markets, Economics, Cost-benefit analysis, Futures markets, Cost-minimization analysis, Economic analysis, Finance, Money markets, Cost-effectiveness analysis, Derivatives markets, Financial management

**Mohamed Abdelkarim**

[orcid.org/0000-0002-0984-6083](https://orcid.org/0000-0002-0984-6083)

Faculty of Medicine of Tunis

Tunisia

**Sections:** Cancer - Basic cancer research, Cancer - Biomarkers, molecular diagnostics and screening, Cell biology - General

**Classifications:** Metastasis, Basic cancer research, Medicine and health sciences, Oncology

**Elsayed Abdelkreem**

[orcid.org/0000-0002-8976-2989](https://orcid.org/0000-0002-8976-2989)

Sohag University Faculty of Medicine

Egypt

**Sections:** Clinical trials, Genetics - Mutation; Genetics of disease; Heredity, Pediatrics

**Classifications:** Metabolic disorders, Inborn errors of metabolism, Glycogen storage diseases, Medicine and health sciences, Genetic diseases, Galactosemia, Congenital disorders, Gaucher's disease, Neonatology, Mucopolysaccharidoses, Clinical genetics, Autosomal recessive diseases, Sickle cell disease, Developmental and pediatric neurology, Tay-Sachs disease, Neonatal care, Cystic fibrosis, Pediatrics, Niemann-Pick disease, Phenylketonuria, Chromosomal disorders, Child abuse, Pediatric critical care, Congenital adrenal hyperplasia, Wilson's disease

**Gaber Abdellrazeq**

[id orcid.org/0000-0002-8677-911X](https://orcid.org/0000-0002-8677-911X)

Washington State University College of Veterinary Medicine  
United States of America

**Sections:** Immunology - Immunity, Veterinary science

**Classifications:** Biology and life sciences, Immunology, Microbiology, Veterinary science

**Elabbass Abdelmahuod**

[id orcid.org/0000-0001-9330-5740](https://orcid.org/0000-0001-9330-5740)

Hamad Medical Corporation  
Qatar

**Sections:** Endocrinology - Cancer, Endocrinology - Diabetes and obesity, Endocrinology - General

**Classifications:** Tuberculosis, Respiratory infections, Antibodies, Celiac disease, Abscesses, Lymphoma, Thrombosis, Kidneys, Diabetes mellitus, Biopsy, COVID 19, Anticoagulant therapy

**Antoine Fakhry AbdelMassih**

[id orcid.org/0000-0001-8876-3229](https://orcid.org/0000-0001-8876-3229)

Cairo University Kasralainy Faculty of Medicine  
Egypt

**Sections:** Cardiovascular science and medicine - Interventional cardiology and cardiovascular surgery, Pediatrics

**Classifications:** Cardiology, Medicine and health sciences, Epidemiology, Pediatrics

**Sameh Abdelnour**

[id orcid.org/0000-0002-6873-0718](https://orcid.org/0000-0002-6873-0718)

Zagazig University Faculty of Agriculture  
Egypt

**Sections:** Agriculture - Animals, Reproductive biology

**Classifications:** Veterinary science, Biology and life sciences, Developmental biology, Cryobiology

**Mohammed Abdelsamea**

[id orcid.org/0000-0002-2728-1127](https://orcid.org/0000-0002-2728-1127)

University of Exeter  
United Kingdom of Great Britain and Northern Ireland

**Sections:** Computer and information sciences - Artificial intelligence, machine learning and data science, Computer and information sciences - Human-Computer interaction

**Classifications:** Medicine and health sciences, Target detection, Neural networks, Computer applications, Computer-aided design, Machine learning, Translational medicine, Computer and information sciences, Artificial neural networks, Biology and life sciences, Computational neuroscience, Digital imaging, Expert systems, Computational biology, Artificial intelligence, Cancer screening, Computer vision, Cancer detection and diagnosis, Diagnostic medicine, Computer aided diagnosis

**Nourtan F. Abdeltawab**

[id orcid.org/0000-0002-1290-2197](https://orcid.org/0000-0002-1290-2197)

Cairo University Faculty of Pharmacy  
Egypt

**Sections:** Complementary and alternative medicine, Immunology - General, Microbiology - Host-pathogen interactions

**Classifications:** Medicine and health sciences, Genetics of disease, Systems biology, Infectious diseases, Phylogenetics, Animal genetics, Microbial genetics, Molecular biology techniques, Clinical immunology, Genetics of the immune system, Biochemistry, Complementary and alternative medicine, Taxonomy, Molecular biology, Research analysis methods, Reverse genetics, Bioinformatics, Infectious disease immunology, Molecular genetics, Mammalian genetics, Genetics, Microbiology, Database and informatics methods, Immunology, Inflammatory diseases, Evolutionary systematics, Clinical medicine, Bacteriology, Biology and life sciences, Bacterial genetics

**Zhaleh Abdi**

Tehran University of Medical Sciences  
Iran, Islamic Republic of

**Sections:** Health care - Health policy, Health care - Health services research, Public health and epidemiology - Health policies, systems and management

**Classifications:** Nutrition, Medicine and health sciences, Health care providers, Health care

**Ibrahim Abdollahpour**

[id orcid.org/0000-0002-8607-4507](https://orcid.org/0000-0002-8607-4507)

Isfahan University of Medical Sciences  
Iran, Islamic Republic of

**Sections:** Health care - General, Neuroscience - General, Public health and epidemiology - General

**Classifications:** Research and analysis methods, Public and occupational health, Medicine and health sciences, Neurology, Neuroscience, Research design, Epidemiology, Open methodology, Clinical trials, Nutrition, Pediatrics, Biology and life sciences

**Ahmed Abdou**

[id orcid.org/0000-0002-4830-4594](https://orcid.org/0000-0002-4830-4594)

Universiti Malaya  
Malaysia

**Sections:** Dentistry and oral health, Health care - General

**Classifications:** Dentistry, Oral medicine, Medicine and health sciences

<

1

2

3

4

5

...

178

1,402 results for **donna adriani**

Sort By: **Date, newest first** ▼

SEARCH ALERT 

Filters: PLOS One 

[Clear all filters](#)

**Journal**

**PLOS One**

PLOS Pathogens (72)

PLOS Genetics (64)

PLOS Medicine (47)

PLOS Computational Biology (44)

PLOS Biology (38)

[show more](#)

**Subject Area**

Biology and life sciences (1,280)

Medicine and health sciences (1,209)

Research and analysis methods (828)

Anatomy (506)

Biochemistry (461)

[show more](#)

**Article Type**

Research Article (1,356)

Study Protocol (25)

Correction (18)

Registered Report Protocol (3)

**Author**

Donna K Arnett (19)

Donna B Stolz (13)

Donna Spiegelman (13)

Donna E Davies (12)

Donna M Slater (9)

[show more](#)

**Where my keywords appear**

References (380)

Body (64)

Materials and Methods (38)

Results and Discussion (13)

Introduction (3)

[show more](#)

**[Association between deployment and Gulf War Illness and adverse COVID outcomes in a nationwide cohort of 1990–1991 Gulf Era war veterans in the VA's Million Veteran Program](#)**

Donna L. White, Alice B. S. NonoDjotsa, Sarah T. Ahmed, Stephen H. Boyle, J. Michael Gaziano, Andrew D. Thompson, Melissa G. Johnson, Elizabeth J. Gifford, Renato Polimanti, Mihaela Aslan, Elizabeth R. Hauser, Drew A. Helmer, on behalf of the Million Veterans Program (MVP)

Research Article | published 15 Jun 2026 PLOS ONE

<https://doi.org/10.1371/journal.pone.0348594>

**Views: 89 • Citations: 0 • Saves: 0 • Shares: 0**

**[Driving factors in pediatric emergency department use: an ecological retrospective study](#)**

Denis Mongin, Hervé Spechbach, Joachim Marti, Frederic Ehrlé, Johan N. Siebert

Research Article | published 28 May 2026 PLOS ONE

<https://doi.org/10.1371/journal.pone.0344153>

**Views: 395 • Citations: 0 • Saves: 1 • Shares: 1**

**[Correction: The impact of maternal versus paternal imprisonment on their children's health: A scoping review](#)**

Naomi Gadian, Abigail Dunn, Donna Arrondelle, Sara Morgan, Paula Harriott, Lucy Wainwright, Emma Plugge

Correction | published 26 May 2026 PLOS ONE

<https://doi.org/10.1371/journal.pone.0350225>

**Views: 159 • Citations: 0 • Saves: 0 • Shares: 0**

**[EGFR-targeted affibody–polyIC polyplex kills EGFR-overexpressing cancer cells without activating the EGFR](#)**

Anne Pettikiriarachchi, Yelena Ugolev, Richard Birkinshaw, Ahmad Wardak, Maree C. Faux, Timothy E. Adams, Salim Joubran, Alexei Shchegolev, Nufar Edinger, Maya Zigler, Alexander Levitzki, Antony W. Burgess

Research Article | published 05 May 2026 PLOS ONE

<https://doi.org/10.1371/journal.pone.0334584>

**Views: 345 • Citations: 0 • Saves: 0 • Shares: 0**

**[Melatonin and Coenzyme Q10 mitigate Senescence in Human Adipose-Derived Mesenchymal Stem Cells by Restoring Mitophagy and Mitochondrial Proteostasis](#)**

Aleena Vikraman, Logeswari Ravi, Naveena Kandasamy, Anuradha Dhanasekaran

Research Article | published 29 Apr 2026 PLOS ONE

<https://doi.org/10.1371/journal.pone.0347781>

**Views: 1062 • Citations: 0 • Saves: 2 • Shares: 3**

**[Evaluating the implementation and impact of the HEart failUre carer support Programme \(HELP\) in the United Kingdom: A study protocol for a multi-centre, mixed-method, implementation study](#)**

Gareth Thompson, Judy Bradley, Martin Dempster, Patrick Stark, Mike Clarke, Nicola Johnston, Lana Dixon, Patricia Campbell, Patrick Donnelly, Theresa McDonagh, Susan Piper, Yvonne Millerick, Loreena Hill, Donna Fitzsimons

Study Protocol | published 17 Apr 2026 PLOS ONE

<https://doi.org/10.1371/journal.pone.0347037>

**Views: 601 • Citations: 0 • Saves: 0 • Shares: 0**

**[Trajectories and associations between wearable-derived mobility, patient-reported outcomes, clinical measures and clinical indicators following total knee arthroplasty: The IMPACT project protocol](#)**

Daniel Hickey, Rory Lambe, Quentin Le Cornu, Anthony Pierce, Ian Byrne, Cailbhe Doherty, Brian Caulfield

Study Protocol | published 15 Apr 2026 PLOS ONE

<https://doi.org/10.1371/journal.pone.0345667>

**Views: 443 • Citations: 0 • Saves: 0 • Shares: 0**

**[Assessment of miRNAs as transcriptional regulators in respiratory syncytial virus infection through computational analysis and molecular docking studies](#)**

Mubashir Hassan, Muhammad Shahzad Iqbal, Muhammad Yasir, Wanjoo Chun, Zainab Yaseen, Saba Shahzadi, Mark E. Peeples, Andrzej Kloczkowski

Research Article | published 30 Mar 2026 PLOS ONE

<https://doi.org/10.1371/journal.pone.0345571>

**Views: 516 • Citations: 0 • Saves: 0 • Shares: 0**

**Nonmyeloablative pentostatin-cyclophosphamide preconditioning improves rates of engraftment in adults undergoing haploidentical HCT for sickle cell disease**

Emily Limerick, Matthew Hsieh, Jackie Queen, Mary Lacy Grecco, Julia Varga, Jennifer Brooks, Wynona Coles, Neal Jeffries, Courtney D Fitzhugh

Research Article | published 23 Mar 2026 PLOS ONE

<https://doi.org/10.1371/journal.pone.0332282>

Views: 689 • Citations: 0 • Saves: 0 • Shares: 0

**Urban land use impact on soil heavy metal levels in Lafayette, Louisiana (USA)**

Holly L. Heafner, Anna A. Paltseva

Research Article | published 18 Mar 2026 PLOS ONE

<https://doi.org/10.1371/journal.pone.0344559>

Views: 696 • Citations: 0 • Saves: 1 • Shares: 1

**Clinical application of fetal Nuchal Translucency combined with noninvasive prenatal testing in screening chromosome abnormalities**

Guangzhen Fu, Shuang Hu

Research Article | published 16 Mar 2026 PLOS ONE

<https://doi.org/10.1371/journal.pone.0344739>

Views: 499 • Citations: 0 • Saves: 0 • Shares: 0

**Towards a systematic framework to assess restoration success of interventions in coral reef ecosystems**

Aldo Croquer, Sergio D. Guendulain-García, Jonathan S. Lefcheck, Leah Harper, Elizabeth Shaver, Rita I. Sellares-Blasco, Maria F. Villapando, Ainhoa L. Zubillaga, Rebecca Garcia-Camps, Andreina Rivera, Eva Salas, Jennifer Humberstone, Lorenzo Alvarez-Filip

Research Article | published 09 Mar 2026 PLOS ONE

<https://doi.org/10.1371/journal.pone.0331083>

Views: 1760 • Citations: 0 • Saves: 17 • Shares: 0

**Diphtheria seroprotection among Indonesian children: Community Health Surveys Riskesdas 2007, 2013 and 2018**

Monica Dwi Hartanti, Sunamo Sunamo, Novaria Sari Dewi Panjaitan, Armedy Ronny Hasugian, Rita Marleta Dewi, Sarwo Handayani, Masri Sembiring Maha, Tubagus Ferdi Fadilah, Firda Fairuza, Nathalia Ningrum, Meiriani Sari, Dita Setiati, Nia Nurul Aziza, Arleen Devita

Research Article | published 27 Feb 2026 PLOS ONE

<https://doi.org/10.1371/journal.pone.0343396>

Views: 789 • Citations: 0 • Saves: 0 • Shares: 0

**Feeding practices of under-two children in Ethiopia: A systematic review and meta-analysis**

Sisay Eshete Tadesse, Amare Tariku, Tefera Belachew

Research Article | published 25 Feb 2026 PLOS ONE

<https://doi.org/10.1371/journal.pone.0342932>

Views: 584 • Citations: 0 • Saves: 0 • Shares: 0

**Longitudinal brain atrophy and mortality among people living in homelessness and precarious housing: A brief report of a longitudinal study**

Jacob L. Stubbs, Andrea A. Jones, Kristina M. Gicas, Thalia S. Field, Manraj K. S. Heran, A. Talia Vertinsky, Donna J. Lang, Wayne Su, Allen E. Thornton, G. William MacEwan, Olga Leonova, Alexander Rauscher, Alasdair M. Barr, William G. Honer, William J. Panenka

Research Article | published 18 Feb 2026 PLOS ONE

<https://doi.org/10.1371/journal.pone.0340056>

Views: 593 • Citations: 0 • Saves: 0 • Shares: 0


RESEARCH ARTICLE

# Diphtheria seroprotection among Indonesian children: Community Health Surveys Riskesdas 2007, 2013 and 2018

Monica Dwi Hartanti<sup>1,2\*</sup>, Sunarno Sunarno<sup>2</sup>, Novaria Sari Dewi Panjaitan<sup>2</sup>, Armedy Ronny Hasugian<sup>3</sup>, Rita Marleta Dewi<sup>2</sup>, Sarwo Handayani<sup>2</sup>, Masri Sembiring Maha<sup>2</sup>, Tubagus Ferdi Fadilah<sup>4</sup>, Firda Fairuza<sup>4</sup>, Nathalia Ningrum<sup>4</sup>, Meiriani Sari<sup>4</sup>, Dita Setiati<sup>4</sup>, Nia Nurul Aziza<sup>4</sup>, Arleen Devita<sup>5</sup>, Donna Adriani<sup>6</sup>, Jihan Samira<sup>5</sup>, Christina Safira Whinie Lestari<sup>2</sup>

**1** Department of Biology, Faculty of Medicine, Universitas Trisakti, West Jakarta, Jakarta, Indonesia, **2** Center for Biomedical Research, Research Organization for Health, National Research and Innovation Agency (BRIN), Bogor, West Java, Indonesia, **3** Research Center for Preclinical and Clinical Medicine, Research Organization for Health, National Research and Innovation Agency (BRIN), Bogor, West Java, Indonesia, **4** Department of Paediatrics, Faculty of Medicine, Universitas Trisakti, West Jakarta, Jakarta, Indonesia, **5** Department of Microbiology, Faculty of Medicine, Universitas Trisakti, West Jakarta, Jakarta, Indonesia, **6** Department of Physiology, Faculty of Medicine, Universitas Trisakti, West Jakarta, Jakarta, Indonesia

\* [mdhartanti@trisakti.ac.id](mailto:mdhartanti@trisakti.ac.id)



**OPEN ACCESS**

**Citation:** Hartanti MD, Sunarno S, Panjaitan NSD, Hasugian AR, Dewi RM, Handayani S, et al. (2026) Diphtheria seroprotection among Indonesian children: Community Health Surveys Riskesdas 2007, 2013 and 2018. *PLoS One* 21(2): e0343396. <https://doi.org/10.1371/journal.pone.0343396>

**Editor:** Samuel Kofi Tchum, Kintampo Health Research Centre, GHANA

**Received:** September 10, 2025

**Accepted:** February 5, 2026

**Published:** February 27, 2026

**Copyright:** © 2026 Hartanti et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data availability statement:** The data are available upon request to the Center of Data and Information, Health Policy Agency (Indonesia: Pusat Data dan Informasi, Badan Kebijakan Pembangunan Kesehatan), Ministry of Health, Indonesia at <https://www.badankebijakan>.

## Abstract

Diphtheria remains a public health concern in Indonesia despite long-standing inclusion of diphtheria-containing vaccines in the national immunization program. This study assessed temporal trends in diphtheria immunity among Indonesian children aged 1–14 years, identified vulnerable age groups, and examined factors associated with seroprotection. We analyzed diphtheria IgG antibody data measured by ELISA from the Indonesian Community Health Surveys (Riskesdas) conducted in 2007, 2013, and 2018. The analysis included 6,622 children (2007), 7,110 (2013), and 7,203 (2018). Bivariate and multivariate logistic regression analyses were performed to identify determinants of seroprotection. Across all surveys, diphtheria IgG levels were lowest at ages 1–6 years, increased at ages 7–10 years, and declined again from age 11 years onward. Overall seroprotection ranged from 71.1% to 83.6%, with a two- to threefold increase in long-term protection observed in 2018 compared with 2007 and 2013. In multivariate analyses, complete DTP immunization consistently remained the strongest independent predictor of seroprotection among children aged 1–4 years ( $p < 0.05$ ). Among children aged 1–14 years, maternal education (Riskesdas 2007) and household economic status (Riskesdas 2018) were also associated with seroprotection. Following the introduction of the DTP4 booster, higher diphtheria IgG concentrations (GMC 0.48 IU/mL to 0.77 IU/mL) were observed among children aged 1–2 years old in 2018 compared with earlier surveys (GMC 0.18 IU/mL to 0.33 IU/mL). Diphtheria immunity among Indonesian children remains suboptimal, with the

[kemkes.go.id/](https://kemkes.go.id/). Select “Menu Layanan Data” (Data service menu), select “Tata Cara Permintaan Data” (Data request procedures). The request must be submitted with a cover letter signed by the head of the institution, Data Request Submission Form, and project proposal and emailed to [datin.bkpk@kemkes.go.id](mailto:datin.bkpk@kemkes.go.id). Data can be used with the following conditions:

1. The data received is not provided to other parties.
2. Include the statement “Data used in reports/articles/thesis/thesis/dissertation and others come from the Health Development Policy Agency which can be accessed with certain requirements and procedures via the link <https://www.litbang.kemkes.go.id> in the data utilization results document.
3. Obligated to submit the results of the analysis to the Health Development Policy Agency (BKPK RI).
4. Attachments are an inseparable part of the submitted letter.

**Funding:** The author(s) received no specific funding for this work.

**Competing interests:** The authors have declared that no competing interests exist.

highest vulnerability at ages 5–6 years and evidence of waning immunity after ten years of age. Ensuring complete routine DTP immunization is critical, and booster strategies may be considered to sustain long-term population immunity.

## Introduction

Diphtheria is an easily transmitted infectious disease and can cause outbreaks with 5–10% case fatality rate (CFR), especially in young children [1]. The main cause of diphtheria is *Corynebacterium diphtheriae* (*C. diphtheriae*), a Gram-positive rod-shaped bacterium that produces diphtheria toxin which has a toxic effect on target cells. This disease is characterized by inflammation at the site of infection, especially in the mucous membranes of the pharynx, larynx, tonsils, nose, and also on the skin. In more severe cases, diphtheria is characterized by difficulty swallowing, shortness of breath, stridor (a high-pitched noisy breathing sound), and swelling of the neck that looks like a cow’s neck (bullneck). Fatal cases usually occur due to obstruction/blockage of the airway, and systemic effects such as heart muscle damage, as well as abnormalities in the central nervous system and kidneys. Transmission occurs due to inhalation of saliva droplets from sufferers when the sufferer sneezes or coughs or through contaminated objects [2–4].

The incidence of diphtheria is spread throughout the world, especially in low-and middle-income countries (LMICs). WHO reported that in 2023, global diphtheria cases reached 24,782 cases, a significant increase compared to the previous year, which was 10,027 (2022) and 8,659 (2021). The most cases of diphtheria were found in Africa and Southeast Asia. In this case, Indonesia has always been among the five countries with the most diphtheria cases in the world from year to year [5,6]. Although diphtheria vaccine has been routinely given in the form of basic and additional vaccines, until now diphtheria cases are still being reported in Indonesia. The number of diphtheria cases reported in Indonesia in 2007, 2013 and 2018 (the data collection period for this study) are as follows, 183, 775 and 1,026 respectively [6]. Nationally, in 2020–2022, there were 964 diphtheria cases reported from 34 provinces in Indonesia [7]. Global data also shows that most diphtheria cases in various countries are related to immunization problems [8].

To date, early immunization against diphtheria in children has been very effective in drastically reducing the number of deaths and morbidity related to diphtheria. WHO recommends vaccination of at least six doses, namely three doses of basic vaccine and three doses of booster vaccine containing diphtheria and tetanus toxoids [9]. In its implementation, the diphtheria vaccination program depends on the policies of each country [8]. Since the early 1990s, Indonesia has implemented routine childhood immunization with three primary doses of diphtheria–tetanus–pertussis vaccine (DTP3) administered during infancy. In Indonesia, the diphtheria vaccination schedule determined by the Ministry of Health (Kemenkes RI) is given at ages 2, 3 and 4 months old for the first, second and third dose respectively, followed by boosters at ages 18 months and elementary school students in the first, second and fifth grades

(Bulan Imunisasi Anak Sekolah, BIAS) which is in line with the recommendation of Indonesian Pediatric Society (IDAI). In addition, IDAI also recommends the booster doses scheduled for children aged 5–7 years and 10–18 years [10,11]. This difference arises from operational and logistical adaptations in the national immunization schedule, rather than from conflicting policy guidance. Consequently, our study's references to school-based boosters should be understood as reflecting the implementation of the DT preparation under the BIAS program, while the IDAI recommendation pertains to the broader pediatric vaccination guidance.

In Indonesia, the vaccination program for diphtheria was executed based on the Expanded Program on Immunization (EPI), which recommends a primary vaccination series of three doses of DTwP-HB-Hib at 2, 3, and 4 months, followed by a booster dose at 18–24 months [11]. In addition to the national DTP vaccination schedule, Indonesia experienced a large diphtheria outbreak in 2017, which affected multiple provinces and prompted extensive outbreak response immunization (ORI) campaigns targeting children and adolescents. This outbreak prompted large-scale outbreak response immunization (ORI) campaigns, which delivered supplemental diphtheria-containing booster doses to children and adolescents, including cohorts beyond the age range typically covered by routine immunization services. These emergency vaccination activities occurred shortly before the Riskesdas 2018 survey and are likely to have influenced population-level immunity profiles observed in that survey year. Accumulating evidence of waning immunity following the primary DTP series, combined with persistent diphtheria transmission, raised concerns regarding the adequacy of long-term protection. In response, a fourth booster dose of DTP (DTP4) was gradually introduced into the national immunization schedule and more systematically implemented prior to the Riskesdas 2018 survey.

Globally, the coverage of three dosages of DTP vaccination in recent years has decreased from 86% in the 2015–2019 periods to 83% in 2020 and 81% in 2021. The Covid-19 pandemic that occurred in 2019–2021 has disrupted routine immunization services worldwide and has had an impact on decreasing immunization coverage [12]. A study conducted in 2023 during the pandemic in Jakarta, Indonesia, among school-aged children showed that only 40.9% of 154 children sampled received the primary DTP vaccination, first booster, and second booster. This finding indicated that complete diphtheria vaccination coverage remains low. Meanwhile, children who received the first and second booster doses had significantly higher anti-diphtheria antibody levels than those who did not receive the two booster doses. Therefore, booster vaccination in school-aged children is crucial for boosting immunity and minimizing the risk of diphtheria outbreaks [13]. The main objective of the 2030 immunization strategy is to expand immunization services to reach children who have not been immunized or whose immunization is incomplete, and to reduce the current inequality in immunization status [14]. While administrative coverage of routine childhood immunization is reported to be high, less is known about population-level immunity across age groups and how protection wanes over time in the post-scale-up period. In particular, evidence from nationally representative serological data remains limited.

The Ministry of Health, Republic of Indonesia (Kemenkes RI) delegated the National Institute of Health Research and Development to conduct a national basic health survey periodically every five years (well known as Riskesdas), starting in 2007, 2013 and 2018, and one of its objectives is to assess the health status of the community and the determinants that influence it. Serological testing for diphtheria was among the parameters evaluated, alongside those for pertussis, tetanus, hepatitis, and other vaccine-preventable diseases [15,16]. The Riskesdas data in 2007, 2013 and 2018 showed that more than half of the respondents in each survey period had complete DTwP vaccination. Accordingly, the three Riskesdas surveys analyzed in this study (2007, 2013, and 2018) represent distinct immunization and epidemiological contexts. Riskesdas 2007 reflects a period dominated by routine DTP3 vaccination, Riskesdas 2013 captures an intermediate phase prior to widespread DTP4 implementation, and Riskesdas 2018 reflects the combined effects of DTP4 introduction and recent ORI activities following the 2017 outbreak.

Most previous studies have relied on surveillance data or outbreak reports, which do not directly measure immunity at the population level. In contrast, this study leverages nationally representative serological data collected through multiple rounds of the Basic Health Research (Riskesdas) survey to characterize age-specific diphtheria antibody profiles over

time. In this study, further analysis of diphtheria serology data aims to obtain trends in children's immunity to diphtheria in Indonesia over a period of more than a decade, identify vulnerable groups and factors that influence protection for planning diphtheria outbreak prevention programs. To our knowledge, this is one of the few studies in the region to examine long-term trends in population immunity using repeated cross-sectional serosurveys.

## Materials and methods

### Study design

This study involves an in-depth analysis of the data obtained from the Basic Health Research (Riskesdas) survey conducted in all provinces of Indonesia, 2007, 2013 and 2018. A cross-sectional study design was employed to conduct Riskesdas which representation of population data on a national scale. In particular, the 2018 survey was conducted after the nationwide diphtheria outbreak in 2017 and subsequent ORI campaigns implemented across many provinces. As a result, serological findings from 2018 may reflect both routine immunization and outbreak-related vaccination activities. This study did not attempt to disentangle the individual effects of routine immunization, booster introduction, or ORI, but instead describes population-level immunity patterns resulting from their combined influence. All datasets were obtained at September 9<sup>th</sup> 2022 from the dataset management laboratory of the Health Development Policy Agency, Ministry of Health, Indonesia [15,16]. Dataset was obtained after submission of a research proposal detailed with the required variables, including the serology data linked to the public health dataset. Proposal was reviewed by internal reviewers. After being accepted, the access to raw dataset would be granted based on the necessity. The principal investigator of this research signed the data transfer agreement for not sharing any data to any third-party. Additionally, all related publications should acknowledge the particular institution. Authors did not have access to the information that can be linked to participants.

### Samples

The sampling frame was developed using calculations from the BPS-Statistics Indonesia using multistage sampling across the stages as seen in the Riskesdas national reports for the years 2007, 2013 and 2018 [17–19]. The results of structured interviews and measurements were then subjected to additional analysis using selected household and individual samples. The chosen samples, that were older than a year old, underwent blood sampling and serological testing. Especially for diphtheria antibody examination, it was conducted on child respondents aged 1–14 years in Riskesdas 2007, 2013 and 2018. Respondents represented urban and rural areas except respondents in Riskesdas 2007 only represented urban areas. The number of child respondents examined for diphtheria antibodies was 6,622 (Riskesdas 2007), 7,110 (Riskesdas 2013) and 7,203 (Riskesdas 2018). Among these numbers, there were toddler respondents (aged 1–4 years) as many as 1,536 (Riskesdas 2007), 568 (Riskesdas 2013) and 1,052 (Riskesdas 2018). Toddler respondents were analyzed separately regarding their DTP immunization status which was only asked to respondents aged 1–4 years.

### Diphtheria antibody test

Antibody examination for diphtheria was performed on serum collected using the Enzyme-Linked Immunosorbent Assay (ELISA) method, according to the protocol in the insert package. The examination kit used was Indec Diagnostics, Germany. The examination was carried out in the laboratory of the National Institute of Health Research and Development, Ministry of Health of the Republic of Indonesia. Antibody titer for diphtheria is expressed in IU/mL units, with the following interpretations; seronegative/ partial protection (titer <0.1 IU/mL); full protection (titer 0.1–1 IU/mL), long protection (titer >1 IU/mL) [4].

### Vaccination history assessment

Individual vaccination history was available only for children aged 1–4 years in the Riskesdas surveys. Vaccination status was ascertained using documented vaccination cards when available; in the absence of a record card, caregiver recall

was used, in accordance with standard Riskesdas procedures. Complete DTP immunization was defined as receipt of all age-appropriate DTP doses recommended under the national immunization schedule at the time of the survey. Children with missing or unverifiable vaccination history were excluded from analyses involving immunization status. The proportion of missing vaccination-history data is reported in the corresponding tables. Because individual-level vaccination data were not available or considered reliable for children older than four years old, analyses involving vaccination status were restricted to the 1–4 year age group. For older children (5–14 years), individual-level immunization data were not systematically documented, particularly for doses received under earlier routine schedules or through outbreak response immunization (ORI) campaigns; therefore, vaccination status for these age groups was not recorded.

### Operational definitions

The criteria for urban and rural residence were determined by the BPS-Statistics Indonesia when selecting the respondent sample. Multivariate models assessing determinants of diphtheria seroprotection included vaccination status only for the 1–4 year age group. For older age groups, analyses were limited to serological outcomes and demographic variables, without inclusion of individual vaccination history. Where relevant, the age-specific serological patterns in older children were compared with available programmatic immunization coverage data at the provincial or cohort level. These comparisons were treated as ecological in nature and interpreted cautiously.

Nutritional status was calculated based on the Body Mass Index (BMI)-for-age Z-score formulation with cut-points of: Malnutrition/ Severe wasted:  $\leq -3$ , Undernutrition/ Wasted:  $\leq 2.0$ , Normal:  $-2.0$ – $2.0$ , Overweight:  $> 2.0$ , Obese:  $> 3.0$  [20,21]. Children aged 1–4, BMI was calculated according to the WHO reference [21], while for children aged over 4 years, BMI was calculated using the CDC reference [20]. The results of this grouping are then grouped again into three large groups for analysis, namely (1) Undernutrition, which is a combination of undernutrition and severe malnutrition, where BMI z-score  $< -2.0$ , (2) Normal nutrition: where BMI z-score  $+2.0$  to  $-2.0$  and (3) Overnutrition: is a combination of overweight and obesity, where BMI z-score  $> +2.0$ . Meanwhile, the family's economic status is calculated based on expenditure quintiles and grouped into five groups, then grouped again into three categories, namely quintile 1–2 (poor), quintile 3–4 (middle) and quintile 5 (rich). Complete DTP immunization status in the analysis of Riskesdas 2007, 2013 and 2018 was defined as having received three doses of basic DTP immunization (DTP3) given at the age of 2–3–4 months. This immunization was given together with the hepatitis-B vaccine in the form of a DTP-HB combo vaccine (2011), which then replaced by the pentavalent DTP-HB-Hib vaccine in 2015. There are three degrees of maternal education: low for those who did not attend school, medium for those who attended elementary school through high school, and high for those who had a diploma-1 (D1) or were enrolled in college.

### Statistical analysis

The analysis was conducted on the samples of Riskesdas 2007, 2013 and 2018, namely children aged 1–14 years. The BPS-Statistics Indonesia determined the weight value of each data for survey analysis. Using univariate analysis, the proportion of participants such as sex, area of residence, age, nutritional status, family economic status, maternal education status, and toddler DTP immunization status, were identified. The age variable was divided into two categories (1–4 year old and 5–14 year old) based on the diphtheria immunization status data availability. Pearson's-chi-squared bivariate analysis was used to assess the relationship between respondent characteristics and other variables related to diphtheria antibody titers. Multivariate analysis was used to assess the relationship of the most significant ( $p < 0.05$ ) variables and conducted using binomial logistic regression to determine factors independently associated with the dependent variable. The analysis steps began with selecting variables included in the binomial multivariate analysis with  $p < 0.25$  in the bivariate analysis. Then, the analysis was conducted by removing variables above  $p > 0.05$  one by one. The results showed no interaction or confounding. The Hosmer–Lemeshow goodness-of-fit test and multicollinearity variance inflation factor (VIF) test demonstrated the suitability of the equation model. The final results are presented as an adjusted odds ratio (AOR)

with a 95% confidence interval (CI). The AOR value illustrates the strength of the association between the independent and dependent variables after controlling for other variables in the model. In this study, diphtheria antibody titers were divided into two categories: protective ( $\geq 0.1$  IU/mL) and negative/partial protective ( $< 0.1$  IU/mL). Stata software version 16 was used for statistical analysis.

### Data limitation

Data analysis was only conducted on variables available in Riskesdas 2007, 2013 and 2018 and data related to antibodies against diphtheria. Immunization status data was only available for respondents aged 1–4 years. Specifically, Riskesdas 2007 data was only available in urban areas. The total number of samples for variables analyzed using bivariate and multivariate methods differed according to the completeness of the available data. The DTP4 vaccination history and the information of diphtheria cases were unavailable.

### Ethical consideration

The request for raw data, de-identified data were obtained via email ([datin.bkpk@kemkes.go.id](mailto:datin.bkpk@kemkes.go.id)) from the Data and Information Center, Health Policy Agency, Ministry of Health, Indonesia (Kemenkes RI), the official data holder. The ethical clearance for this analysis study was obtained from Research Ethic Committee, Faculty of Medicine, Universitas Trisakti, Jakarta with registry number No. 164/KER/FK/VIII/2022.

### Results

Characteristics of respondents aged 1–14 years who participated in the Riskesdas 2007, 2013 and 2018, and were examined for antibody titers against diphtheria can be seen in [Table 1](#). In this study, the age range was divided into two; 1–4 and 5–14 years old based on the available immune status data in the Riskesdas database. The majority of respondents were in the 5–14 years age group for Riskesdas 2007, 2013 and 2018 (76.8%, 92.01% and 85.4% respectively). The proportion of respondents by sex was nearly equal. In Riskesdas 2007, all respondents lived in urban areas, while in Riskesdas 2013 there were more respondents living in rural areas, and vice versa in Riskesdas 2018. Associations between complete DTP immunization and diphtheria seroprotection are presented only for children aged 1–4 years, for whom individual vaccination history data were available. Most toddler respondents had complete basic immunization of DTP for Riskesdas 2007, 2013 and 2018 (67.1%, 74.6% and 78.3% respectively). Although there were still respondents with under nutrition status, most respondents had normal nutritional status for Riskesdas 2007, 2013 and 2018 (77.7%, 85.1% and 84.3% respectively). Based on family economic status, most respondents were at the poor to middle level (36.9% – 47.9%). The highest maternal education level was in the medium group for Riskesdas 2007, 2013 and 2018 (77.7%, 80.2% and 82.5% respectively).

[Fig 1](#) generally shows a similar pattern in the three periods of Riskesdas. The proportion of respondents who had protective diphtheria antibody titers was still quite low at the age of 1–6 years, then increased at the age of 7–10 years, and decreased back simultaneously—often with the increasing age. The respondents living in urban areas in the Riskesdas 2007 showed a fairly high proportion of non-protective titers ( $< 0.1$  IU/mL) at the age of 1–6 years (34.7% – 38.0%). Meanwhile, long-term protective diphtheria antibodies ( $> 1$  IU/mL) increased with age, especially in the 7–8 group (42.0%), with the highest geometric mean concentration (GMC) at the age of 7–8 years (0.54 IU/mL), then gradually decreased ([Fig 1](#)).

The proportion of non-protective titers in Riskesdas 2013 was found to be lower than that in Riskesdas 2007 (18.0% – 37.6%). Meanwhile, long-term protective diphtheria antibody remained stable, but not as high as in Riskesdas 2007 in older age groups. The GMC in Riskesdas 2013 was lower than that in Riskesdas 2007, where the highest GMC was in the 7–10 year group (0.36 IU/mL) with a drastic decrease in the 11–14 year age group ([Fig 1](#)).

The proportion of non-protective titers in Riskesdas 2018 was found to be lower than that in both Riskesdas 2007 and 2013, especially in the 7–14 age groups. Meanwhile, the long-term protective diphtheria antibody level was found to be

**Table 1. Distribution of the respondents aged 1-14 years old based on their characteristics.**

| Characteristics                   | Value            | *Riskesdas 2007      |       | Riskesdas 2013       |       | Riskesdas 2018       |      |
|-----------------------------------|------------------|----------------------|-------|----------------------|-------|----------------------|------|
|                                   |                  | <i>n</i> unweighting | %     | <i>n</i> unweighting | %     | <i>n</i> unweighting | %    |
| Age                               |                  | 6,622                |       | 7,110                |       | 7,203                |      |
|                                   | 1-4 y.o          |                      | 23.2  |                      | 7.99  |                      | 14.6 |
|                                   | 5-14 y.o         |                      | 76.8  |                      | 92.01 |                      | 85.4 |
| Sex                               |                  | 6,622                |       | 7,110                |       | 7,203                |      |
|                                   | Boy              |                      | 50.6  |                      | 48.4  |                      | 51.7 |
|                                   | Girl             |                      | 49.4  |                      | 51.6  |                      | 48.3 |
| Areas                             |                  | 6,622                |       | 7,110                |       | 7,203                |      |
|                                   | Urban            |                      | 100.0 |                      | 48.7  |                      | 66.5 |
|                                   | Rural            |                      |       |                      | 51.3  |                      | 33.5 |
| DTP Immunization Status (1–4 y.o) |                  | 1,486                |       | 485                  |       | 825                  |      |
|                                   | Complete         |                      | 67.1  |                      | 74.6  |                      | 78.3 |
|                                   | Incomplete       |                      | 32.9  |                      | 25.4  |                      | 21.7 |
| BMI Nutrition Status              |                  | 5,936                |       | 6,124                |       | 7,142                |      |
|                                   | Undernutrition   |                      | 14.0  |                      | 9.2   |                      | 7.3  |
|                                   | Normal nutrition |                      | 77.7  |                      | 85.1  |                      | 84.3 |
|                                   | Overnutrition    |                      | 8.3   |                      | 5.7   |                      | 8.3  |
| Family Economy Status             |                  | 6,622                |       | 7,110                |       | 6,195                |      |
|                                   | Poor             |                      | 47.9  |                      | 36.9  |                      | 45.8 |
|                                   | Middle           |                      | 38.2  |                      | 47.7  |                      | 36.9 |
|                                   | Rich             |                      | 13.9  |                      | 15.4  |                      | 17.3 |
| Maternal Education Level          |                  | 5,822                |       | 6,324                |       | 6,474                |      |
|                                   | Low              |                      | 15.7  |                      | 16.1  |                      | 11.6 |
|                                   | Medium           |                      | 77.7  |                      | 80.2  |                      | 82.5 |
|                                   | High             |                      | 6.6   |                      | 3.7   |                      | 5.9  |


Note \* Riskesdas 2007 was only conducted at urban areas.

<https://doi.org/10.1371/journal.pone.0343396.t001>

higher significantly, around two to three folds higher than those in Riskesdas 2007 and 2013, especially in the 7–12 age groups (59% – 69%). The highest GMC is at the age of 7–8 years (0.85 IU/mL) (Fig 1).

For respondents living in rural areas in Riskesdas 2013, most children have protective diphtheria antibody titers (0.1–1 IU/mL) (Fig 2). The proportion of children with non-protective titers (<0.1 IU/mL) is quite high at the age of 1–6 years (27%–37%) and increases again at the age of 11–14 years. Meanwhile, long-term protective diphtheria antibodies (>1 IU/mL) are relatively low in all age groups, with a high proportion in the age group of 7–10 years (30% – 40%). The GMC increases from the age of 7–8 years (0.36 IU/mL), then decreases slightly but remains quite stable until the age of 13–14 years (0.214 IU/mL). Meanwhile, the seroprotective diphtheria in urban and rural areas was found to be almost the same (Fig 2).

In Riskesdas 2018, the proportion of children with non-protective diphtheria antibody titers decreased, while the proportion of children with long-term protective diphtheria titers increased drastically, especially in the 7–10 year age group (about 53%). In addition, seroprotective diphtheria in urban areas was found to be higher than in rural areas. Protective diphtheria antibody titers increased linearly with age. The GMC titer is about two fold higher than that in Riskesdas 2013, especially in the 7–10 year age group (0.62–0.68 IU/mL). After the age of ten, the GMC began to decline but was still higher than that in Riskesdas 2013 (Fig 2).



**Fig 1. The trend of diphtheria titer in children aged 1-14 years, urban area on Riskesdas 2007, 2013 and 2018.** Antibody concentrations (IU/mL) and corresponding protection categories (seronegative/partial, full or long protection) are shown across age groups for each survey year. Stacked bars present the distribution of seronegative/partial protection, full protection, and long-term protection. Antibody titer for diphtheria is expressed in IU/mL units. The seronegative/partial protection titer is defined as <0.1 IU/mL. Full protection titer is defined as 0.1-1 IU/mL. And long protection titer is defined as >1 IU/mL). The solid line represents the geometric mean concentration (GMC, IU/mL) for each age group.


<https://doi.org/10.1371/journal.pone.0343396.g001>

Table 2 shows the results of the analysis to assess factors related to the status of diphtheria antibody protection in children aged 1–14 years in Indonesia. The percentage of protective diphtheria IgG antibodies is 71.1% (Riskesdas 2007), 72.6% (Riskesdas 2013), and 83.6% (Riskesdas 2018). These results indicate that around one-third of children in the 1–4 year age group were susceptible to diphtheria infection, with seronegative/partial protective diphtheria antibodies (diphtheria IgG <0.1 IU/mL), both in the data of Riskesdas 2007 (36.4%), 2013 (28.4%) and 2018 (27.4%).

In Riskesdas 2007 (Table 2A) bivariate analysis results found that age, gender, DTP immunization status, family socio-economic status, nutritional status, and maternal education level were significantly associated with protective diphtheria antibody status ( $p < 0.05$ ). Children aged 5–14 years were 2.74 times more likely to have significant protective diphtheria antibody status than children aged 1–4 years ( $POR = 2.74$ ;  $p = 0.000$ ). Boys also had significant higher of protective diphtheria antibody than girls ( $POR = 2.64$ ;  $p = 0.000$ ). In addition, children who received complete DTP immunization showed significant higher chance of protection compared to children with incomplete immunization ( $POR = 1.98$ ;  $p = 0.000$ ).

Family economic status also showed a significant relationship, where children from middle-class ( $POR = 2.67$ ;  $p = 0.000$ ) and rich ( $POR = 2.39$ ;  $p = 0.000$ ) families had significant higher protective diphtheria antibodies than children from poor families. Likewise, normal nutritional status ( $POR = 2.46$ ;  $p = 0.000$ ) and over nutrition ( $POR = 2.55$ ;  $p = 0.000$ ) had approximately 2.5 times the chance of having significant protective diphtheria antibodies compared to children with under nutrition nutritional status. Maternal education was also a significant factor, where children with highly educated mothers had a 2.42 times greater chance of having significant protective diphtheria antibodies than those with low-educated mothers ( $p = 0.000$ ).

However, after multivariate analysis, only two factors remained significant as independent predictors of protective diphtheria antibody status, namely complete DTP immunization status and maternal education status. Complete DTP immunization status ( $APOR = 1.46$ ; 95% CI: 1.10–2.00;  $p = 0.020$ ), showed that children who received complete immunization



**Fig 2. The trend of diphtheria titer in children aged 1-14 years, urban and rural area on Riskesdas 2013 and 2018.** Stacked bars show the distribution of seronegative/partial protection, full protection, and long-term protection across age groups and survey years by urban/rural strata.

<https://doi.org/10.1371/journal.pone.0343396.g002>

were 1.46 times more likely to have significant protective diphtheria antibody status compared to those who were incomplete. Furthermore, children from mothers with high education status (APOR=3.61; 95% CI: 1.50–8.68;  $p=0.004$ ), showed a significant increase in the protective diphtheria antibody compared to mothers with low education. While the economic status of middle class (APOR= 1.02,  $p=0.932$ ) and rich class (APOR=0.64,  $p=0.078$ ) do not seem to show significant results, yet in the statistical test, this variable cannot be removed from the multivariate analysis. These results indicate that the relationship between socioeconomic status and protective diphtheria antibody status can be explained by the existence of other variables, especially the completeness of DTP immunization, which has a direct and strong influence on the protective diphtheria antibody status.

In Riskesdas 2013 and 2018 (Table 2B and 2C), based on bivariate analysis, it was found that child age, sex, area, DTP immunization status, socioeconomic status, nutritional status, and maternal education level were factors that played a significant role ( $p<0.001$ ) on protective diphtheria antibody status. Children with complete DTP immunization status were 2.02 times (Riskesdas 2013, Adjusted POR=2.02; 95% CI: 1.09–3.74;  $p=0.027$ ) and 2.19 times (Riskesdas 2018, Adjusted POR=2.19; 95% CI: 1.33–3.60;  $p=0.002$ ) more likely to have significant protective diphtheria antibody status compared to children with incomplete immunization. Other factors such as age, gender, residence, socioeconomic status, nutritional status, and maternal education were no longer significant in the final model, indicating that their influence on diphtheria antibody seroprotective status was not independent, but rather through other pathways such as access to immunization. Only complete DTP immunization consistently remained a strong independent predictor across all three surveys.

## Discussion

Differences in sample sizes across the three Riskesdas periods were primarily attributable to the expansion of sampling areas within provinces. These variations were appropriately addressed by applying sampling weights in accordance

**Table 2. Bivariate and multivariate analysis of diphtheriae immunity based on characteristic in children aged 1-14 years on Riskesdas 2007, 2013 and 2018#.**

|   | <i>n</i>           |                      | Bivariate                                       |                           |      |          | Multivariate |                  |              |
|---|--------------------|----------------------|---|---------------------------|------|----------|--------------|------------------|--------------|
|   | <i>n</i> Weighting | <i>n</i> Unweighting | % Seronegative/ partial protective (<0.1 IU/mL) | % Protective (≥0.1 IU/mL) | POR  | <i>p</i> | APOR         | Lower-Upper      | <i>p</i>     |
| <b>A. Riskesdas 2007</b>                |                    |                      |   |                           |      |          |              |                  |              |
| <b>Age</b>                              |                    |                      |   |                           |      |          |              |                  |              |
| 1-4                                     | 364,351            | 1,230                | 36.4  | 63.6                      | ref  |          |              |                  |              |
| 5-14                                    | 1,236,593          | 4,372                | 26.7  | 73.3                      | 2.74 | 0.000    |              |                  |              |
| <b>Sex</b>                              |                    |                      |   |                           |      |          |              |                  |              |
| Female                                  | 790,044            | 2,721                | 30.5  | 69.5                      | ref  |          |              |                  |              |
| Male                                    | 810,899            | 2,881                | 27.4  | 72.6                      | 2.74 | 0.000    |              |                  |              |
| <b>Areas</b>                            |                    |                      |   |                           |      |          |              |                  |              |
| Urban                                   | 1,600,943          | 5,602                | 28.9  | 71.1                      |      |          |              |                  |              |
| Rural                                   |                    |                      |   |                           |      |          |              |                  |              |
| <b>DTP Immunization Status (1–4 yo)</b> |                    |                      |   |                           |      |          |              |                  |              |
| Complete                                | 245,120            | 870                  | 33.5  | 66.5                      | 1.98 | 0.000    | <b>1.46</b>  | <b>1.1-2.00</b>  | <b>0.020</b> |
| Incomplete                              | 119,230            | 360                  | 42.5  | 57.5                      | ref  |          |              |                  |              |
| <b>Family Economy Status</b>            |                    |                      |   |                           |      |          |              |                  |              |
| Poor                                    | 772,704            | 2,708                | 30.1  | 69.9                      | ref  |          |              |                  |              |
| Middle                                  | 612,974            | 2,129                | 27.3  | 72.7                      | 2.67 | 0.000    | 1.02         | 0.70-1.47        | 0.932        |
| Rich                                    | 215,265            | 765                  | 29.5  | 70.5                      | 2.39 | 0.000    | 0.64         | 0.39-1.05        | 0.078        |
| <b>BMI Nutritional Status</b>           |                    |                      |   |                           |      |          |              |                  |              |
| Undernutrition                          | 208,839            | 702                  | 32.0  | 68                        | ref  |          |              |                  |              |
| Normal nutrition                        | 1,126,797          | 3,936                | 28.9  | 71.1                      | 2.46 | 0.000    |              |                  |              |
| Overnutrition                           | 116,779            | 439                  | 28.2  | 71.8                      | 2.55 | 0.000    |              |                  |              |
| <b>Maternal Education level</b>         |                    |                      |   |                           |      |          |              |                  |              |
| Low                                     | 216,292            | 681                  | 32.3  | 67.7                      | ref  |          |              |                  |              |
| Medium                                  | 1,095,486          | 3,851                | 28.6  | 71.4                      | 2.50 | 0.000    | 1.38         | 0.78-2.46        | 0.266        |
| High                                    | 89,265             | 387                  | 29.3  | 70.8                      | 2.42 | 0.000    | <b>3.61</b>  | <b>1.50-8.68</b> | <b>0.004</b> |
| <b>B. Riskesdas 2013</b>                |                    |                      |   |                           |      |          |              |                  |              |
| <b>Age</b>                              |                    |                      |   |                           |      |          |              |                  |              |
| 1-4                                     | 229,958            | 568                  | 28.4  | 71.6                      | ref  |          |              |                  |              |
| 5-14                                    | 2,489,130          | 6,542                | 27.3  | 72.7                      | 2.67 | 0.000    |              |                  |              |
| <b>Sex</b>                              |                    |                      |   |                           |      |          |              |                  |              |
| Female                                  | 1,317,226          | 3,446                | 27.4  | 72.6                      | ref  |          |              |                  |              |
| Male                                    | 1,401,862          | 3,664                | 27.3  | 72.7                      | 2.66 | 0.000    |              |                  |              |
| <b>Areas</b>                            |                    |                      |   |                           |      |          |              |                  |              |
| Urban                                   | 1,324,241          | 2,940                | 27.9  | 72.1                      | ref  | 0.000    |              |                  |              |
| Rural                                   | 1,394,847          | 4,170                | 26.8  | 73.2                      | 2.73 |          |              |                  |              |
| <b>DTP Immunization Status (1–4 yo)</b> |                    |                      |   |                           |      |          |              |                  |              |
| Complete                                | 151,225            | 375                  | 24.1  | 75.9                      | 3.15 | 0.000    | <b>2.02</b>  | <b>1.09-3.74</b> | <b>0.027</b> |
| Incomplete                              | 51,408             | 110                  | 39.1  | 60.9                      | ref  |          |              |                  |              |
| <b>Family Economy Status</b>            |                    |                      |   |                           |      |          |              |                  |              |
| Poor                                    | 1,003,564          | 2,980                | 30.6  | 69.4                      | ref  |          |              |                  |              |
| Middle                                  | 1,296,652          | 3,061                | 25.7  | 74.3                      | 2.89 | 0.000    |              |                  |              |
| Rich                                    | 418,872            | 1,069                | 24.8  | 75.2                      | 3.02 | 0.000    |              |                  |              |

(Continued)

Table 2. (Continued)

|   | n           |               | Bivariate                                       |                           |      |       | Multivariate |                  |              |
|---|-------------|---------------|---|---------------------------|------|-------|--------------|------------------|--------------|
|   | n Weighting | n Unweighting | % Seronegative/ partial protective (<0.1 IU/mL) | % Protective (≥0.1 IU/mL) | POR  | p     | APOR         | Lower-Upper      | p            |
| <b>BMI Nutritional Status</b>           |             |               |   |                           |      |       |              |                  |              |
| Undernutrition                          | 214,351     | 640           | 26.6  | 73.4                      | ref  |       |              |                  |              |
| Normal nutrition                        | 1,984,818   | 5,138         | 26.7  | 73.3                      | 2.74 | 0.000 |              |                  |              |
| Overnutrition                           | 133,776     | 346           | 19.3  | 80.7                      | 4.17 | 0.000 |              |                  |              |
| <b>Maternal Education level</b>         |             |               |   |                           |      |       |              |                  |              |
| Low                                     | 394,893     | 1,153         | 26.9  | 73.1                      | ref  |       |              |                  |              |
| Medium                                  | 1,966,464   | 4,916         | 27.6  | 72.4                      | 2.27 | 0.000 |              |                  |              |
| High                                    | 90,822      | 255           | 21.2  | 78.8                      | 3.03 | 0.000 |              |                  |              |
| <b>C. Riskesdas 2018</b>                |             |               |   |                           |      |       |              |                  |              |
| <b>Age</b>                              |             |               |   |                           |      |       |              |                  |              |
| 1-4                                     | 590,061     | 991           | 27.4  | 72.6                      | ref  |       |              |                  |              |
| 5-14                                    | 3,461,039   | 6,207         | 14.6  | 85.4                      | 5.86 | 0.000 |              |                  |              |
| <b>Sex</b>                              |             |               |   |                           |      |       |              |                  |              |
| Female                                  | 1,958,156   | 3,386         | 16.2  | 83.8                      | ref  |       |              |                  |              |
| Male                                    | 2,092,944   | 3,812         | 16.7  | 83.3                      | 4.99 | 0.000 |              |                  |              |
| <b>Areas</b>                            |             |               |   |                           |      |       |              |                  |              |
| Urban                                   | 2,696,317   | 3,752         | 15.7  | 84.3                      | ref  |       |              |                  |              |
| Rural                                   | 1,354,783   | 3,446         | 17.9  | 82.1                      | 4.59 | 0.000 |              |                  |              |
| <b>DTP Immunization Status (1–4 yo)</b> |             |               |   |                           |      |       |              |                  |              |
| Complete                                | 385,919     | 657           | 21.4  | 78.6                      | 3.68 | 0.000 | 2.19         | <b>1.33-3.60</b> | <b>0.002</b> |
| Incomplete                              | 107,222     | 167           | 35.3  | 64.7                      | ref  |       |              |                  |              |
| <b>Family Economy Status</b>            |             |               |   |                           |      |       |              |                  |              |
| Poor                                    | 1,585,208   | 3,010         | 19.4  | 80.6                      | ref  |       |              |                  |              |
| Middle                                  | 1,276,772   | 2,261         | 15.2  | 84.8                      | 5.59 | 0.000 | 1.76         | <b>1.06-2.93</b> | <b>0.028</b> |
| Rich                                    | 600,335     | 919           | 12.8  | 87.2                      | 6.8  | 0.000 | 1.26         | 0.66-2.39        | 0.479        |
| <b>BMI Nutritional Status</b>           |             |               |   |                           |      |       |              |                  |              |
| Undernutrition                          | 295,107     | 543           | 16.1  | 83.9                      | ref  |       |              |                  |              |
| Normal nutrition                        | 3,389,695   | 6,012         | 16.6  | 83.4                      | 5.03 | 0.000 |              |                  |              |
| Overnutrition                           | 334,438     | 582           | 15.6  | 84.4                      | 5.41 | 0.000 |              |                  |              |
| <b>Maternal Education level</b>         |             |               |   |                           |      |       |              |                  |              |
| Low                                     | 427,220     | 795           | 20.6  | 79.4                      | ref  |       |              |                  |              |
| Medium                                  | 3,045,551   | 5,268         | 16.0  | 84                        | 5.25 | 0.000 |              |                  |              |
| High                                    | 216,953     | 407           | 13.4  | 86.6                      | 6.46 | 0.000 |              |                  |              |

Note: #Multiple Regression Logistic Analysis, POR: Prevalence Odds Ratio, APOR: Adjusted Prevalence Odds Ratio.

<https://doi.org/10.1371/journal.pone.0343396.t002>

with the national survey design. As a result, the analyses preserve population representativeness, allowing valid inferences regarding immunization coverage and serological protection among the Indonesian child population across survey years. Based on further data analysis Riskesdas 2007, 2013 and 2018 the proportion of non-protective diphtheria IgG titers (<0.1 IU/mL) is quite high at the age of 1–6 years, possibly because there were still around 25–30% of toddlers who had not received complete diphtheria immunization (Table 1, Figs 1 and 2). These results are similar to research conducted by Le et al on the population in Vietnam, namely around 31.7% of children aged 0–5 years are susceptible to diphtheria [22].

During the data collection of Riskesdas 2007, 2013 and 2018, national immunization program for diphtheria in Indonesia was given to infants aged 2, 3 and 4 months as basic immunization. Furthermore, booster or follow-up immunization was given to children aged 18 months and elementary school students in the first, second and fifth grades [13]. For infants and children aged 18 months, the diphtheria vaccine was given in the form of a DTP-HB-Hib, diphtheria vaccine prepared together with tetanus, pertussis, hepatitis B, and *Haemophilus influenzae* type-B (Hib) vaccines. Meanwhile, for elementary school students, the diphtheria vaccine was given in the form of a DT vaccine preparation for elementary school students in the first grade, and the Td vaccine with a lower diphtheria toxoid concentration to avoid increased reactogenicity in the fourth and fifth doses was given to elementary school students in the second and fifth grades [23–25]. Therefore, in line with the national immunization program of diphtheria booster vaccination for elementary school students, according to Riskeddas data, the diphtheria IgG antibody titer had increased again and was highest at the age of 7–10 years (Figs 1 and 2). However, after reaching the age of ten years old, there was a decrease in the titer of diphtheria IgG antibody. Meanwhile, the most vulnerable age group (with non-protective diphtheria IgG titer) is 5–6 years old (Figs 1 and 2) in all three periods of Riskesdas. Previous study reported by Yusoff *et al* (2021) on the population in Malaysia with a sample size of 3,317 respondents also showed the same results, where children aged 5–6 years were most susceptible to diphtheria infection [26]. These results suggest that diphtheria vaccination boosters should be considered for both 5–6 years old of age and adolescents.

Diphtheria seroprotection in Riskesdas 2007, 2013 and 2018 ranged from 71.1%–83.6%, consisting of full protection and long protection. Long-term protection is defined as an antibody concentration  $\geq 1$  IU/mL [4]. Previous study showed that five years post-vaccination the antibodies started to wane slightly, but still remained higher than pre-vaccination [27]. The percentage of diphtheria long-term protective antibody in Riskesdas 2018 is found to be two to three fold higher than those in Riskesdas 2007 and 2013, in both urban and rural areas (2018 compared to 2013) (Figs 1 and 2). This is likely due to the diphtheria outbreak resulting in an increase in the immune response due to exposure to natural toxigenic *C. diphtheriae* infection and the additional diphtheria immunization program. During 2017, there was a diphtheria outbreak in 170 districts/cities from 30 provinces with 954 cases and 44 deaths, continuing until 2018. So that in December 2017–2018 through the outbreak response immunization (ORI) program, diphtheria vaccination was carried out targeting children aged 1–19 years. Diphtheria vaccine was given in the form of DTP-HB-Hib preparations for children aged 1–5 years, DT vaccine for children aged 5–7 years and Td vaccine for children aged over seven years. ORI aimed to increase community immunity so that it can break the chain of transmission. ORI diphtheria was implemented in three rounds, where the first round was implemented in 12 districts/cities in three provinces, namely DKI Jakarta, Banten and West Java, with an average coverage of 68.36% with a total target of 7.9 million. Furthermore, it was gradually implemented in 11 other provinces with the criteria of districts/cities that still have new case reports, which often report diphtheria outbreaks during 2017, which have diphtheria deaths, which have low routine immunization coverage <90% [24]. This result is also in accordance with the research conducted by Hughes *et al*, which showed that although DTP immunization coverage was higher in districts with low diphtheria incidence, immunity was significantly lower compared to districts with high diphtheria incidence. The higher levels of seroprotection observed in 2018 likely reflect the combined effects of routine immunization, booster dose implementation, and emergency vaccination responses, rather than survey year effects alone. Accordingly, DTP4 introduction and ORI activities are best regarded as plausible contributors to improved population-level immunity. Given the cross-sectional nature of the data, causal attribution to specific interventions is not possible, and observed patterns should be interpreted as descriptive of cumulative programmatic impact. High immunity in districts with high incidence is most likely due to natural immunity obtained through exposure to toxigenic *C. diphtheriae* infection and receiving a diphtheria vaccination booster [28].

Bivariate analysis of Riskesdas 2007, 2013 and 2018 data showed several factors that influence diphtheria seroprotection in children in Indonesia, such as age, gender, immunization status, family economic status, nutritional status and maternal education level (Table 2). However, multivariate analysis in the three Riskesdas periods showed that complete

DTP immunization status in children aged 1–4 years was a factor that significantly influenced (Riskesdas 2007:  $p=0.020$ , Riskesdas 2013:  $p=0.027$ , Riskesdas 2018:  $p=0.002$ ) diphtheria seroprotection.

Factors influencing the completeness of immunization status in children aged under five years include maternal education level. Mothers with higher educational levels are often associated with a better understanding of child health, including the importance of immunization. In addition, older maternal age is also a contributing factor, as it is associated with a greater ability to make independent decisions. Furthermore, the presence of professional midwives during childbirth, who provided antenatal and perinatal services, including immunization, also played a significant role [29–32]. Accessibility of healthcare facilities, such as Puskesmas (primary healthcare) or Posyandu (integrated health posts), were also reported to play a crucial role in increasing immunization coverage [33,34]. Adequate vaccine availability at healthcare facilities, along with friendly and informative healthcare workers who foster maternal trust in immunization programs, were also found as important factors contributing to increased immunization coverage [35–38].

In children who have completed the DTP3 immunization series, the highest GMC of diphtheria IgG antibodies was observed in one year old, with seroprotective proportions of 77% (Riskesdas 2007) and 81.37% (Riskesdas 2013). These proportions declined with age, reaching 67.69% (Riskesdas 2007) and 60.88% (Riskesdas 2013) by four years of age (S1 Table). However, data from Riskesdas 2018 indicated a slightly different trend: while seroprotective proportion of diphtheria was high in one year old (82.8%), it peaked at two years of age (89.75%) before declining to 72.94% by four years of age (S1 Table). Riskesdas 2013 data showed a decrease of IgG diphtheria titer (GMC 0.33 IU/mL to 0.18 IU/mL – S1 Table). Meanwhile, Riskesdas 2018 data showed an increase of IgG diphtheria in children aged 1–2 years old (GMC 0.48 IU/mL to 0.77 IU/mL – S1 Table). The rise in GMC levels observed in 2018 should be interpreted in the context of overlapping immunization activities. Although the introduction of DTP4 represents a programmatic strengthening of the routine vaccination schedule, the extensive ORI campaigns conducted during the 2017–2018 national diphtheria outbreak may also have contributed to the enhanced antibody response. Similar to findings from previous outbreak response evaluations, supplemental booster doses delivered through ORI are known to elevate population-level immunity, particularly in older children and adolescents who may have waning protection [39,40]. Given that vaccination data did not allow us to differentiate between doses obtained through routine services versus ORI, the relative contribution of DTP4 alone cannot be fully disentangled. Therefore, the 2018 GMC increase is best interpreted as the cumulative effect of both routine schedule enhancement and intensified outbreak response measures. Nonetheless, immunity appears to decrease again after two years of age.

We acknowledge that observed patterns of declining diphtheria antibody levels with age are consistent with waning immunity post-vaccination, as documented in multiple seroepidemiological studies across different settings. Systematic reviews of DTP-containing vaccines have demonstrated measurable declines in post-vaccination immunity for diphtheria over time, highlighting the potential need for booster doses to maintain protection beyond early childhood [41]. Age-stratified serosurveys in other populations reveal similar decreases in protective antibody titers in older children and adults in the absence of recent boosting, suggesting that immunity gaps may persist despite high routine coverage [26]. While these cross-sectional findings support consideration of booster strategies, definitive conclusions regarding optimal booster timing and causal programmatic effects require longitudinal cohort studies, program evaluations, or formal transmission and immunity modeling that explicitly account for waning dynamics and vaccination history [40]. These findings suggest that completing the diphtheria immunization series significantly enhances children's immunity against diphtheria, but this immunity wanes over time.

Immunization that is given completely according to the recommended dose can trigger an optimal adaptive immune response so that it can form long-term immunity. Although high maternal antibodies in newborns can cause low antibody titers after two doses of diphtheria immunization, after completing three doses of primary immunization, most infants have protective antibodies and as many as 94–100% of children have minimal seroprotection (titer  $>0.01$  IU/mL) [42]. These results confirm that complete basic immunization coverage according to the immunization schedule is very important.

Meanwhile, data from the three periods of Riskesdas indicated that the coverage of complete basic immunization remains below 80% (Table 1), thereby underscoring the need to intensify efforts to increase the coverage of both the third (DTP3) and fourth (DTP4) doses of the diphtheria vaccine. By maintaining national immunization coverage above 80%, herd immunity or immunity in the community is expected to be achieved so that the threat of outbreaks in the future can be reduced [43]. A meta-analysis of 266 articles on diphtheria and 55 articles on diphtheria outbreaks showed that three doses of diphtheria toxoids were effective in preventing symptomatic disease by 87% and reducing transmission by 60%. However, vaccination alone is certainly not enough and needs to be accompanied by active surveillance and appropriate antibiotic treatment [44].

The apparent discrepancy between the IDAI recommendation and the school-based immunization program warrants clarification. According to IDAI, the second DTP booster is recommended at approximately five years of age, before school entry, to sustain immunity against all three antigens [10]. However, under Indonesia's national school-based immunization program (Bulan Imunisasi Anak Sekolah, BIAS), children in Grade 1 of elementary school typically receive a DT (diphtheria–tetanus) vaccine, which omits the pertussis component. This difference arises from operational and logistical adaptations in the national immunization schedule, rather than from conflicting policy guidance. Consequently, references of our study to school-based boosters should be understood as reflecting the implementation of the DT vaccine preparation under the BIAS program, while the IDAI recommendation pertains to the broader pediatric vaccination guidance.

National evidence showed that closing the gap in vaccination coverage had proven to be more effective and cost-effective than controlling the outbreak itself, as was the case with the diphtheria outbreaks in East and West Java in 2017 and 2023 respectively [39,45]. In Riskesdas 2007, in addition to immunization status, low maternal education level was also an influential factor (APOR = 3.61,  $p = 0.004$ ) on diphtheria seroprotection compared to higher education. Maternal education plays an important role in improving health knowledge, attitudes, and practices, including compliance with the child immunization schedule. Mothers with higher education better understand the importance of immunization and its schedule. Education is also often associated with the ability to access valid health information and better use of health services. Many studies have shown that maternal education is significantly related to the completeness or incompleteness of children's basic immunization, which has an impact on increasing immunization coverage and the resulting immunity [46,47].

In Riskesdas 2018, seroprotection was also significantly associated with household economic status, with individuals from poor households showing different odds of seroprotection compared with those from middle-income households (APOR = 1.76;  $p = 0.028$ ). From a social determinants of health perspective, socioeconomic status influences health outcomes through access to key intermediary factors, including education, healthcare services, and adequate nutrition. However, in the context of immunological protection, immunization completeness appears to be a more proximal and dominant intermediary determinant. Household economic status is closely linked to complete versus incomplete immunization, which in turn affects overall immunization coverage and levels of seroprotection. This relationship is supported by studies from Afghanistan and India, which reported that children from wealthier households had a 36% higher likelihood of receiving complete immunization compared with children from the poorest households, even after adjustment for potential confounders [48,49].

This study is based on available secondary data, which might lack specificity about the brand, lot consistency and exact formulation type of the vaccine [50]. Additionally, there was little information available regarding the circumstances in which vaccinations were given, such as whether they took place just in public health centers or also in private medical facilities which limits this study scope. Our capacity to evaluate possible variations in vaccination quality, handling, and administration procedures is hampered by the lack of these specifics. Secondarily, the observed variations in seroprotection levels could have been caused by regional variations in the types of diphtheria-tetanus-pertussis (DTP) vaccinations used. For instance, a higher prevalence of acellular pertussis (DPaT) vaccine usage in private healthcare settings, as opposed to whole-cell pertussis (DPwT) vaccinations more frequently used in public immunization programs, may be the

reason for lower seroprotection rates seen in certain urban area. These variations in vaccine formulation and cold chain are known to affect profiles of immunogenicity, which might complicate the comparisons [51,52].

The limitation of this study is that individual-level immunization history was available only for children aged 1–4 years. As a result, findings related to complete DTP immunization cannot be directly extrapolated to older age groups. Interpretations for these age groups are therefore based on observed age-specific serological patterns rather than confirmed individual vaccination histories. Observed serological patterns among older children likely reflect cumulative programmatic effects and waning immunity, and any comparisons with immunization coverage data at broader levels should be interpreted as ecological. Additionally, Riskesdas 2007 included only urban respondents, which may reduce comparability with later surveys and introduce urban–rural bias when interpreting changes over time. These limitations should be considered when generalizing the findings, and future studies incorporating detailed vaccine registry data, heterologous immunity between DTP and Covid-19 vaccines and mixed-methods assessments of immunization practices are warranted to better elucidate the determinants of diphtheria seroprotection.

## Conclusions

Using nationally representative Riskesdas data from 2007, 2013, and 2018, this study identifies persistent immunity gaps against diphtheria in Indonesia, with a high proportion of children aged 1–6 years lacking protective antibody levels and a marked decline in diphtheria IgG titers after 10 years of age. Although population-level seroprotection improved in 2018 following the introduction of the DTP4 booster and ORI activities, immunity remains suboptimal. Across all survey years, complete DTP immunization consistently emerged as the strongest independent determinant of diphtheria seroprotection, highlighting the central role of achieving and sustaining complete routine immunization coverage. These findings underscore the need to strengthen routine DTP delivery and to optimize booster dose strategies, including consideration of earlier and adolescent boosters, to mitigate waning immunity and prevent recurrent diphtheria outbreaks.

## Supporting information

**S1 Table. Diphtheria immunity status in children aged 1–4 years old with complete DTP vaccination status in the Riskesdas 2007, 2013 and 2018.**

(DOCX)

## Acknowledgments

We gratefully acknowledge the Head of the Health Development Policy Agency, the Ministry of Health of the Republic of Indonesia (Kemenkes RI), as well as the data management laboratory team, for granting access to and permission to use the datasets of Riskesdas 2007, 2013 and 2018. We also thank all members of the research teams—particularly those from the Health Research and Development Agency, Ministry of Health—who were involved in data collection, laboratory analyses, and data management for the three periods of Riskesdas.

## Author contributions

**Conceptualization:** Monica Dwi Hartanti, Christina Safira Whinie Lestari, Novaria Sari Dewi Panjaitan, Armedy Ronny Hasugian, Sunarno Sunarno.

**Data curation:** Monica Dwi Hartanti, Christina Safira Whinie Lestari, Novaria Sari Dewi Panjaitan, Armedy Ronny Hasugian, Sunarno Sunarno.

**Formal analysis:** Monica Dwi Hartanti, Christina Safira Whinie Lestari, Novaria Sari Dewi Panjaitan, Armedy Ronny Hasugian, Rita Marleta Dewi, Sarwo Handayani, Masri Sembiring Maha, Sunarno Sunarno.

**Investigation:** Monica Dwi Hartanti, Christina Safira Whinie Lestari, Novaria Sari Dewi Panjaitan, Armedy Ronny Hasugian, Sunarno Sunarno.

**Methodology:** Monica Dwi Hartanti, Christina Safira Whinie Lestari, Novaria Sari Dewi Panjaitan, Armedy Ronny Hasugian, Sunarno Sunarno.

**Validation:** Monica Dwi Hartanti, Christina Safira Whinie Lestari, Novaria Sari Dewi Panjaitan, Armedy Ronny Hasugian, Sarwo Handayani, Masri Sembiring Maha, Tubagus Ferdi Fadilah, Firda Fairuza, Nathalia Ningrum, Meiriani Sari, Dita Setiati, Nia Nurul Aziza, Donna Adriani, Jihan Samira, Sunarno Sunarno.

**Visualization:** Monica Dwi Hartanti, Christina Safira Whinie Lestari, Novaria Sari Dewi Panjaitan, Armedy Ronny Hasugian, Rita Marleta Dewi, Sarwo Handayani, Masri Sembiring Maha, Arleen Devita, Sunarno Sunarno.

**Writing – original draft:** Monica Dwi Hartanti, Christina Safira Whinie Lestari, Novaria Sari Dewi Panjaitan, Armedy Ronny Hasugian, Rita Marleta Dewi, Sarwo Handayani, Masri Sembiring Maha, Sunarno Sunarno.

**Writing – review & editing:** Monica Dwi Hartanti, Christina Safira Whinie Lestari, Novaria Sari Dewi Panjaitan, Armedy Ronny Hasugian, Rita Marleta Dewi, Sarwo Handayani, Masri Sembiring Maha, Tubagus Ferdi Fadilah, Firda Fairuza, Nathalia Ningrum, Meiriani Sari, Dita Setiati, Nia Nurul Aziza, Arleen Devita, Donna Adriani, Jihan Samira, Sunarno Sunarno.

## References

1. PAHO. Diphtheria. <https://www.paho.org/en/topics/diphtheria#:~:text=Diphtheria is fatal in 5,mortality rate in young children>
2. Sharma NC, Efstratiou A, Mokrousov I, Mutreja A, Das B, Ramamurthy T. Diphtheria. *Nat Rev Dis Primers*. 2019;5(1):81. <https://doi.org/10.1038/s41572-019-0131-y> PMID: 31804499
3. Sunarno S, Puspendari N, Sariadji K, Febriyana D, Febrianti T, Saraswati RD, et al. Microbiological and Clinical Aspects of Diphtheria-Confirmed Cases from Capital City of Indonesia, Jakarta, and Surrounding Areas in 2017. *Jundishapur J Microbiol*. 2021;14(8). <https://doi.org/10.5812/jjm.118751>
4. World Health Organization. WHO laboratory manual for the diagnosis of diphtheria and other related infections. 2021. <https://apps.who.int/iris/handle/10665/352275>
5. Dwi Hartanti M, Sari Dewi Panjaitan N, Hidayat S, Fitriana F, Sunarno S, Susanty S. Diphtheria Incidence is a Public Health Challenge in Low- and Middle-Income Countries (LMICs). *Public Health of Indonesia*. 2025;11(2):71–80. <https://doi.org/10.36685/phi.v11i2.953>
6. World Health Organization. Diphtheria reported cases and incidence. <https://immunizationdata.who.int/global/wiise-detail-page/diphtheria-reported-cases-and-incidence?CODE=Global&YEAR=>
7. Fardani SA, Wahyono TYM. Distribusi Kasus Difteri, Riwayat Imunisasi Difteri, Tingkat Keparahan Gejala dan Risiko Kematian pada Penderita Difteri di Indonesia Tahun 2020 – 2022. *J Epidemiol Kesehat Indones*. 2023;7(2):77. <https://doi.org/10.7454/epidkes.v7i2.1081>
8. Clarke KEN, MacNeil A, Hadler S, Scott C, Tiwari TSP, Cherian T. Global Epidemiology of Diphtheria, 2000–2017. *Emerg Infect Dis*. 2019;25(10):1834–42. <https://doi.org/10.3201/eid2510.190271> PMID: 31538559
9. World Health Organization. Immunization, Vaccines and Biologicals. [https://www.who.int/teams/immunization-vaccines-and-biologicals/diseases/diphtheria#:~:text=WHO\\_recommends\\_a\\_3-dose,of\\_4\\_weeks\\_between\\_doses](https://www.who.int/teams/immunization-vaccines-and-biologicals/diseases/diphtheria#:~:text=WHO_recommends_a_3-dose,of_4_weeks_between_doses)
10. Indonesian Pediatric Society (IDAI). Jadwal Imunisasi Anak Usia 0-18 Tahun, Rekomendasi Ikatan Dokter Anak Indonesia Tahun 2024. <https://www.idai.or.id/news-event/agenda-nasional/others/6798>
11. Sitaremi MN, Soedjatmiko S, Gunardi H, Kaswandani N, Handryastuti S, Raihan R, et al. Jadwal Imunisasi Anak Usia 0 – 18 Tahun Rekomendasi Ikatan Dokter Anak Indonesia Tahun 2023. *SP*. 2023;25(1):64. <https://doi.org/10.14238/sp25.1.2023.64-74>
12. Rachlin A, Danovaro-Holliday MC, Murphy P, Sodha SV, Wallace AS. Routine Vaccination Coverage - Worldwide, 2021. *MMWR Morb Mortal Wkly Rep*. 2022;71(44):1396–400. <https://doi.org/10.15585/mmwr.mm7144a2> PMID: 36327156
13. Santi T, Prayitno A, Munasir Z, Hadinegoro SRS, Harahap AR, Werdhani RA, et al. Evaluation of anti-diphtheria toxoid antibody persistence in school-age children in Jakarta, Indonesia. *PI*. 2024;64(5):447–53. <https://doi.org/10.14238/pi64.5.2024.447-53>
14. World Health Organization. Immunization agenda 2030. A global strategy to leave no one behind. 2022. <https://www.who.int/teams/immunization-vaccines-and-biologicals/strategies/ia2030>
15. Hartanti MD, Panjaitan NSD, Sunarno S, Ningrum N, Hasugian AR, Dewi RM, et al. Seroprevalence of Bordetella pertussis infection in children 1-14 years old: Indonesia basic health research (Riskesdas) 2013 and 2018 data. *PLoS One*. 2024;19(9):e0311362. <https://doi.org/10.1371/journal.pone.0311362> PMID: 39348411

16. Lestari CSW, Dewi RM, Sunarno S, Hasugian AR, Handayani S, Maha MS, et al. The effectiveness of hepatitis B vaccine in toddlers based on the five-year period national basic health research (Riskesdas 2007, 2013 and 2018) in Indonesia. *PeerJ*. 2023;11:e15199. <https://doi.org/10.7717/peerj.15199> PMID: 37214093
17. Kementerian Kesehatan RI. Laporan riset kesehatan dasar 2007. 2008. <https://repository.badankebijakan.kemkes.go.id/id/eprint/4378/1/Laporan%20Riset%20Kesehatan%20Dasar%20Nasiona%3B%202007.pdf>
18. Kementerian Kesehatan RI. Riset Kesehatan Dasar 2013. 2013. [https://repository.badankebijakan.kemkes.go.id/id/eprint/4467/1/Laporan\\_riskesdas\\_2013\\_final.pdf](https://repository.badankebijakan.kemkes.go.id/id/eprint/4467/1/Laporan_riskesdas_2013_final.pdf)
19. Kementerian Kesehatan RI. Laporan Nasional Riskesdas 2018. 2018. <https://repository.badankebijakan.kemkes.go.id/id/eprint/3514/1/Laporan%20Riskesdas%202018%20Nasional.pdf>
20. Centers for Disease Control and Prevention CDC. Child and Teen BMI Calculator. 2024. <https://www.cdc.gov/bmi/child-teen-calculator/index.html>
21. WHO. Child growth standards. <https://www.who.int/toolkits/child-growth-standards/standards/body-mass-index-for-age-bmi-for-age>
22. Le TV, Nguyen VTT, Nguyen QH, Nguyen TTT, Duong TTN, Ly TTT, et al. The evaluation of anti-diphtheria toxoid antibodies in healthy population in Kon Tum, Vietnam: a population-based study. *IJID Reg*. 2022;3:171–6. <https://doi.org/10.1016/j.ijregi.2022.03.019> PMID: 35755469
23. Kementerian Kesehatan RI. Peraturan Menteri Kesehatan Republik Indonesia Nomor 42 Tahun 2013 Tentang Penyelenggaraan Imunisasi. 2013. <https://id.scribd.com/doc/215861710/PMK-No-42-ttg-Penyelenggaraan-Imunisasi-pdf>
24. Kementerian Kesehatan Republik Indonesia. Peraturan Menteri Kesehatan Republik Indonesia Nomor 12 Tahun 2017 Tentang Penyelenggaraan Imunisasi. 2017. <https://peraturan.go.id/files/bn559-2017.pdf>
25. Rengganis I. Adult Diphtheria Vaccination. *Acta Med Indones*. 2018;50(3):268–72. PMID: 30333279
26. Yusoff AF, Mohd Sharani ZZ, Kee CC, Md Iderus NH, Md Zamri ASS, Nagalingam T, et al. Seroprevalence of diphtheria toxoid IgG antibodies in the Malaysian population. *BMC Infect Dis*. 2021;21(1):581. <https://doi.org/10.1186/s12879-021-06285-3> PMID: 34134646
27. Le TV, Nguyen VTT, Nguyen QH, Tran HLT, Tran SD, Vien CC. The evaluation of anti-diphtheria toxoid antibodies after 5 years with the primary Tetanus-Diphtheria vaccine in persons aged 6-25 years in Kon Tum, Vietnam: a follow-up study. *J Infect Dev Ctries*. 2025;19(1):22–7. <https://doi.org/10.3855/jidc.19390> PMID: 39977457
28. Hughes GJ, Mikhail AFW, Husada D, Irawan E, Kafatos G, Bracebridge S, et al. Seroprevalence and Determinants of Immunity to Diphtheria for Children Living in Two Districts of Contrasting Incidence During an Outbreak in East Java, Indonesia. *Pediatr Infect Dis J*. 2015;34(11):1152–6. <https://doi.org/10.1097/INF.0000000000000846> PMID: 26226444
29. Matthew Ayodele A, Fasasi MI, Rejoice Uche O, Gideon Ikemdinachi N, Henry Ugochukwu U. Factors associated with full childhood vaccination coverage among young mothers in Northern Nigeria. *Pan Afr Med J*. 2024;47:4. <https://doi.org/10.11604/pamj.2024.47.4.37517> PMID: 38371647
30. Ariyibi S, Ojuawo A, Ibraheem R, Afolayan F, Ariyibi R, Akanbi P. Factors influencing routine vaccination uptake and completion among children aged 12–23 months in Ilorin, North-Central Nigeria: A cross-sectional survey. *Int J Med Health Dev*. 2023;28(4):314. [https://doi.org/10.4103/ijmh.ijmh\\_20\\_23](https://doi.org/10.4103/ijmh.ijmh_20_23)
31. Holipah, Maharani A, Kuroda Y. Determinants of immunization status among 12- to 23-month-old children in Indonesia (2008-2013): a multilevel analysis. *BMC Public Health*. 2018;18(1):288. <https://doi.org/10.1186/s12889-018-5193-3> PMID: 29482562
32. Setiawan MS, Wijayanto AW. Determinants of immunization status of children under two years old in Sumatera, Indonesia: A multilevel analysis of the 2020 Indonesia National Socio-Economic Survey. *Vaccine*. 2022;40(12):1821–8. <https://doi.org/10.1016/j.vaccine.2022.02.010> PMID: 35153089
33. Cintyamina U, Azizatunnisa' L, Ahmad RA, Mahendradhata Y. Scaling up public health interventions: case study of the polio immunization program in Indonesia. *BMC Public Health*. 2021;21(1):614. <https://doi.org/10.1186/s12889-021-10647-6> PMID: 33781243
34. Nainggolan O, Hapsari D, Indrawati L. Pengaruh Akses ke Fasilitas Kesehatan terhadap Kelengkapan Imunisasi Baduta (Analisis Riskesdas 2013). *Media Litbangkes*. 2016;26(1). <https://doi.org/10.22435/mpk.v26i1.4900.15-28>
35. Ekezie W, Igein B, Varughese J, Butt A, Ukoha-Kalu BO, Ikhile I, et al. Vaccination Communication Strategies and Uptake in Africa: A Systematic Review. *Vaccines (Basel)*. 2024;12(12):1333. <https://doi.org/10.3390/vaccines12121333> PMID: 39771995
36. Kasahun AW, Zewdie A, Shitu S, Alemayehu G. Vaccine cold chain management practice and associated factors among health professionals in Ethiopia: systematic review and meta-analysis. *J Pharm Policy Pract*. 2023;16(1):55. <https://doi.org/10.1186/s40545-023-00560-1> PMID: 37046331
37. Lin C, Mullen J, Smith D, Kotarba M, Kaplan SJ, Tu P. Healthcare Providers' Vaccine Perceptions, Hesitancy, and Recommendation to Patients: A Systematic Review. *Vaccines (Basel)*. 2021;9(7):713. <https://doi.org/10.3390/vaccines9070713> PMID: 34358132
38. Zameer M, Phillips-White N, Folorunso O, Belt R, Setayesh H, Asghar N, et al. Promoting equity in immunization coverage through supply chain design in Pakistan. *Gates Open Res*. 2020;4:31. <https://doi.org/10.12688/gatesopenres.13121.1> PMID: 33709056
39. Husada D, Puspitasari D, Kartina L, Basuki PS, Moedjito I, Susanto H, et al. Impact of a three-dose diphtheria outbreak response immunization in East Java, Indonesia, 6 months after completion. *Hum Vaccin Immunother*. 2020;16(9):2144–50. <https://doi.org/10.1080/21645515.2020.1778918> PMID: 32692596
40. Kitamura N, Bahkali K, Chem ED, Quilty BJ, Edwards T, Toizumi M, et al. Waning rate of immunity and duration of protective immunity against diphtheria toxoid as a function of age and number of doses: Systematic review and quantitative data analysis. *Hum Vaccin Immunother*. 2022;18(6):2099700. <https://doi.org/10.1080/21645515.2022.2099700> PMID: 35862651

41. Gao H, Lau EHY, Cowling BJ. Waning Immunity After Receipt of Pertussis, Diphtheria, Tetanus, and Polio-Related Vaccines: A Systematic Review and Meta-analysis. *J Infect Dis.* 2022;225(4):557–66. <https://doi.org/10.1093/infdis/jiab480> PMID: [34543411](https://pubmed.ncbi.nlm.nih.gov/34543411/)
42. World Health Organization. Diphtheria vaccines: WHO position paper – August 2017. *Weekly Epidemiological Record.* 2017. <https://www.who.int/publications/item/diphtheria-vaccines-who-position-paper-august-2017>
43. Orenstein WA, Offit PA, Plotkin SA. *Vaccines.* 6th ed. Elsevier. 2012.
44. Truelove SA, Keegan LT, Moss WJ, Chaisson LH, Macher E, Azman AS, et al. Clinical and Epidemiological Aspects of Diphtheria: A Systematic Review and Pooled Analysis. *Clin Infect Dis.* 2020;71(1):89–97. <https://doi.org/10.1093/cid/ciz808> PMID: [31425581](https://pubmed.ncbi.nlm.nih.gov/31425581/)
45. Fauzi IS, Nuraini N, Sari AM, Wardani IB, Taurustiati D, Simanullang PM, et al. Assessing the impact of booster vaccination on diphtheria transmission: Mathematical modeling and risk zone mapping. *Infect Dis Model.* 2024;9(1):245–62. <https://doi.org/10.1016/j.idm.2024.01.004> PMID: [38312350](https://pubmed.ncbi.nlm.nih.gov/38312350/)
46. Asif AM, Akbar M, Tahir MR, Arshad IA. Role of Maternal Education and Vaccination Coverage: Evidence From Pakistan Demographic and Health Survey. *Asia Pac J Public Health.* 2019;31(8):679–88. <https://doi.org/10.1177/1010539519889765> PMID: [31852229](https://pubmed.ncbi.nlm.nih.gov/31852229/)
47. Gebreyesus A, Tesfay K. Effect of maternal education on completing childhood vaccination in Ethiopia: systematic review and meta-analysis. *Sci Rep.* 2024;14(1):17453. <https://doi.org/10.1038/s41598-024-68182-4> PMID: [39075119](https://pubmed.ncbi.nlm.nih.gov/39075119/)
48. Farzad F, A Reyer J, Yamamoto E, Hamajima N. Socio-economic and demographic determinants of full immunization among children of 12-23 months in Afghanistan. *Nagoya J Med Sci.* 2017;79(2):179–88. <https://doi.org/10.18999/nagjms.79.2.179> PMID: [28626253](https://pubmed.ncbi.nlm.nih.gov/28626253/)
49. Srivastava S, Fledderjohann J, Upadhyay AK. Explaining socioeconomic inequalities in immunisation coverage in India: new insights from the fourth National Family Health Survey (2015-16). *BMC Pediatr.* 2020;20(1):295. <https://doi.org/10.1186/s12887-020-02196-5> PMID: [32546138](https://pubmed.ncbi.nlm.nih.gov/32546138/)
50. Fadlyana E, Rusmil K, Dhamayanti M, Tarigan R, Kartasasmita CB, Sari RM, et al. Comparison of Immunogenicity and Safety of Diphtheria-Tetanus-Pertussis-Hepatitis B-Haemophilus influenza B (Bio Farma) with Pentabio® Vaccine Primed with Recombinant Hepatitis B at Birth (Using Different Source of Hepatitis B) in Indonesian Infants. *Vaccines (Basel).* 2023;11(3):498. <https://doi.org/10.3390/vaccines11030498> PMID: [36992082](https://pubmed.ncbi.nlm.nih.gov/36992082/)
51. Tang X, Xiao Y, Chen J, Su Y, Zhou Y, Luo L, et al. Immunogenicity and safety of co-purified diphtheria, tetanus and acellular pertussis vaccine in 6-year-old Chinese children. *Nat Commun.* 2025;17(1):214. <https://doi.org/10.1038/s41467-025-66890-7> PMID: [41318685](https://pubmed.ncbi.nlm.nih.gov/41318685/)
52. Kartoglu U, Ames H. Ensuring quality and integrity of vaccines throughout the cold chain: the role of temperature monitoring. *Expert Rev Vaccines.* 2022;21(6):799–810. <https://doi.org/10.1080/14760584.2022.2061462> PMID: [35373686](https://pubmed.ncbi.nlm.nih.gov/35373686/)

# Diphtheria seroprotection among Indonesian children: Community Health Surveys Riskesdas 2007, 2013 and 2018

*By* Monica Dwi Hartanti

---

WORD COUNT

11374

TIME SUBMITTED

18-JUN-2026 08:52AM

PAPER ID

122181767

RESEARCH ARTICLE

# Diphtheria seroprotection among Indonesian children: Community Health Surveys Riskesdas 2007, 2013 and 2018

Monica Dwi Hartanti<sup>1,2\*</sup>, Sunarno Sunarno<sup>2</sup>, Novaria Sari Dewi Panjaitan<sup>2</sup>, Armedy Ronny Hasugian<sup>3</sup>, Rita Marleta Dewi<sup>2</sup>, Sarwo Handayani<sup>2</sup>, Masri Sembiring Maha<sup>2</sup>, Tubagus Ferdi Fadilah<sup>4</sup>, Firda Fairuza<sup>4</sup>, Nathalia Ningrum<sup>4</sup>, Meiriani Sari<sup>4</sup>, Dita Setiaty<sup>4</sup>, Nia Nurul Aziza<sup>4</sup>, Arleen Devita<sup>5</sup>, Donna Adriani<sup>6</sup>, Jihan Samira<sup>2</sup>, Christina Safira Whinie Lestari<sup>2</sup>

**1** Department of Biology, Faculty of Medicine, Universitas Trisakti, West Jakarta, Jakarta, Indonesia, **2** Center for Biomedical Research, Research Organization for Health, National Research and Innovation Agency (BRIN), Bogor, West Java, Indonesia, **3** Research Center for Preclinical and Clinical Medicine, Research Organization for Health, National Research and Innovation Agency (BRIN), Bogor, West Java, Indonesia, **4** Department of Paediatrics, Faculty of Medicine, Universitas Trisakti, West Jakarta, Jakarta, Indonesia, **5** Department of Microbiology, Faculty of Medicine, Universitas Trisakti, West Jakarta, Jakarta, Indonesia, **6** Department of Physiology, Faculty of Medicine, Universitas Trisakti, West Jakarta, Jakarta, Indonesia

\*mdhartant@trisakti.ac.id



**OPEN ACCESS**

**Citation:** Hartanti MD, Sunarno S, Panjaitan NSD, Hasugian AR, Dewi RM, Handayani S, et al. (2026) Diphtheria seroprotection among Indonesian children: Community Health Surveys Riskesdas 2007, 2013 and 2018. *PLoS One* 21(2): e0343396. <https://doi.org/10.1371/journal.pone.0343396>

**Editor:** Samuel Kofi Tchum, Kintampo Health Research Centre, GHANA

**Received:** September 10, 2025

**Accepted:** February 5, 2026

**Published:** February 27, 2026

**Copyright:** © 2026 Hartanti et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data availability statement:** The data are available upon request to the Center of Data and Information, Health Policy Agency (Indonesia: Pusat Data dan Informasi, Badan Kebijakan Pembangunan Kesehatan), Ministry of Health, Indonesia at <https://www.badankebijakan>.

## Abstract

Diphtheria remains a public health concern in Indonesia despite long-standing inclusion of diphtheria-containing vaccines in the national immunization program. This study assessed temporal trends in diphtheria immunity among Indonesian children aged 1–14 years, identified vulnerable age groups, and examined factors associated with seroprotection. We analyzed diphtheria IgG antibody data measured by ELISA from the Indonesian Community Health Surveys (Riskesdas) conducted in 2007, 2013, and 2018. The analysis included 6,622 children (2007), 7,110 (2013), and 7,203 (2018). Bivariate and multivariate logistic regression analyses were performed to identify determinants of seroprotection. Across all surveys, diphtheria IgG levels were lowest at ages 1–6 years, increased at ages 7–10 years, and declined again from age 11 years onward. Overall seroprotection ranged from 71.1% to 83.6%, with a two- to threefold increase in long-term protection observed in 2018 compared with 2007 and 2013. In multivariate analyses, complete DTP immunization consistently remained the strongest independent predictor of seroprotection among children aged 1–4 years ( $p < 0.05$ ). Among children aged 1–14 years, maternal education (Riskesdas 2007) and household economic status (Riskesdas 2018) were also associated with seroprotection. Following introduction of the DTP4 booster, higher diphtheria IgG concentrations (GMC 0.48 IU/mL to 0.77 IU/mL) were observed among children aged 1–2 years old in 2018 compared with earlier surveys (GMC 0.18 IU/mL to 0.33 IU/mL). Diphtheria immunity among Indonesian children remains suboptimal, with the

[kemkes.go.id/](https://kemkes.go.id/). Select "Menu Layanan Data" (Data service menu), select "Tata Cara Permintaan Data" (Data request procedures). The request must be submitted with a cover letter signed by the head of the institution, Data Request Submission Form, and project proposal and emailed to [dati.n.bkpk@kemkes.go.id](mailto:dati.n.bkpk@kemkes.go.id). Data can be used with the following conditions:

1. The data received is not provided to other parties.
2. Include the statement "Data used in reports/articles/thesis/dissertation and others come from the Health Development Policy Agency which can be accessed via certain requirements and procedures via the link <https://www.litbang.kemkes.go.id> in the data utilization results document.
3. Obligated to submit the results of the analysis to the Health Development Policy Agency (BKPK RI).
4. Attachments are an inseparable part of the submitted letter.

**Funding:** The author(s) received no specific funding for this work.

**Competing interests:** The authors have declared that no competing interests exist.

highest vulnerability at ages 5–6 years and evidence of waning immunity after ten years of age. Ensuring complete routine DTP immunization is critical, and booster strategies may be considered to sustain long-term population immunity.

## Introduction

Diphtheria is an easily transmitted infectious disease and can cause outbreaks with 5–10% case fatality rate (CFR), especially in young children [1]. The main cause of diphtheria is *Corynebacterium diphtheriae* (*C. diphtheriae*), a Gram-positive rod-shaped bacterium that produces diphtheria toxin which has a toxic effect on target cells. This disease is characterized by inflammation at the site of infection, especially in the mucous membranes of the pharynx, larynx, tonsils, nose, and also the skin. In more severe cases, diphtheria is characterized by difficulty swallowing, shortness of breath, stridor (a high-pitched noisy breathing sound), and swelling of the neck that looks like a cow's neck (bullneck). Fatal cases usually occur due to obstruction/blockage of the airway, and systemic effects such as heart muscle damage, as well as abnormalities in the central nervous system and kidneys. Transmission occurs due to inhalation of saliva droplets from sufferers when the sufferer sneezes or coughs or through contaminated objects [2–4].

The incidence of diphtheria is spread throughout the world, especially in low-and middle-income countries (LMICs). WHO reported that in 2023, global diphtheria cases reached 24,782 cases, a significant increase compared to the previous year, which was 10,027 (2022) and 8,659 (2021). The most cases of diphtheria were found in Africa and Southeast Asia. In this case, Indonesia has always been among the five countries with the most diphtheria cases in the world from year to year [5, 6]. Although diphtheria vaccine has been routinely given in the form of basic and additional vaccines, until now diphtheria cases are still being reported in Indonesia. The number of diphtheria cases reported in Indonesia in 2007, 2013 and 2018 (the data collection period for this study) are as follows, 183, 775 and 1,026 respectively [6]. Nationally, in 2020–2022, there were 964 diphtheria cases reported from 34 provinces in Indonesia [7]. Global data also shows that most diphtheria cases in various countries are related to immunization problems [8].

To date, early immunization against diphtheria in children has been very effective in drastically reducing the number of deaths and morbidity related to diphtheria. WHO recommends vaccination of at least six doses, namely three doses of basic vaccine and three doses of booster vaccine containing diphtheria and tetanus toxoids [9]. In its implementation, the diphtheria vaccination program depends on the policies of each country [8]. Since the early 1990s, Indonesia has implemented routine childhood immunization with three primary doses of diphtheria–tetanus–pertussis vaccine (DTP3) administered during infancy. In Indonesia, the diphtheria vaccination schedule determined by the Ministry of Health (Kemenkes RI) is given at ages 2, 3 and 4 months old for the first, second and third dose respectively, followed by boosters at ages 18 months and elementary school students in the first, second and fifth grades

(Bulan Imunisasi Anak Sekolah, BIAS) which is in line with the recommendation of Indonesian Pediatric Society (IDAI). In addition, IDAI also recommends the booster doses scheduled for children aged 5–7 years and 10–18 years [10,11]. This difference arises from operational and logistical adaptations in the national immunization schedule, rather than from conflicting policy guidance. Consequently, our study's references to school-based boosters should be understood as reflecting the implementation of the DT preparation under the BIAS program, while the IDAI recommendation pertains to the broader pediatric vaccination guidance.

In Indonesia, the vaccination program for diphtheria was expanded based on the Expanded Program on Immunization (EPI), which recommends a primary vaccination series of three doses of DTwP-HB-Hib at 2, 3, and 4 months, followed by a booster dose at 18–24 months [11]. In addition to the national DTP vaccination schedule, Indonesia experienced a large diphtheria outbreak in 2017, which affected multiple provinces and prompted extensive outbreak response immunization (ORI) campaigns targeting children and adolescents. This outbreak prompted large-scale outbreak response immunization (ORI) campaigns, which delivered supplemental diphtheria-containing booster doses to children and adolescents, including cohorts beyond the age range typically covered by routine immunization services. These emergency vaccination activities occurred shortly before the Riskesdas 2018 survey and are likely to have influenced population-level immunity profiles observed in that survey year. Accumulating evidence of waning immunity following the primary DTP series, combined with persistent diphtheria transmission, raised concerns regarding the adequacy of long-term protection. In response, a fourth booster dose of DTP (DTP4) was gradually introduced into the national immunization schedule and more systematically implemented prior to the Riskesdas 2018 survey.

Globally, the coverage of three dosages of DTP vaccination in recent years has decreased from 86% in the 2015–2019 periods to 83% in 2020 and 81% in 2021. The Covid-19 pandemic that occurred in 2019–2021 has disrupted routine immunization services worldwide and has had an impact on decreasing immunization coverage [12]. A study conducted in 2023 during the pandemic in Jakarta, Indonesia, among school-aged children showed that only 40.9% of 154 children sampled received the primary DTP vaccination, first booster, and second booster. This finding indicated that complete diphtheria vaccination coverage remains low. Meanwhile, children who received the first and second booster doses had significantly higher anti-diphtheria antibody levels than those who did not receive the two booster doses. Therefore, booster vaccination in school-aged children is crucial for boosting immunity and minimizing the risk of diphtheria outbreaks [13]. The main objective of the 2030 immunization strategy is to expand immunization services to reach children who have not been immunized or whose immunization is incomplete, and to reduce the current inequality in immunization status [14]. While administrative coverage of routine childhood immunization is reported to be high, less is known about population-level immunity across age groups and how protection wanes over time in the post-scale-up period. In particular, evidence from nationally representative serological data remains limited.

The Ministry of Health, Republic of Indonesia (Kemenkes RI) delegated the National Institute of Health Research and Development to conduct a national basic health survey periodically every five years (well known as Riskesdas), starting in 2007, 2013 and 2018, and one of its objectives is to assess the health status of the community and the determinants that influence it. Serological testing for diphtheria was among the parameters evaluated, alongside those for pertussis, tetanus, hepatitis, and other vaccine-preventable diseases [15,16]. The Riskesdas data in 2007, 2013 and 2018 showed that more than half of the respondents in each survey period had complete DTwP vaccination. Accordingly, the three Riskesdas surveys analyzed in this study (2007, 2013, and 2018) represent distinct immunization and epidemiological contexts. Riskesdas 2007 reflects a period dominated by routine DTP3 vaccination, Riskesdas 2013 captures an intermediate phase prior to widespread DTP4 implementation, and Riskesdas 2018 reflects the combined effects of DTP4 introduction and recent ORI activities following the 2017 outbreak.

Most previous studies have relied on surveillance data or outbreak reports, which do not directly measure immunity at the population level. In contrast, this study leverages nationally representative serological data collected through multiple rounds of the Basic Health Research (Riskesdas) survey to characterize age-specific diphtheria antibody profiles over

time. In this study, further analysis of diphtheria serology data aims to obtain trends in children's immunity to diphtheria in Indonesia over a period of more than a decade, identify vulnerable groups and factors that influence protection for planning diphtheria outbreak prevention programs. To our knowledge, this is one of the few studies in the region to examine long-term trends in population immunity using repeated cross-sectional serosurveys.

## Materials and methods

### Study design

This study involves an in-depth analysis of the data obtained from the Basic Health Research (Riskesdas) survey conducted in all provinces of Indonesia, 2007, 2013 and 2018. A cross-sectional study design was employed to conduct Riskesdas which representation of population data on a national scale. In particular, the 2018 survey was conducted after the nationwide diphtheria outbreak in 2017 and subsequent ORI campaigns implemented across many provinces. As a result, serological findings from 2018 may reflect both routine immunization and outbreak-related vaccination activities. This study did not attempt to disentangle the individual effects of routine immunization, booster introduction, or ORI, but instead describes population-level immunity patterns resulting from their combined influence. All datasets were obtained at September 9<sup>th</sup> 2022 from the dataset management laboratory of the Health Development Policy Agency, Ministry of Health, Indonesia [15,16]. Dataset was obtained after submission of a research proposal detailed with the required variables, including the serology data linked to the public health dataset. Proposal was reviewed by internal reviewers. After being accepted, the access to raw dataset would be granted based on the necessity. The principal investigator of this research signed the data transfer agreement for not sharing any data to any third-party. Additionally, all related publications should acknowledge the particular institution. Authors did not have access to the information that can be linked to participants.

### Samples

The sampling frame was developed using calculations from the BPS-Statistics Indonesia using multistage sampling across the stages as seen in the Riskesdas national reports for the years 2007, 2013 and 2018 [17–19]. The results of structured interviews and measurements were then subjected to additional analysis using selected household and individual samples. The chosen samples, that were older than a year old, underwent blood sampling and serological testing. Especially for diphtheria antibody examination, it was conducted on child respondents aged 1–14 years in Riskesdas 2007, 2013 and 2018. Respondents represented urban and rural areas except respondents in Riskesdas 2007 only represented urban areas. The number of child respondents examined for diphtheria antibodies was 6,622 (Riskesdas 2007), 7,110 (Riskesdas 2013) and 7,203 (Riskesdas 2018). Among these numbers, there were toddler respondents (aged 1–4 years) as many as 1,536 (Riskesdas 2007), 568 (Riskesdas 2013) and 1,052 (Riskesdas 2018). Toddler respondents were analyzed separately regarding their DTP immunization status which was only asked to respondents aged 1–4 years.

### Diphtheria antibody test

Antibody examination for diphtheria was performed on serum collected using the Enzyme-Linked Immunosorbent Assay (ELISA) method, according to the protocol in the insert package. The examination kit used was Indec Diagnostics, Germany. The examination was carried out in the laboratory of the National Institute of Health Research and Development, Ministry of Health of the Republic of Indonesia. A body titer for diphtheria is expressed in IU/mL units, with the following interpretations; seronegative/ partial protection (titer <0.1 IU/mL); full protection (titer 0.1–1 IU/mL), long protection (titer >1 IU/mL) [4].

### Vaccination history assessment

Individual vaccination history was available only for children aged 1–4 years in the Riskesdas surveys. Vaccination status was ascertained using documented vaccination cards when available; in the absence of a record card, caregiver recall

was used, in accordance with standard Riskesdas procedures. Complete DTP immunization was defined as receipt of all age-appropriate DTP doses recommended under the national immunization schedule at the time of the survey. Children with missing or unverifiable vaccination history were excluded from analyses involving immunization status. The proportion of missing vaccination-history data is reported in the corresponding tables. Because individual-level vaccination data were not available or considered reliable for children older than four years old, analyses involving vaccination status were restricted to the 1–4 year age group. For older children (5–14 years), individual-level immunization data were not systematically documented, particularly for doses received under earlier routine schedules or through outbreak response immunization (ORI) campaigns; therefore, vaccination status for these age groups was not recorded.

### Operational definitions

The criteria for urban and rural residence were determined by the BPS-Statistics Indonesia when selecting the respondent sample. Multivariate models assessing determinants of diphtheria seroprotection included vaccination status only for the 1–4 year age group. For older age groups, analyses were limited to serological outcomes and demographic variables, without inclusion of individual vaccination history. Where relevant, the age-specific serological patterns in older children were compared with available programmatic immunization coverage data at the provincial or cohort level. These comparisons were treated as ecological in nature and interpreted cautiously.

Nutritional status was calculated based on the Body Mass Index (BMI)-for-age Z-score formulation with cut-points of: Malnutrition/ Severe wasted:  $\leq -3$ , Undernutrition/ Wasted:  $\leq 2.0$ , Normal:  $-2.0$ – $2.0$ , Overweight:  $> 2.0$ , Obese:  $> 3.0$  [20,21]. Children aged 1–4, BMI was calculated according to the WHO reference [21], while for children aged over 4 years, BMI was calculated using the CDC reference [20]. The results of this grouping are then grouped again into three large groups for analysis, namely (1) Undernutrition, which is a combination of undernutrition and severe malnutrition, where BMI z-score  $< -2.0$ , (2) Normal nutrition: where BMI z-score  $+2.0$  to  $-2.0$  and (3) Overnutrition: is a combination of overweight and obesity, where BMI z-score  $> +2.0$ . Meanwhile, the family's economic status is calculated based on expenditure quintiles and grouped into five groups, then grouped again into three categories, namely quintile 1–2 (poor), quintile 3 (middle) and quintile 5 (rich). Complete DTP immunization status in the analysis of Riskesdas 2007, 2013 and 2018 was defined as having received three doses of basic DTP immunization (DTP3) given at the age of 2–3–4 months. This immunization was given together with the hepatitis-B vaccine in the form of a DTP-HB combo vaccine (2011), which then replaced by the pentavalent DTP-HB-Hib vaccine in 2015. There are three degrees of maternal education: low for those who did not attend school, medium for those who attended elementary school through high school, and high for those who had a diploma-1 (D1) or were enrolled in college.

### Statistical analysis

The analysis was conducted on the samples of Riskesdas 2007, 2013 and 2018, namely children aged 1–14 years. The BPS-Statistics Indonesia determined the weight value of each data for survey analysis. Using univariate analysis, the proportion of participants such as sex, area of residence, age, nutritional status, family economic status, maternal education status, and toddler DTP immunization status, were identified. The age variable was divided into two categories (1–4 year old and 5–14 year old) based on the diphtheria immunization status data availability. Pearson's-chi-squared bivariate analysis was used to assess the relationship between respondent characteristics and other variables related to diphtheria antibody titers. Multivariate analysis was used to assess the relationship of the most significant ( $p < 0.05$ ) variables and conducted using binomial logistic regression to determine factors independently associated with the dependent variable. The analysis steps began with selecting variables included in the binomial multivariate analysis with  $p < 0.25$  in the bivariate analysis. Then, the analysis was conducted by removing variables above  $p > 0.05$  one by one. The results showed no interaction or confounding. The Hosmer–Lemeshow goodness-of-fit test and multicollinearity variance inflation factor (VIF) test demonstrated the suitability of the equation model. The final results are presented as an adjusted odds ratio (AOR)

with a 95% confidence interval (CI). The AOR value illustrates the strength of the association between the independent and dependent variables after controlling for other variables in the model. In this study, diphtheria antibody titers were divided into two categories: protective ( $\geq 0.1$  IU/mL) and negative/partial protective ( $< 0.1$  IU/mL). Stata software version 16 was used for statistical analysis.

### Data limitation

Data analysis was only conducted on variables available in Riskesdas 2007, 2013 and 2018 and data related to antibodies against diphtheria. Immunization status data was only available for respondents aged 1–4 years. Specifically, Riskesdas 2007 data was only available in urban areas. The total number of samples for variables analyzed using bivariate and multivariate methods differed according to the completeness of the available data. The DTP4 vaccination history and the information of diphtheria cases were unavailable.

### Ethical consideration

The request for raw data, de-identified data were obtained via email ([datin.bkpk@kemkes.go.id](mailto:datin.bkpk@kemkes.go.id)) from the Data Information Center, Health Policy Agency, Ministry of Health, Indonesia (Kemenkes RI), the official data holder. The ethical clearance for this analysis study was obtained from Research Ethic Committee, Faculty of Medicine, Universitas Trisakti, Jakarta with registry number No. 164/KER/FK/VIII/2022.

### Results

Characteristics of respondents aged 1–14 years who participated in the Riskesdas 2007, 2013 and 2018, and were examined antibody titers against diphtheria can be seen in Table 1. In this study, the age range was divided into two: 1–4 and 5–14 years old based on the available immune status data in the Riskesdas database. The majority of respondents were in the 5–14 years age group for Riskesdas 2007, 2013 and 2018 (76.8%, 92.01% and 85.4% respectively). The proportion of respondents by sex was nearly equal. In Riskesdas 2007, all respondents lived in urban areas, while in Riskesdas 2013 there were more respondents living in rural areas, and vice versa in Riskesdas 2018. Associations between complete DTP immunization and diphtheria seroprotection are presented only for children aged 1–4 years, for whom individual vaccination history data were available. Most toddler respondents had complete basic immunization of DTP for Riskesdas 2007, 2013 and 2018 (67.1%, 74.6% and 78.3% respectively). Although there were still respondents with under nutrition status, most respondents had normal nutritional status for Riskesdas 2007, 2013 and 2018 (77.7%, 85.1% and 84.3% respectively). Based on family economic status, most respondents were at the poor to middle level (36.9% – 47.9%). The highest maternal education level was in the medium group for Riskesdas 2007, 2013 and 2018 (77.7%, 80.2% and 82.5% respectively).

Fig 1 generally shows a similar pattern in the three periods of Riskesdas. The proportion of respondents who had protective diphtheria antibody titers was still quite low at the age of 1–6 years, then increased at the age of 7–10 years, and decreased back simultaneously—often with the increasing age. The respondents living in urban areas in the Riskesdas 2007 showed a fairly high proportion of non-protective titers ( $< 0.1$  IU/mL) at the age of 1–6 years (34.7% – 38.0%). Meanwhile, long-term protective diphtheria antibodies ( $> 1$  IU/mL) increased with age, especially in the 7–8 group (42.0%), with the highest geometric mean concentration (GMC) at the age of 7–8 years (0.54 IU/mL), then gradually decreased (Fig 1).

The proportion of non-protective titers in Riskesdas 2013 was found to be lower than that in Riskesdas 2007 (18.0% – 37.6%). Meanwhile, long-term protective diphtheria antibody remained stable, but not as high as in Riskesdas 2007 in older age groups. The GMC in Riskesdas 2013 was lower than that in Riskesdas 2007, where the highest GMC was in the 7–10 year group (0.36 IU/mL) with a drastic decrease in the 11–14 year age group (Fig 1).

The proportion of non-protective titers in Riskesdas 2018 was found to be lower than that in both Riskesdas 2007 and 2013, especially in the 7–14 age groups. Meanwhile, the long-term protective diphtheria antibody level was found to be

**Table 1. Distribution of the respondents aged 1-14 years old based on their characteristics.**

| Characteristics                   | Value            | *Riskesdas 2007 |       | Riskesdas 2013 |       | Riskesdas 2018 |      |
|-----------------------------------|------------------|-----------------|-------|----------------|-------|----------------|------|
|                                   |                  | n unweighting   | %     | n unweighting  | %     | n unweighting  | %    |
| Age                               |                  | 6,622           |       | 7,110          |       | 7,203          |      |
|                                   | 1-4 y.o          |                 | 23.2  |                | 7.99  |                | 14.6 |
|                                   | 5-14 y.o         |                 | 76.8  |                | 92.01 |                | 85.4 |
| Sex                               |                  | 6,622           |       | 7,110          |       | 7,203          |      |
|                                   | Boy              |                 | 50.6  |                | 48.4  |                | 51.7 |
|                                   | Girl             |                 | 49.4  |                | 51.6  |                | 48.3 |
| Areas                             |                  | 6,622           |       | 7,110          |       | 7,203          |      |
|                                   | Urban            |                 | 100.0 |                | 48.7  |                | 66.5 |
|                                   | Rural            |                 |       |                | 51.3  |                | 33.5 |
| DTP Immunization Status (1-4 y.o) |                  | 1,486           |       | 485            |       | 825            |      |
|                                   | Complete         |                 | 67.1  |                | 74.6  |                | 78.3 |
|                                   | Incomplete       |                 | 32.9  |                | 25.4  |                | 21.7 |
| BMI Nutrition Status              |                  | 5,936           |       | 6,124          |       | 7,142          |      |
|                                   | Undernutrition   |                 | 14.0  |                | 9.2   |                | 7.3  |
|                                   | Normal nutrition |                 | 77.7  |                | 85.1  |                | 84.3 |
|                                   | Overnutrition    |                 | 8.3   |                | 5.7   |                | 8.3  |
| Family Economy Status             |                  | 6,622           |       | 7,110          |       | 6,195          |      |
|                                   | Poor             |                 | 47.9  |                | 36.9  |                | 45.8 |
|                                   | Middle           |                 | 38.2  |                | 47.7  |                | 36.9 |
|                                   | Rich             |                 | 13.9  |                | 15.4  |                | 17.3 |
| Maternal Education Level          |                  | 5,822           |       | 6,324          |       | 6,474          |      |
|                                   | Low              |                 | 15.7  |                | 16.1  |                | 11.6 |
|                                   | Medium           |                 | 77.7  |                | 80.2  |                | 82.5 |
|                                   | High             |                 | 6.6   |                | 3.7   |                | 5.9  |


\* Riskesdas 2007 was only conducted at urban areas.

<https://doi.org/10.1371/journal.pone.0343396.t001>

higher significantly, around two to three folds higher than those in Riskesdas 2007 and 2013, especially in the 7–12 age groups (59% – 69%). The highest GMC is at the age of 7–8 years (0.85 IU/mL) (Fig 1).

For respondents living in rural areas in Riskesdas 2013, most children have protective diphtheria antibody titers (0.1–1 IU/mL) (Fig 2). The proportion of children with non-protective titers (<0.1 IU/mL) is quite high at the age of 1–6 years (27%–37%) and increases again at the age of 11–14 years. Meanwhile, long-term protective diphtheria antibodies (>1 IU/mL) are relatively low in all age groups, with a high proportion in the age group of 7–10 years (30% – 40%). The GMC increases from the age of 7–8 years (0.36 IU/mL), then decreases slightly but remains quite stable until the age of 13–14 years (0.214 IU/mL). Meanwhile, the seroprotective diphtheria in urban and rural areas was found to be almost the same (Fig 2).

In Riskesdas 2018, the proportion of children with non-protective diphtheria antibody titers decreased, while the proportion of children with long-term protective diphtheria titers increased drastically, especially in the 7–10 year age group (about 53%). In addition, seroprotective diphtheria in urban areas was found to be higher than in rural areas. Protective diphtheria antibody titers increased linearly with age. The GMC titer is about two fold higher than that in Riskesdas 2013, especially in the 7–10 year age group (0.62–0.68 IU/mL). After the age of ten, the GMC began to decline but was still higher than that in Riskesdas 2013 (Fig 2).



**Fig 1. The trend of diphtheria titer in children aged 1–14 years, urban area on Riskesdas 2007, 2013 and 2018.** Antibody concentrations (IU/mL) and corresponding protection categories (seronegative/partial, full or long protection) are shown across age groups for each survey year. Stacked bars present the distribution of seronegative/partial protection, full protection, and long-term protection. An antibody titer for diphtheria is expressed in IU/mL units. The seronegative/partial protection titer is defined as <math><0.1\text{ IU/mL}</math>. Full protection titer is defined as <math>0.1\text{--}1\text{ IU/mL}</math>. And long protection titer is defined as >math>1\text{ IU/mL}</math>. The solid line represents the geometric mean concentration (GMC, IU/mL) for each age group.


<https://doi.org/10.1371/journal.pone.0343396.g001>

Table 2 shows the results of the analysis to assess factors related to the status of diphtheria antibody protection in children aged 1–14 years in Indonesia. The percentage of protective diphtheria IgG antibodies is 71.1% (Riskesdas 2007), 72.6% (Riskesdas 2013), and 83.6% (Riskesdas 2018). These results indicate that around one-third of children in the 1–4 year age group were susceptible to diphtheria infection, with seronegative/partial protective diphtheria antibodies (diphtheria IgG <math><0.1\text{ IU/mL}</math>), both in the data of Riskesdas 2007 (36.4%), 2013 (28.4%) and 2018 (27.4%).

In Riskesdas 2007 (Table 19) bivariate analysis results found that age, gender, DTP immunization status, family socioeconomic status, nutritional status, and maternal education level were significantly associated with protective diphtheria antibody status ( $p < 0.05$ ). Children aged 5–14 years were 2.74 times more likely to have significant protective diphtheria antibody status than children aged 1–4 years (POR = 2.74;  $p = 0.000$ ). Boys also had significant higher of protective diphtheria antibody than girls (POR = 2.64;  $p = 0.000$ ). In addition, children who received complete DTP immunization showed significant higher chance of protection compared to children with incomplete immunization (POR = 1.98;  $p = 0.000$ ).

Family economic status also showed a significant relationship, where children from middle-class (POR = 2.67;  $p = 0.000$ ) and rich (POR = 2.39;  $p = 0.000$ ) families had significant higher protective diphtheria antibodies than children from poor families. Likewise, normal nutritional status (POR = 2.46;  $p = 0.000$ ) and over nutrition (POR = 2.55;  $p = 0.000$ ) had approximately 2.5 times the chance of having significant protective diphtheria antibodies compared to children with under nutritional status. Maternal education was also a significant factor, where children with highly educated mothers had 17.42 times greater chance of having significant protective diphtheria antibodies than those with low-educated mothers ( $p = 0.000$ ).

However, after multivariate analysis, only two factors remained significant as independent predictors of protective diphtheria antibody status, namely complete DTP immunization status and maternal education status. Complete DTP immunization status (APOR = 1.46; 95% CI: 1.10–2.00;  $p = 0.020$ ), showed that children who received complete immunization



**Fig 2. The trend of diphtheria titer in children aged 1-14 years, urban and rural area on Riskesdas 2013 and 2018.** Stacked bars show the distribution of seronegative/partial protection, full protection, and long-term protection across age groups and survey years by urban/rural strata.

<https://doi.org/10.1371/journal.pone.0343396.g002>

were 1.46 times more likely to have significant protective diphtheria antibody status compared to those who were incomplete. Furthermore, children from mothers with high education status (APOR=3.61; 95% CI: 1.50–8.68;  $p=0.004$ ), showed a significant increase in the protective diphtheria antibody compared to mothers with low education. While the economic status of middle class (APOR=1.02,  $p=0.932$ ) and rich class (APOR=0.64,  $p=0.078$ ) do not seem to show significant results, yet in the statistical test, this variable cannot be removed from the multivariate analysis. These results indicate that the relationship between socioeconomic status and protective diphtheria antibody status can be explained by the existence of other variables, especially the completeness of DTP immunization, which has a direct and strong influence on the protective diphtheria antibody status.

In Riskesdas 2013 and 2018 (Table 2B and 2C), based on bivariate analysis, it was found that child age, sex, area, DTP immunization status, socioeconomic status, nutritional status, and maternal education level were factors that played a significant role ( $p<0.001$ ) on protective diphtheria antibody status. Children with complete DTP immunization status were 2.02 times (Riskesdas 2013, Adjusted POR=2.02; 95% CI: 1.09–3.74;  $p=0.027$ ) and 2.19 times (Riskesdas 2018, Adjusted POR=2.19; 95% CI: 1.33–3.60;  $p=0.002$ ) more likely to have significant protective diphtheria antibody status compared to children with incomplete immunization. Other factors such as age, gender, residence, socioeconomic status, nutritional status, and maternal education were no longer significant in the final model, indicating that their influence on diphtheria antibody seroprotective status was not independent, but rather through other pathways such as access to immunization. Only complete DTP immunization consistently remained a strong independent predictor across all three surveys.

## Discussion

Differences in sample sizes across the three Riskesdas periods were primarily attributable to the expansion of sampling areas within provinces. These variations were appropriately addressed by applying sampling weights in accordance

**Table 2. Bivariate and multivariate analysis of diphtheriae immunity based on characteristic in children aged 1-14 years on Riskesdas 2007, 2013 and 2018\*.**

|   | n           |               | Bivariate                                       |                           |      |       | Multivariate |                  |              |
|---|-------------|---------------|---|---------------------------|------|-------|--------------|------------------|--------------|
|   | n Weighting | n Unweighting | 9 Seronegative/ partial protective (<0.1 IU/mL) | % Protective (≥0.1 IU/mL) | POR  | p     | APOR         | Lower-Upper      | p            |
| <b>A. Riskesdas 2007</b>                |             |               |   |                           |      |       |              |                  |              |
| <b>Age</b>                              |             |               |   |                           |      |       |              |                  |              |
| 1-4                                     | 364,351     | 1,230         | 36.4  | 63.6                      | ref  |       |              |                  |              |
| 5-14                                    | 1,236,593   | 4,372         | 26.7  | 73.3                      | 2.74 | 0.000 |              |                  |              |
| <b>Sex</b>                              |             |               |   |                           |      |       |              |                  |              |
| Female                                  | 790,044     | 2,721         | 30.5  | 69.5                      | ref  |       |              |                  |              |
| Male                                    | 810,899     | 2,881         | 27.4  | 72.6                      | 2.74 | 0.000 |              |                  |              |
| <b>Areas</b>                            |             |               |   |                           |      |       |              |                  |              |
| Urban                                   | 1,500,943   | 5,602         | 28.9  | 71.1                      |      |       |              |                  |              |
| Rural                                   |             |               |   |                           |      |       |              |                  |              |
| <b>DTP Immunization Status (1-4 yo)</b> |             |               |   |                           |      |       |              |                  |              |
| Complete                                | 245,120     | 870           | 33.5  | 66.5                      | 1.98 | 0.000 | <b>1.46</b>  | <b>1.1-2.00</b>  | <b>0.020</b> |
| Incomplete                              | 119,230     | 380           | 42.5  | 57.5                      | ref  |       |              |                  |              |
| <b>Family Economy Status</b>            |             |               |   |                           |      |       |              |                  |              |
| Poor                                    | 772,704     | 2,708         | 30.1  | 69.9                      | ref  |       |              |                  |              |
| Middle                                  | 612,974     | 2,129         | 27.3  | 72.7                      | 2.67 | 0.000 | 1.02         | 0.70-1.47        | 0.932        |
| Rich                                    | 215,265     | 765           | 29.5  | 70.5                      | 2.39 | 0.000 | 0.64         | 0.39-1.05        | 0.078        |
| <b>BMI Nutritional Status</b>           |             |               |   |                           |      |       |              |                  |              |
| Undernutrition                          | 208,839     | 702           | 32.0  | 68                        | ref  |       |              |                  |              |
| Normal nutrition                        | 1,126,797   | 3,936         | 28.9  | 71.1                      | 2.46 | 0.000 |              |                  |              |
| Ovenutrition                            | 116,779     | 439           | 28.2  | 71.8                      | 2.55 | 0.000 |              |                  |              |
| <b>Maternal Education level</b>         |             |               |   |                           |      |       |              |                  |              |
| Low                                     | 216,292     | 681           | 32.3  | 67.7                      | ref  |       |              |                  |              |
| Medium                                  | 1,095,486   | 3,851         | 28.6  | 71.4                      | 2.50 | 0.000 | 1.38         | 0.78-2.46        | 0.266        |
| High                                    | 89,265      | 387           | 29.3  | 70.8                      | 2.42 | 0.000 | <b>3.61</b>  | <b>1.50-8.68</b> | <b>0.004</b> |
| <b>B. Riskesdas 2013</b>                |             |               |   |                           |      |       |              |                  |              |
| <b>Age</b>                              |             |               |   |                           |      |       |              |                  |              |
| 1-4                                     | 229,958     | 568           | 28.4  | 71.6                      | ref  |       |              |                  |              |
| 5-14                                    | 2,489,130   | 6,542         | 27.3  | 72.7                      | 2.67 | 0.000 |              |                  |              |
| <b>Sex</b>                              |             |               |   |                           |      |       |              |                  |              |
| Female                                  | 1,317,226   | 3,446         | 27.4  | 72.6                      | ref  |       |              |                  |              |
| Male                                    | 1,401,862   | 3,664         | 27.3  | 72.7                      | 2.66 | 0.000 |              |                  |              |
| <b>Areas</b>                            |             |               |   |                           |      |       |              |                  |              |
| Urban                                   | 1,324,241   | 2,940         | 27.9  | 72.1                      | ref  | 0.000 |              |                  |              |
| Rural                                   | 1,394,847   | 4,170         | 26.8  | 73.2                      | 2.73 |       |              |                  |              |
| <b>DTP Immunization Status (1-4 yo)</b> |             |               |   |                           |      |       |              |                  |              |
| Complete                                | 151,225     | 375           | 24.1  | 75.9                      | 3.15 | 0.000 | <b>2.02</b>  | <b>1.09-3.74</b> | <b>0.027</b> |
| Incomplete                              | 51,408      | 110           | 39.1  | 60.9                      | ref  |       |              |                  |              |
| <b>Family Economy Status</b>            |             |               |   |                           |      |       |              |                  |              |
| Poor                                    | 1,003,564   | 2,980         | 30.6  | 69.4                      | ref  |       |              |                  |              |
| Middle                                  | 1,296,652   | 3,061         | 25.7  | 74.3                      | 2.89 | 0.000 |              |                  |              |
| Rich                                    | 418,872     | 1,069         | 24.8  | 75.2                      | 3.02 | 0.000 |              |                  |              |

(Continued)

Table 2. (Continued)

|   | n           |               | Bivariate                                       |                           |      |       | Multivariate |             |       |
|---|-------------|---------------|---|---------------------------|------|-------|--------------|-------------|-------|
|   | n Weighting | n Unweighting | 9 Seronegative/ partial protective (<0.1 IU/mL) | % Protective (≥0.1 IU/mL) | POR  | p     | APOR         | Lower-Upper | p     |
| <b>BMI Nutritional Status</b>           |             |               |   |                           |      |       |              |             |       |
| Undernutrition                          | 214,351     | 640           | 26.6  | 73.4                      | ref  |       |              |             |       |
| Normal nutrition                        | 1,984,818   | 5,138         | 26.7  | 73.3                      | 2.74 | 0.000 |              |             |       |
| Overnutrition                           | 133,776     | 346           | 19.3  | 80.7                      | 4.17 | 0.000 |              |             |       |
| <b>Maternal Education level</b>         |             |               |   |                           |      |       |              |             |       |
| Low                                     | 394,893     | 1,153         | 26.9  | 73.1                      | ref  |       |              |             |       |
| Medium                                  | 1,966,464   | 4,916         | 27.6  | 72.4                      | 2.27 | 0.000 |              |             |       |
| High                                    | 90,822      | 255           | 21.2  | 78.8                      | 3.03 | 0.000 |              |             |       |
| <b>C. Riskesdas 2018</b>                |             |               |   |                           |      |       |              |             |       |
| <b>Age</b>                              |             |               |   |                           |      |       |              |             |       |
| 1-4                                     | 590,061     | 991           | 27.4  | 72.6                      | ref  |       |              |             |       |
| 5-14                                    | 3,461,039   | 6,207         | 14.6  | 85.4                      | 5.86 | 0.000 |              |             |       |
| <b>Sex</b>                              |             |               |   |                           |      |       |              |             |       |
| Female                                  | 1,958,156   | 3,386         | 16.2  | 83.8                      | ref  |       |              |             |       |
| Male                                    | 2,092,944   | 3,812         | 16.7  | 83.3                      | 4.99 | 0.000 |              |             |       |
| <b>Areas</b>                            |             |               |   |                           |      |       |              |             |       |
| Urban                                   | 2,696,317   | 3,752         | 15.7  | 84.3                      | ref  |       |              |             |       |
| Rural                                   | 1,354,783   | 3,446         | 17.9  | 82.1                      | 4.59 | 0.000 |              |             |       |
| <b>DTP Immunization Status (1–4 yo)</b> |             |               |   |                           |      |       |              |             |       |
| Complete                                | 385,919     | 657           | 21.4  | 78.6                      | 3.68 | 0.000 | 2.19         | 1.33-3.60   | 0.002 |
| Incomplete                              | 107,222     | 167           | 35.3  | 64.7                      | ref  |       |              |             |       |
| <b>Family Economy Status</b>            |             |               |   |                           |      |       |              |             |       |
| Poor                                    | 1,585,208   | 3,010         | 19.4  | 80.6                      | ref  |       |              |             |       |
| Middle                                  | 1,276,772   | 2,261         | 15.2  | 84.8                      | 5.59 | 0.000 | 1.76         | 1.06-2.93   | 0.028 |
| Rich                                    | 600,335     | 919           | 12.8  | 87.2                      | 6.8  | 0.000 | 1.26         | 0.66-2.39   | 0.479 |
| <b>BMI Nutritional Status</b>           |             |               |   |                           |      |       |              |             |       |
| Undernutrition                          | 295,107     | 543           | 16.1  | 83.9                      | ref  |       |              |             |       |
| Normal nutrition                        | 3,389,695   | 6,012         | 16.6  | 83.4                      | 5.03 | 0.000 |              |             |       |
| Overnutrition                           | 334,438     | 582           | 15.6  | 84.4                      | 5.41 | 0.000 |              |             |       |
| <b>Maternal Education level</b>         |             |               |   |                           |      |       |              |             |       |
| Low                                     | 427,220     | 795           | 20.6  | 79.4                      | ref  |       |              |             |       |
| Medium                                  | 3,045,551   | 5,268         | 16.0  | 84                        | 5.25 | 0.000 |              |             |       |
| High                                    | 216,953     | 407           | 13.4  | 86.6                      | 6.46 | 0.000 |              |             |       |

Note: \*Multiple Regression Logistic Analysis, POR: Prevalence Odds Ratio, APOR: Adjusted Prevalence Odds Ratio.

<https://doi.org/10.1371/journal.pone.0343396.t002>

with the national survey design. As a result, the analyses preserve population representativeness, allowing valid inferences regarding immunization coverage and serological protection among the Indonesian child population across survey years. Based on further data analysis Riskesdas 2007, 2013 and 2018 the proportion of non-protective diphtheria IgG titers (<0.1 IU/mL) is quite high at the age of 1–6 years, possibly because there were still around 25–30% of toddlers who had not received complete diphtheria immunization (Table 1, Figs 1 and 5). These results are similar to research conducted by Le et al on the population in Vietnam, namely around 31.7% of children aged 0–5 years are susceptible to diphtheria [22].

During the data collection of Riskesdas 2007, 2013 and 2018, national immunization program for diphtheria in Indonesia was given to infants aged 2, 3 and 4 months as basic immunization. Furthermore, booster or follow-up immunization was given to children aged 18 months and elementary school students in the first, second and fifth grades [13]. For infants and children aged 18 months, the diphtheria vaccine was given in the form of a DTP-HB-Hib, diphtheria vaccine prepared together with tetanus, pertussis, hepatitis B, and *Haemophilus influenzae* type-B (Hib) vaccines. Meanwhile, for elementary school students, the diphtheria vaccine was given in the form of a DT vaccine preparation for elementary school students in the first grade, and the Td vaccine with a lower diphtheria toxoid concentration to avoid increased reactogenicity in the fourth and fifth doses was given to elementary school students in the second and fifth grades [23–25]. Therefore, in line with the national immunization program of diphtheria booster vaccination for elementary school students, according to Riskeddas data, the diphtheria IgG antibody titer had increased again and was highest at the age of 7–10 years (Figs 1 and 2). However, after reaching the age of ten years old, there was a decrease in the titer of diphtheria IgG antibody. Meanwhile, the most vulnerable age group (with non-protective diphtheria IgG titer) is 5–6 years old (Figs 1 and 2) in all three periods of Riskesdas. Previous study reported by Yusoff *et al* (2021) on the population in Malaysia with a sample size of 3,317 respondents also showed the same results, where children aged 5–6 years were most susceptible to diphtheria infection [26]. These results suggest that diphtheria vaccination boosters should be considered for both 5–6 years old of age and adolescents.

Diphtheria seroprotection in Riskesdas 2007, 2013 and 2018 ranged from 71.1%–83.6%, consisting of full protection and long protection. Long-term protection is defined as an antibody concentration  $\geq 1$  IU/mL [4]. Previous study showed that five years post-vaccination the antibodies started to wane slightly, but still remained higher than pre-vaccination [27]. The percentage of diphtheria long-term protective antibody in Riskesdas 2018 is found to be two to three fold higher than those in Riskesdas 2007 and 2013, in both urban and rural areas (2018 compared to 2013) (Figs 1 and 2). This is likely due to the diphtheria outbreak resulting in an increase in the immune response due to exposure to natural toxigenic *C. diphtheriae* infection and the additional diphtheria immunization program. During 2017, there was a diphtheria outbreak in 170 districts/cities from 30 provinces with 954 cases and 44 deaths, continuing until 2018. So that in December 2017–2018 through the outbreak response immunization (ORI) program, diphtheria vaccination was carried out targeting children aged 1–19 years. Diphtheria vaccine was given in the form of DTP-HB-Hib preparations for children aged 1–5 years, DT vaccine for children aged 5–7 years and Td vaccine for children aged over seven years. ORI aimed to increase community immunity so that it can break the chain transmission. ORI diphtheria was implemented in three rounds, where the first round was implemented in 12 districts/cities in three provinces, namely DKI Jakarta, Banten and West Java, with an average coverage of 68.36% with a total target of 7.9 million. Furthermore, it was gradually implemented in 11 other provinces with the criteria of districts/cities that still have new case reports, which often report diphtheria outbreaks during 2017, which have diphtheria deaths, which have low routine immunization coverage <90% [24]. This result is also in accordance with the research conducted by Hughes *et al*, which showed that although DTP immunization coverage was higher in districts with low diphtheria incidence, immunity was significantly lower compared to districts with high diphtheria incidence. The higher levels of seroprotection observed in 2018 likely reflect the combined effects of routine immunization, booster dose implementation, and emergency vaccination responses, rather than survey year effects alone. Accordingly, DTP4 production and ORI activities are best regarded as plausible contributors to improved population-level immunity. Given the cross-sectional nature of the data, causal attribution to specific interventions is not possible, and observed patterns should be interpreted as descriptive of cumulative programmatic impact. High immunity in districts with high incidence is most likely due to natural immunity obtained through exposure to toxigenic *C. diphtheriae* infection and receiving a diphtheria vaccination booster [28].

Bivariate analysis of Riskesdas 2007, 2013 and 2018 data showed several factors that influence diphtheria seroprotection in children in Indonesia, such as age, gender, immunization status, family economic status, nutritional status and maternal education level (Table 2). However, multivariate analysis in the three Riskesdas periods showed that complete

DTP immunization status in children aged 1–4 years was a factor that significantly influenced (Riskesdas 2007:  $p=0.020$ , Riskesdas 2013:  $p=0.027$ , Riskesdas 2018:  $p=0.002$ ) diphtheria seroprotection.

Factors influencing the completeness of immunization status in children aged under five years include maternal education level. Mothers with higher educational levels are often associated with a better understanding of child health, including the importance of immunization. In addition, older maternal age is also a contributing factor, as it is associated with a greater ability to make independent decisions. Furthermore, the presence of professional midwives during childbirth, who provided antenatal and perinatal services, including immunization, also played a significant role [29–32]. Accessibility of healthcare facilities, such as Puskesmas (primary healthcare) or Posyandu (integrated health posts), were also reported to play a crucial role in increasing immunization coverage [33,34]. Adequate vaccine availability at healthcare facilities, along with friendly and informative healthcare workers who foster maternal trust in immunization programs, were also found as important factors contributing to increased immunization coverage [35–38].

In children who have completed the DTP3 immunization series, the highest GMC of diphtheria IgG antibodies was observed in one year old, with seroprotective proportions of 77% (Riskesdas 2007) and 81.37% (Riskesdas 2013). These proportions declined with age, reaching 67.69% (Riskesdas 2007) and 60.88% (Riskesdas 2013) by four years of age (S1 Table). However, data from Riskesdas 2018 indicated a slightly different trend: while seroprotective proportion of diphtheria was high in one year old (82.8%), it peaked at two years of age (89.75%) before declining to 72.94% by four years of age (S1 Table). Riskesdas 2013 data showed a decrease of IgG diphtheria titer (GMC 0.33 IU/mL to 0.18 IU/mL – S1 Table). Meanwhile, Riskesdas 2018 data showed an increase of IgG diphtheria in children aged 1–2 years old (GMC 0.48 IU/mL to 0.77 IU/mL – S1 Table). The rise in GMC levels observed in 2018 should be interpreted in the context of overlapping immunization activities. Although the introduction of DTP4 represents a programmatic strengthening of the routine vaccination schedule, the extensive ORI campaigns conducted during the 2017–2018 national diphtheria outbreak may also have contributed to the enhanced antibody response. Similar to findings from previous outbreak response evaluations, supplemental booster doses delivered through ORI are known to elevate population-level immunity, particularly in older children and adolescents who may have waning protection [39,40]. Given that vaccination data did not allow us to differentiate between doses obtained through routine services versus ORI, the relative contribution of DTP4 alone cannot be fully disentangled. Therefore, the 2018 GMC increase is best interpreted as the cumulative effect of both routine schedule enhancement and intensified outbreak response measures. Nonetheless, immunity appears to decrease again after two years of age.

We acknowledge that observed patterns of declining diphtheria antibody levels with age are consistent with waning immunity post-vaccination, as documented in multiple seroepidemiological studies across different settings. Systematic reviews of DTP-containing vaccines have demonstrated measurable declines in post-vaccination immunity for diphtheria over time, highlighting the potential need for booster doses to maintain protection beyond early childhood [41]. Age-stratified serosurveys in other populations reveal similar decreases in protective antibody titers in older children and adults in the absence of recent boosting, suggesting that immunity gaps may persist despite high routine coverage [26]. While these cross-sectional findings support consideration of booster strategies, definitive conclusions regarding optimal booster timing and causal programmatic effects require longitudinal cohort studies, program evaluations, or formal transmission and immunity modeling that explicitly account for waning dynamics and vaccination history [40]. These findings suggest that completing the diphtheria immunization series significantly enhances children's immunity against diphtheria, but this immunity wanes over time.

Immunization that is given completely according to the recommended dose can trigger an optimal adaptive immune response so that it can form long-term immunity. Although high maternal antibodies in newborns can cause low antibody titers after two doses of diphtheria immunization, after completing three doses of primary immunization, most infants have protective antibodies and as many as 94–100% of children have minimal seroprotection (titer  $>0.01$  IU/mL) [42]. These results confirm that complete basic immunization coverage according to the immunization schedule is very important.

Meanwhile, data from the three periods of Riskesdas indicated that the coverage of complete basic immunization remains below 80% (Table 1), thereby underscoring the need to intensify efforts to increase the coverage of both the third (DTP3) and fourth (DTP4) doses of the diphtheria vaccine. By maintaining national immunization coverage above 80%, herd immunity or immunity in the community is expected to be achieved so that the threat of outbreaks in the future can be reduced [43]. A meta-analysis of 266 articles on diphtheria and 55 articles on diphtheria outbreaks showed that three doses of diphtheria toxoids were effective in preventing symptomatic disease by 87% and reducing transmission by 60%. However, vaccination alone is certainly not enough and needs to be accompanied by active surveillance and appropriate antibiotic treatment [44].

The apparent discrepancy between the IDAI recommendation and the school-based immunization program warrants clarification. According to IDAI, the second DTP booster is recommended at approximately five years of age, before school entry, to sustain immunity against all three antigens [10]. However, under Indonesia's national school-based immunization program (Bulan Imunisasi Anak Sekolah, BIAS), children in Grade 1 of elementary school typically receive a DT (diphtheria–tetanus) vaccine, which omits the pertussis component. This difference arises from operational and logistical adaptations in the national immunization schedule, rather than from conflicting policy guidance. Consequently, references of our study to school-based boosters should be understood as reflecting the implementation of the DT vaccine preparation under the BIAS program, while the IDAI recommendation pertains to the broader pediatric vaccination guidance.

National evidence showed that closing the gap in vaccination coverage had proven to be more effective and cost-effective than controlling the outbreak itself, as was the case with the diphtheria outbreaks in East and West Java in 2017 and 2023 respectively [39,45]. In Riskesdas 2007, in addition to immunization status, low maternal education level was also an influential factor (APOR = 3.61,  $p = 0.004$ ) on diphtheria seroprotection compared to higher education. Maternal education plays an important role in improving health knowledge, attitudes, and practices, including compliance with the child immunization schedule. Mothers with higher education better understand the importance of immunization and its schedule. Education is also often associated with the ability to access valid health information and better use of health services. Many studies have shown that maternal education is significantly related to the completeness or incompleteness of children's basic immunization, which has an impact on increasing immunization coverage and the resulting immunity [46,47].

In Riskesdas 2018, seroprotection was also significantly associated with household economic status, with individuals from poor households showing different odds of seroprotection compared with those from middle-income households (APOR = 1.76;  $p = 0.028$ ). From a social determinants of health perspective, socioeconomic status influences health outcomes through access to key intermediary factors, including education, healthcare services, and adequate nutrition. However, in the context of immunological protection, immunization completeness appears to be a more proximal and dominant intermediary determinant. Household economic status is closely linked to complete versus incomplete immunization, which in turn affects overall immunization coverage and levels of seroprotection. This relationship is supported by studies from Afghanistan and India, which reported that children from wealthier households had a 36% higher likelihood of receiving complete immunization compared with children from the poorest households, even after adjustment for potential confounders [48,49].

This study is based on available secondary data, which might lack specificity about the brand, lot consistency and exact formulation type of the vaccine [50]. Additionally, there was little information available regarding the circumstances in which vaccinations were given, such as whether they took place just in public health centers or also in private medical facilities which limits this study scope. Our capacity to evaluate possible variations in vaccination quality, handling, and administration procedures is hampered by the lack of these specifics. Secondly, the observed variations in seroprotection levels could have been caused by regional variations in the types of diphtheria-tetanus-pertussis (DTP) vaccinations used. For instance, a higher prevalence of acellular pertussis (DPaT) vaccine usage in private healthcare settings, as opposed to whole-cell pertussis (DPwT) vaccinations more frequently used in public immunization programs, may be the

reason for lower seroprotection rates seen in certain urban area. These variations in vaccine formulation and cold chain are known to affect profiles of immunogenicity, which might complicate the comparisons [51,52].

The limitation of this study is that individual-level immunization history was available only for children aged 1–4 years. As a result, findings related to complete DTP immunization cannot be directly extrapolated to older age groups. Interpretations for these age groups are therefore based on observed age-specific serological patterns rather than confirmed individual vaccination histories. Observed serological patterns among older children likely reflect cumulative programmatic effects and waning immunity, and any comparisons with immunization coverage data at broader levels should be interpreted as ecological. Additionally, Riskesdas 2007 included only urban respondents, which may reduce comparability with later surveys and introduce urban–rural bias when interpreting changes over time. These limitations should be considered when generalizing the findings, and future studies incorporating detailed vaccine registry data, heterologous immunity between DTP and Covid-19 vaccines and mixed-methods assessments of immunization practices are warranted to better elucidate the determinants of diphtheria seroprotection.

## Conclusions

Using nationally representative Riskesdas data from 2007, 2013, and 2018, this study identifies persistent immunity gaps against diphtheria in Indonesia, with a high proportion of children aged 1–6 years lacking protective antibody levels and a marked decline in diphtheria IgG titers after 10 years of age. Although population-level seroprotection improved in 2018 following the introduction of the DTP4 booster and ORI activities, immunity remains suboptimal. Across all survey years, complete DTP immunization consistently emerged as the strongest independent determinant of diphtheria seroprotection, highlighting the central role of achieving and sustaining complete routine immunization coverage. These findings underscore the need to strengthen routine DTP delivery and to optimize booster dose strategies, including consideration of earlier and adolescent boosters, to mitigate waning immunity and prevent recurrent diphtheria outbreaks.

## Supporting information

**S1 Table. Diphtheria immunity status in children aged 1–4 years old with complete DTP vaccination status in the Riskesdas 2007, 2013 and 2018.**

(DOCX)

## Acknowledgments

We gratefully acknowledge the Head of the Health Development Policy Agency, the Ministry of Health of the Republic of Indonesia (Kemenkes RI), as well as the data management laboratory team, for granting access to and permission to use datasets of Riskesdas 2007, 2013 and 2018. We also thank all members of the research teams—particularly those from the Health Research and Development Agency, Ministry of Health—who were involved in data collection, laboratory analyses, and data management for the three periods of Riskesdas.

## Author contributions

**Conceptualization:** Monica Dwi Hartanti, Christina Safira Whinie Lestari, Novaria Sari Dewi Panjaitan, Armedy Ronny Hasugian, Sunarno Sunarno.

**Data curation:** Monica Dwi Hartanti, Christina Safira Whinie Lestari, Novaria Sari Dewi Panjaitan, Armedy Ronny Hasugian, Sunarno Sunarno.

**Formal analysis:** Monica Dwi Hartanti, Christina Safira Whinie Lestari, Novaria Sari Dewi Panjaitan, Armedy Ronny Hasugian, Rita Marleta Dewi, Sarwo Handayani, Masri Sembiring Maha, Sunarno Sunarno.

**Investigation:** Monica Dwi Hartanti, Christina Safira Whinie Lestari, Novaria Sari Dewi Panjaitan, Armedy Ronny Hasugian, Sunarno Sunarno.

**Methodology:** Monica Dwi Hartanti, Christina Safira Whinie Lestari, Novaria Sari Dewi Panjaitan, Armedy Ronny Hasugian, Sunarno Sunarno.

**Validation:** Monica Dwi Hartanti, Christina Safira Whinie Lestari, Novaria Sari Dewi Panjaitan, Armedy Ronny Hasugian, Sarwo Handayani, Masri Sembiring Maha, Tubagus Ferdi Fadilah, Firda Fairuza, Nathalia Ningrum, Meiriani Sari, Dita Setiati, Nia Nurul Aziza, Donna Adriani, Jihan Samira, Sunarno Sunarno.

**Visualization:** Monica Dwi Hartanti, Christina Safira Whinie Lestari, Novaria Sari Dewi Panjaitan, Armedy Ronny Hasugian, Rita Marleta Dewi, Sarwo Handayani, Masri Sembiring Maha, Arleen Devita, Sunarno Sunarno.

**Writing – original draft:** Monica Dwi Hartanti, Christina Safira Whinie Lestari, Novaria Sari Dewi Panjaitan, Armedy Ronny Hasugian, Rita Marleta Dewi, Sarwo Handayani, Masri Sembiring Maha, Sunarno Sunarno.

**Writing – review & editing:** Monica Dwi Hartanti, Christina Safira Whinie Lestari, Novaria Sari Dewi Panjaitan, Armedy Ronny Hasugian, Rita Marleta Dewi, Sarwo Handayani, Masri Sembiring Maha, Tubagus Ferdi Fadilah, Firda Fairuza, Nathalia Ningrum, Meiriani Sari, Dita Setiati, Nia Nurul Aziza, Arleen Devita, Donna Adriani, Jihan Samira, Sunarno Sunarno.

## References

1. PAHO. Diphtheria. <https://www.paho.org/en/topics/diphtheria#:~:text=Diphtheria is fatal in 5,mortality rate in young children>
2. Sharma NC, Elstratliou A, Mokrousov I, Mutreja A, Das B, Ramamurthy T. Diphtheria. *Nat Rev Dis Primers*. 2019;5(1):81. <https://doi.org/10.1038/s41572-019-0131-y> PMID: 31804499
3. Sunarno S, Puspandari N, Sariadji K, Febriyana D, Febrianti T, Saraswati RD, et al. Microbiological and Clinical Aspects of Diphtheria-Confirmed Cases from Capital City of Indonesia, Jakarta, and Surrounding Areas in 2017. *Jundishapur J Microbiol*. 2021;14(8). <https://doi.org/10.5812/jjm.118751>
4. World Health Organization. WHO laboratory manual for the diagnosis of diphtheria and other related infections. 2021. <https://apps.who.int/iris/handle/10665/352275>
5. Dwi Hartanti M, Sari Dewi Panjaitan N, Hidayat S, Fitriana F, Sunarno S, Susanty S. Diphtheria Incidence is a Public Health Challenge in Low- and Middle-Income Countries (LMICs). *Public Health of Indonesia*. 2025;11(2):71–80. <https://doi.org/10.36685/phi.v11i2.953>
6. World Health Organization. Diphtheria reported cases and incidence. <https://immunizationdata.who.int/global/wise-detail-page/diphtheria-reported-cases-and-incidence?CODE=Global&YEAR=>
7. Fardani SA, Wahyono TYM. Distribusi Kasus Difteri, Riwayat Imunisasi Difteri, Tingkat Keparahan Gejala dan Risiko Kematian pada Penderita Difteri di Indonesia Tahun 2020 – 2022. *J Epidemiol Kesehatan Indones*. 2023;7(2):77. <https://doi.org/10.7454/epickes.v7i2.1081>
8. Clarke KEN, MacNeil A, Hadler S, Scott C, Tiwari TSP, Cheria T. Global Epidemiology of Diphtheria, 2000–2017. *Emerg Infect Dis*. 2019;25(10):1834–42. <https://doi.org/10.3201/eid2510.190271> PMID: 31538559
9. World Health Organization. Immunization, Vaccines and Biologicals. <https://www.who.int/teams/immunization-vaccines-and-biologicals/diseases/diphtheria#:~:text=WHO recommends a 3-dose of 4 weeks between doses>
10. Indonesian Pediatric Society (IDAI). Jadwal Imunisasi Anak Usia 0-18 Tahun, Rekomendasi Ikatan Dokter Anak Indonesia Tahun 2024. <https://www.idai.or.id/news-event/agenda-nasional/others/6798>
11. Sitaremi MN, Soedjatmiko S, Gunardi H, Kaswandani N, Handryastuti S, Raihan R, et al. Jadwal Imunisasi Anak Usia 0 – 18 Tahun Rekomendasi Ikatan Dokter Anak Indonesia Tahun 2023. *SP*. 2023;25(1):64. <https://doi.org/10.14238/sp25.1.2023.64-74>
12. Rachlin A, Danovaro-Holliday MC, Murphy P, Sodha SV, Wallace AS. Routine Vaccination Coverage - Worldwide, 2021. *MMWR Morb Mortal Wkly Rep*. 2022;71(44):1396–400. <https://doi.org/10.15585/mmwr.mm7144a2> PMID: 36327156
13. Santi T, Prayitno A, Munasir Z, Hadinegoro SRS, Harahap AR, Werdhani RA, et al. Evaluation of anti-diphtheria toxoid antibody persistence in school-age children in Jakarta, Indonesia. *PL*. 2024;64(5):447–53. <https://doi.org/10.14238/pi64.5.2024.447-53>
14. World Health Organization. Immunization agenda 2030. A global strategy to leave no one behind. 2022. <https://www.who.int/teams/immunization-vaccines-and-biologicals/strategies/a2030>
15. Hartanti MD, Panjaitan NSD, Sunarno S, Ningrum N, Hasugian AR, Dewi RM, et al. Seroprevalence of Bordetella pertussis infection in children 1–14 years old: Indonesia basic health research (Risikesdas) 2013 and 2018 data. *PLoS One*. 2024;19(9):e0311362. <https://doi.org/10.1371/journal.pone.0311362> PMID: 39348411

16. Lestari CSW, Dewi RM, Sunarno S, Hasugian AR, Handayani S, Maha MS, et al. The effectiveness of hepatitis B vaccine in toddlers based on the five-year period national basic health research (Riskesdas 2007, 2013 and 2018) in Indonesia. *PeerJ*. 2023;11:e15199. <https://doi.org/10.7717/peerj.15199> PMID: 37214093
17. Kementerian Kesehatan RI. Laporan riset kesehatan dasar 2007. 2008. <https://repository.badankebijakan.kemkes.go.id/eprint/4375/1/Laporan%20Riset%20Kesehatan%20Dasar%20Nasiona%3B%202007.pdf>
18. Kementerian Kesehatan RI. Riset Kesehatan Dasar 2013. 2013. [https://repository.badankebijakan.kemkes.go.id/eprint/44671/Laporan\\_riskesdas\\_2013\\_final.pdf](https://repository.badankebijakan.kemkes.go.id/eprint/44671/Laporan_riskesdas_2013_final.pdf)
19. Kementerian Kesehatan RI. Laporan Nasional Riskesdas 2018. 2018. <https://repository.badankebijakan.kemkes.go.id/eprint/3514/1/Laporan%20Riskesdas%202018%20Nasional.pdf>
20. Centers for Disease Control and Prevention CDC. Child and Teen BMI Calculator. 2024. <https://www.cdc.gov/bmi/child-teen-calculator/index.html>
21. WHO. Child growth standards. <https://www.who.int/toolkits/child-growth-standards/standards/body-mass-index-for-age-bmi-for-age>
22. Le TV, Nguyen VTT, Nguyen QH, Nguyen TTT, Duong TTN, Ly TTT, et al. The evaluation of anti-diphtheria toxoid antibodies in healthy population in Kon Tum, Vietnam: a population-based study. *IJID Reg*. 2022;3:171–6. <https://doi.org/10.1016/j.ijregi.2022.03.019> PMID: 35755469
23. Kementerian Kesehatan RI. Peraturan Menteri Kesehatan Republik Indonesia Nomor 42 Tahun 2013 Tentang Penyelenggaraan Imunisasi. 2013. <https://id.scribd.com/doc/215861710/PMK-No-42-ttg-Penyelenggaraan-Imunisasi-pdf>
24. Kementerian Kesehatan Republik Indonesia. Peraturan Menteri Kesehatan Republik Indonesia Nomor 12 Tahun 2017 Tentang Penyelenggaraan Imunisasi. 2017. <https://peraturan.go.id/files/bn559-2017.pdf>
25. Rengganis I. Adult Diphtheria Vaccination. *Acta Med Indones*. 2018;50(3):268–72. PMID: 30333279
26. Yusoff AF, Mohd Sharani ZZ, Kee CC, Md Iderus NH, Md Zamri ASS, Nagalingam T, et al. Seroprevalence of diphtheria toxoid IgG antibodies in the Malaysian population. *BMC Infect Dis*. 2021;21(1):581. <https://doi.org/10.1186/s12879-021-06285-3> PMID: 34134646
27. Le TV, Nguyen VTT, Nguyen QH, Tran HLT, Tran SD, Vien CC. The evaluation of anti-diphtheria toxoid antibodies after 5 years with the primary Tetanus-Diphtheria vaccine in persons aged 6-25 years in Kon Tum, Vietnam: a follow-up study. *J Infect Dev Ctries*. 2025;19(1):22–7. <https://doi.org/10.3855/jidc.19390> PMID: 39977457
28. Hughes GJ, Mikhail AFW, Husada D, Irawan E, Kafatos G, Bracebridge S, et al. Seroprevalence and Determinants of Immunity to Diphtheria for Children Living in Two Districts of Contrasting Incidence During an Outbreak in East Java, Indonesia. *Pediatr Infect Dis J*. 2015;34(11):1152–6. <https://doi.org/10.1097/INF.0000000000000346> PMID: 26226444
29. Matthew Ayodele A, Fasasi MI, Rejoice Uche O, Gideon Ikemdinachi N, Henry Ugochukwu U. Factors associated with full childhood vaccination coverage among young mothers in Northern Nigeria. *Pan Afr Med J*. 2024;47:4. <https://doi.org/10.11604/pamj.2024.47.4.37517> PMID: 38371647
30. Ariyibi S, Ojuawo A, Ibraheem R, Afolayan F, Ariyibi R, Akanbi P. Factors influencing routine vaccination uptake and completion among children aged 12–23 months in Ilorin, North-Central Nigeria: A cross-sectional survey. *Int J Med Health Dev*. 2023;28(4):314. [https://doi.org/10.4103/ijmh.ijmh\\_20\\_23](https://doi.org/10.4103/ijmh.ijmh_20_23)
31. Hollpah, Maharani A, Kuroda Y. Determinants of immunization status among 12- to 23-month-old children in Indonesia (2008-2013): a multilevel analysis. *BMC Public Health*. 2018;18(1):288. <https://doi.org/10.1186/s12889-018-5193-3> PMID: 29482562
32. Setiawan MS, Wijayanto AW. Determinants of immunization status of children under two years old in Sumatera, Indonesia: A multilevel analysis of the 2020 Indonesia National Socio-Economic Survey. *Vaccine*. 2022;40(12):1821–8. <https://doi.org/10.1016/j.vaccine.2022.02.010> PMID: 35153089
33. Cintyamenia U, Azizatunnisa' L, Ahmad RA, Mahendradhata Y. Scaling up public health interventions: case study of the polio immunization program in Indonesia. *BMC Public Health*. 2021;21(1):614. <https://doi.org/10.1186/s12889-021-10647-6> PMID: 33781243
34. Nainggolan O, Hapsari D, Indrawati L. Pengaruh Akses ke Fasilitas Kesehatan terhadap Kelengkapan Imunisasi Baduta (Analisis Riskesdas 2013). *Media Litbangkes*. 2016;26(1). <https://doi.org/10.22435/mpk.v26i1.4900.15-28>
35. Ekezie W, Igein B, Varughese J, Butt A, Ukoha-Kalu BO, Ikhele I, et al. Vaccination Communication Strategies and Uptake in Africa: A Systematic Review. *Vaccines (Basel)*. 2024;12(12):1333. <https://doi.org/10.3390/vaccines12121333> PMID: 39771995
36. Kasahun AW, Zewdie A, Shitu S, Alemayehu G. Vaccine cold chain management practice and associated factors among health professionals in Ethiopia: systematic review and meta-analysis. *J Pharm Policy Pract*. 2023;16(1):55. <https://doi.org/10.1186/s40545-023-00560-1> PMID: 37046331
37. Lin C, Mullen J, Smith D, Kotarba M, Kaplan SJ, Tu P. Healthcare Providers' Vaccine Perceptions, Hesitancy, and Recommendation to Patients: A Systematic Review. *Vaccines (Basel)*. 2021;9(7):713. <https://doi.org/10.3390/vaccines9070713> PMID: 34358132
38. Zameer M, Phillips-White N, Folorunso O, Bell R, Setayesh H, Asghar N, et al. Promoting equity in immunization coverage through supply chain design in Pakistan. *Gates Open Res*. 2020;4:31. <https://doi.org/10.12688/gatesopenres.13121.1> PMID: 33709056
39. Husada D, Puspitasari D, Kartina L, Basuki PS, Moedjito I, Susanto H, et al. Impact of a three-dose diphtheria outbreak response immunization in East Java, Indonesia, 6 months after completion. *Hum Vaccin Immunother*. 2020;16(9):2144–50. <https://doi.org/10.1080/21645515.2020.1778918> PMID: 32692596
40. Kitamura N, Bahkali K, Chem ED, Quilty BJ, Edwards T, Toizumi M, et al. Waning rate of immunity and duration of protective immunity against diphtheria toxoid as a function of age and number of doses: Systematic review and quantitative data analysis. *Hum Vaccin Immunother*. 2022;18(6):2099700. <https://doi.org/10.1080/21645515.2022.2099700> PMID: 35862651

41. Gao H, Lau EHY, Cowling BJ. Waning Immunity After Receipt of Pertussis, Diphtheria, Tetanus, and Polio-Related Vaccines: A Systematic Review and Meta-analysis. *J Infect Dis.* 2022;225(4):557–66. <https://doi.org/10.1093/infdis/iab480> PMID: 34543411
42. World Health Organization. Diphtheria vaccines: WHO position paper – August 2017. *Weekly Epidemiological Record.* 2017. <https://www.who.int/publications/item/diphtheria-vaccines-who-position-paper-august-2017>
43. Orenstein WA, Offit PA, Plotkin SA. *Vaccines.* 6th ed. Elsevier. 2012.
44. Truelove SA, Keegan LT, Moss WJ, Chaisson LH, Macher E, Azman AS, et al. Clinical and Epidemiological Aspects of Diphtheria: A Systematic Review and Pooled Analysis. *Clin Infect Dis.* 2020;71(1):89–97. <https://doi.org/10.1093/cid/ciz808> PMID: 31425581
45. Fauzi IS, Nuraini N, Sari AM, Wardani IB, Taurustiati D, Simanullang PM, et al. Assessing the impact of booster vaccination on diphtheria transmission: Mathematical modeling and risk zone mapping. *Infect Dis Model.* 2024;9(1):245–62. <https://doi.org/10.1016/j.idm.2024.01.004> PMID: 38312350
46. Asif AM, Akbar M, Tahir MR, Arshad IA. Role of Maternal Education and Vaccination Coverage: Evidence From Pakistan Demographic and Health Survey. *Asia Pac J Public Health.* 2019;31(8):679–88. <https://doi.org/10.1177/1010539519889765> PMID: 31852229
47. Gebreyesus A, Tesfay K. Effect of maternal education on completing childhood vaccination in Ethiopia: systematic review and meta-analysis. *Sci Rep.* 2024;14(1):17453. <https://doi.org/10.1038/s41598-024-68182-4> PMID: 39075119
48. Farzad F, A Reyer J, Yamamoto E, Hamajima N. Socio-economic and demographic determinants of full immunization among children of 12-23 months in Afghanistan. *Nagoya J Med Sci.* 2017;79(2):179–88. <https://doi.org/10.18999/nagjms.79.2.179> PMID: 28626253
49. Srivastava S, Fledderjohann J, Upadhyay AK. Explaining socioeconomic inequalities in immunisation coverage in India: new insights from the fourth National Family Health Survey (2015-16). *BMC Pediatr.* 2020;20(1):295. <https://doi.org/10.1186/s12887-020-02196-5> PMID: 32546138
50. Fadlyana E, Rusmil K, Dhamayanti M, Tarigan R, Kartasasmita CB, Sari RM, et al. Comparison of Immunogenicity and Safety of Diphtheria-Tetanus-Pertussis-Hepatitis B-Haemophilus influenza B (Bio Farma) with Pentabio® Vaccine Primed with Recombinant Hepatitis B at Birth (Using Different Source of Hepatitis B) in Indonesian Infants. *Vaccines (Basel).* 2023;11(3):498. <https://doi.org/10.3390/vaccines11030498> PMID: 36992082
51. Tang X, Xiao Y, Chen J, Su Y, Zhou Y, Luo L, et al. Immunogenicity and safety of co-purified diphtheria, tetanus and acellular pertussis vaccine in 6-year-old Chinese children. *Nat Commun.* 2025;17(1):214. <https://doi.org/10.1038/s41467-025-66890-7> PMID: 41318685
52. Kartoglu U, Ames H. Ensuring quality and integrity of vaccines throughout the cold chain: the role of temperature monitoring. *Expert Rev Vaccines.* 2022;21(6):799–810. <https://doi.org/10.1080/14760584.2022.2061462> PMID: 35373686

# Diphtheria seroprotection among Indonesian children: Community Health Surveys Riskesdas 2007, 2013 and 2018

ORIGINALITY REPORT

# 13%

SIMILARITY INDEX

## PRIMARY SOURCES

- 1** [eprints.bournemouth.ac.uk](https://eprints.bournemouth.ac.uk) 175 words — 2%  
Internet
- 2** Aaron A. Heeren, Eduard J. van Beers, Bart J. Biemond, Myrthe J. van Dijk, Erfan Nur, Charlotte F.J. van Tuijn, Merel A. Timmer. "Movement behavior in adults with sickle cell disease compared to healthy adults: a cross-sectional study", PLOS One, 2026 63 words — 1%  
Crossref
- 3** [www.frontiersin.org](http://www.frontiersin.org) 53 words — 1%  
Internet
- 4** [e-mfp.org](http://e-mfp.org) 48 words — 1%  
Internet
- 5** [ir.tum.ac.ke](http://ir.tum.ac.ke) 48 words — 1%  
Internet
- 6** [researchonline.lshtm.ac.uk](http://researchonline.lshtm.ac.uk) 45 words — < 1%  
Internet
- 7** Hughes, Gareth J., Amy F. W. Mikhail, Dominicus Husada, Eveline Irawan, George Kafatos, Samantha Bracebridge, Richard Pebody, and Androulla Efstratiou. "Seroprevalence and Determinants of Immunity to Diphtheria for Children Living in Two Districts of Contrasting Incidence During an Outbreak in East Java, Indonesia :", The Pediatric Infectious Disease Journal, 2015. 29 words — < 1%  
Crossref

|    |  |                 |
|----|--|-----------------|
| 8  | <a href="http://wprim.whocc.org.cn">wprim.whocc.org.cn</a><br>Internet   | 29 words — < 1% |
| 9  | <a href="http://bmcinfectdis.biomedcentral.com">bmcinfectdis.biomedcentral.com</a><br>Internet   | 28 words — < 1% |
| 10 | <a href="http://bmcpediatr.biomedcentral.com">bmcpediatr.biomedcentral.com</a><br>Internet   | 27 words — < 1% |
| 11 | <a href="http://pubmed.ncbi.nlm.nih.gov">pubmed.ncbi.nlm.nih.gov</a><br>Internet   | 27 words — < 1% |
| 12 | <a href="http://villages.pubmedia.id">villages.pubmedia.id</a><br>Internet   | 25 words — < 1% |
| 13 | Ayunina Rizky Ferdina, Prisca Petty Arfines, Ni Ketut Aryastami. "Obesity in urban Indonesia: evidence from the 2007 and 2018 Basic Health Research", <i>Medical Journal of Indonesia</i> , 2024<br>Crossref   | 24 words — < 1% |
| 14 | <a href="http://paediatricaindonesiana.org">paediatricaindonesiana.org</a><br>Internet   | 21 words — < 1% |
| 15 | Piyarat Suntarattiwong, Warunee Punpanich Vandepitte, Pon Singhamatr, Tawee Chotpitayasunondh. "Seroprotection rate in adults after 1-dose, 2-dose, and 3-dose series of a reduced-diphtheria-tetanus toxoid vaccine (Td) during a diphtheria outbreak in Thailand", <i>Vaccine</i> , 2020<br>Crossref | 20 words — < 1% |
| 16 | <a href="http://ejournal.unisba.ac.id">ejournal.unisba.ac.id</a><br>Internet   | 19 words — < 1% |
| 17 | "Abstract", <i>Hepatology International</i> , 2022<br>Crossref   | 18 words — < 1% |
| 18 | Bernadette Walter, Katharina Lück, Maja Adam, Bettina Winter et al. "Prevalence of diphtheria and antimicrobial-resistant wound infections among asylum  | 18 words — < 1% |

---

19 [assets.publishing.service.gov.uk](https://assets.publishing.service.gov.uk) 16 words — < 1%  
Internet

---

20 [mdpi-res.com](https://mdpi-res.com) 16 words — < 1%  
Internet

---

21 [www.tobaccopreventioncessation.com](https://www.tobaccopreventioncessation.com) 16 words — < 1%  
Internet

---

22 Yul Fitria, Niko Febrianto, Rahmi E. Putri, Ibenu  
Rahmadani, Didik T. Subekti. "Evaluation of In-  
House ELISA for Antirabies Antibodies Detection in Domestic  
Canine", Veterinary Medicine International, 2023  
Crossref

---

23 [journal.uii.ac.id](https://journal.uii.ac.id) 15 words — < 1%  
Internet

---

24 [repository.unj.ac.id](https://repository.unj.ac.id) 15 words — < 1%  
Internet

---

25 I Made Adi Parmana, Cindy Elfira Boom, Lisnawati  
Rachmadi, Dudy Arman Hanafy et al. "Myocardial  
Protecting Role of Glutamine in Patients with Low Ejection  
Fraction Undergoing Elective On-Pump Coronary Artery Bypass  
Graft Surgery", Vascular Health and Risk Management, 2022  
Crossref

---

26 Munif Arifin. "RECOMMENDATION OF  
DIPHtheria ANTIToxIN TO DIFFERENT SUSPECTS  
DURING THE DIPHtheria OUTBREAKS, LUMAJANG DISTRICT IN  
2018", The Indonesian Journal of Public Health, 2020  
Crossref

---

27 [ophrp.org](https://ophrp.org) 14 words — < 1%  
Internet

---

28 [www.wjgnet.com](https://www.wjgnet.com)

14 words — &lt; 1%

29 Fitriana Fitriana, Novi Amalia, Yudi Hartoyo, Sundari Nursofiah et al. "Polymorphisms of dtxR Gene of *Corynebacterium diphtheriae* Isolated from Diphtheria Outbreak in Indonesia", *Jundishapur Journal of Microbiology*, 2022  
Crossref

30 [mncareclinic.blogspot.com](http://mncareclinic.blogspot.com)  
Internet

13 words — &lt; 1%

31 Paloma Lanza-León, David Cantarero-Prieto, Marta Pascual-Sáez. "Exploring trends and determinants of basic childhood vaccination coverage: Empirical evidence over 41 years", *PLOS ONE*, 2024  
Crossref

12 words — &lt; 1%

32 Resti Wahyuni, Titik Harsanti. "INDIVIDUAL AND CONTEXTUAL FACTORS AFFECTING DPT IMMUNIZATION IN INDONESIA", *Parameter: Journal of Statistics*, 2021  
Crossref

12 words — &lt; 1%

33 [scholars.ln.edu.hk](http://scholars.ln.edu.hk)  
Internet

12 words — &lt; 1%

34 Nino Khetsuriani, Oleksandr Zaika, Liudmyla Slobodianyuk, Heather M. Scobie et al. "Diphtheria and tetanus seroepidemiology among children in Ukraine, 2017", *Vaccine*, 2022  
Crossref

10 words — &lt; 1%

35 Novaria Sari Dewi Panjaitan. "A Response to Article Anlotinib Hydrochloride and PD-1 Blockade as a Salvage Second-Line Treatment in Patients with Progress of Local Advanced Non-Small Cell Lung Cancer in Half a Year after Standard Treatment [Letter]", *OncoTargets and Therapy*, 2022  
Crossref

10 words — &lt; 1%

36 [ouci.dntb.gov.ua](https://ouci.dntb.gov.ua) 10 words — < 1%  
Internet

37 Arindam Ghosh, Saba Annigeri, Sunil Kumar Hemram, Pranab Kumar Dey, Sangita Mazumder, Pritam Ghosh. "Demography and determinants of incomplete immunization in children aged 1–5 years and vaccine-hesitancy among caregivers: An Eastern Indian perspective", *Clinical Epidemiology and Global Health*, 2022  
Crossref

38 Bemhembra Iba, Vershima Daniel Zar, Joseph Oteng. "Determinants of uptake of childhood immunization in Gboko, Benue State, Nigeria", *BMC Public Health*, 2025  
Crossref

39 Ebele Eugenia Onwuchuluba, Sandra Ogochukwu Uchendu. "Assessing the factors affecting routine childhood immunization among caregivers of children under five years in Southwestern Nigeria: a cross-sectional study", *Discover Public Health*, 2025  
Crossref

40 Mekuanint Geta, Demeke Endalamaw, Tazeb Molla, Getasew Asmare, Habtie Tadese, Asrat Hailu, Yimtubezinash Woldeamanuel. "Anti-HBs antibody levels among HB-vaccinated children attending public health facilities in Bahir Dar (northwest Ethiopia) and investigation of associated factors", *Vaccine: X*, 2026  
Crossref

41 Tuan Van Le, Van Thi Tuyet Nguyen, Quan Hoang Nguyen, Tram Thi Thu Nguyen et al. "The evaluation of anti-diphtheria toxoid antibodies in healthy population in Kon Tum, Vietnam: a population-based study", *IJID Regions*, 2022  
Crossref

42 [council.science](https://council.science) 9 words — < 1%  
Internet

- 
- 43 [cris.unibo.it](http://cris.unibo.it)  
Internet 9 words — < 1%
- 
- 44 [discovery.ucl.ac.uk](http://discovery.ucl.ac.uk)  
Internet 9 words — < 1%
- 
- 45 [public-pages-files-2025.frontiersin.org](http://public-pages-files-2025.frontiersin.org)  
Internet 9 words — < 1%
- 
- 46 [www.deepdyve.com](http://www.deepdyve.com)  
Internet 9 words — < 1%
- 
- 47 [www.researchsquare.com](http://www.researchsquare.com)  
Internet 9 words — < 1%
- 
- 48 "1-E4: COPD 5 : Poster Sessions", *Respirology*, 2013.  
Crossref 8 words — < 1%
- 
- 49 Amrin Madolan, Ridwan M Thaha, Muhammad Syafar, Sudirman Nasir, Nurhaedar Jafar, A Arsunan Arsin. "Factors Affecting Maternal Behavior in Achieving Complete Basic Immunization for Toddlers Aged 12-23 in Banggai Laut Regency, Indonesia", *National Journal of Community Medicine*, 2025  
Crossref 8 words — < 1%
- 
- 50 Christiana Rialine Titaley, Bertha J. Que, Filda V. I. de Lima, Ony W. Angkejaya et al. "Health Care-Seeking Behavior of Children With Acute Respiratory Infections Symptoms: Analysis of the 2012 and 2017 Indonesia Demographic and Health Surveys", *Asia Pacific Journal of Public Health*, 2020  
Crossref 8 words — < 1%
- 
- 51 Eka Desi Purwanti, Siti Masitoh, Sudarto Ronoatmodjo. "Association Between Basic Immunization Status and Stunting in Toddlers Aged 12-59 Months in Indonesia", *Journal of Preventive Medicine and Public Health*, 2025  
Crossref 8 words — < 1%

---

52 Gbadebo Collins Adeyanju. "Immunisation decision-making and barriers to vaccine uptake among children under-5 in limited-resource settings", *Scientific Reports*, 2025 8 words — < 1%  
Crossref

---

53 Henry Candra, Tjhwa Endang Djuana, Kuat Rahardjo Ts, Monica Dwi Hartanti, Rifai Chai. "Smart Container Design for Transporting Virus Sample in Remote Areas", 2021 IEEE International Conference on Health, Instrumentation & Measurement, and Natural Sciences (InHeNce), 2021 8 words — < 1%  
Crossref

---

54 Nabil Muhammad Raihan, Widya Cholil, Muhammad Adrezo, Seeunghye Han, Prihandoko, Didit Widiyanto. "Clustering Immunization Reception Data Using K-Means in Districts of DKI Jakarta Province", 2024 International Conference on Informatics, Multimedia, Cyber and Information System (ICIMCIS), 2024 8 words — < 1%  
Crossref

---

55 [boletines.finlay.edu.cu](http://boletines.finlay.edu.cu) 8 words — < 1%  
Internet

---

56 [content.scirp.org](http://content.scirp.org) 8 words — < 1%  
Internet

---

57 [e-journal.unair.ac.id](http://e-journal.unair.ac.id) 8 words — < 1%  
Internet

---

58 [eprints.nottingham.ac.uk](http://eprints.nottingham.ac.uk) 8 words — < 1%  
Internet

---

59 [f1000research.com](http://f1000research.com) 8 words — < 1%  
Internet

---

60 [link.springer.com](http://link.springer.com) 8 words — < 1%  
Internet

---

61 [roczniki.pzh.gov.pl](http://roczniki.pzh.gov.pl)

Internet

8 words — < 1%

62 [urfjournals.org](http://urfjournals.org)  
Internet

8 words — < 1%

63 [www.ipm2kpe.or.id](http://www.ipm2kpe.or.id)  
Internet

8 words — < 1%

64 [www.iscientific.org](http://www.iscientific.org)  
Internet

8 words — < 1%

65 [www.nature.com](http://www.nature.com)  
Internet

8 words — < 1%

66 [www.researchgate.net](http://www.researchgate.net)  
Internet

8 words — < 1%

67 [www.science.gov](http://www.science.gov)  
Internet

8 words — < 1%

68 Farid Agushybana, Syamsulhuda BM, Sutopo Patria Jati, Martini Martini, Ayun Sriatmi.  
"Description of complete basic immunization coverage among infant", International Journal of Public Health Science (IJPHS), 2019  
Crossref

7 words — < 1%

69 Lindsay Nicholson, Elizabeth Adkins, Mulya Rahma Karyanti, Anna Ong-Lim et al. "What is the true burden of diphtheria, tetanus, pertussis and poliovirus in children aged 3–18 years in Asia? A systematic literature review.", International Journal of Infectious Diseases, 2022  
Crossref

7 words — < 1%

70 Phung Nguyen The Nguyen, Ulrich Heininger, Rudzani Muloiwa, Carl Heinz Wirsing von König et al. "Pertussis in Southeast Asia: country-level burden and recommendations from the Global Pertussis Initiative", IJID Regions, 2024  
Crossref

6 words — < 1%

---

71 Theresia Santi, Ari Prayitno, Zakiudin Munasir, Sri Rezeki S. Hadinegoro et al. "Evaluation of anti-diphtheria toxoid antibody persistence in school-age children in Jakarta, Indonesia", Paediatrica Indonesiana, 2024 6 words — < 1%

Crossref

---

EXCLUDE QUOTES ON

EXCLUDE SOURCES OFF

EXCLUDE BIBLIOGRAPHY ON

EXCLUDE MATCHES OFF